Immunomodulatory role of helminth-derived antigens and C-type lectin receptors on inflammatory mast cells by Vukman, Krisztina Visnovitzné
  
 
Immunomodulatory role of helminth-derived antigens 
and C-type lectin receptors on inflammatory mast cells 
 
 
 
 A thesis submitted for the degree of Ph.D. 
by 
Krisztina Visnovitzné Vukman (M.Sc.) 
 
 
 
 
Supervisor: Dr Sandra M O’Neill 
School of Nursing and Human Sciences 
Dublin City University 
 
2013 
i 
 
 
 
Immunomodulatory role of helminth-derived antigens 
and C-type lectin receptors on inflammatory mast cells 
 
 
 
 A thesis submitted for the degree of Ph.D. 
by 
Krisztina Visnovitzné Vukman (M.Sc.) 
 
 
 
 
Supervisor: Dr Sandra M O’Neill 
School of Nursing and Human Sciences 
Dublin City University 
 
Submitted: 2013 
i 
 
Declaration 
 
 
 
 
 
I hereby certify that this material, which I now submit for assessment on the 
programme of study leading to the award of PhD is entirely my own work, and that I 
have exercised reasonable care to ensure that the work is original, and does not to 
the best of my knowledge breach any low of copyright, and has not been taken from 
the work of others save and to the extent that such work has been cited and 
acknowledged within the text of my work. 
 
Signed:                                                                                      . ID No: 58116729 
Date:                                                                               . 
 
  
ii 
 
Acknowledgement 
 
· First of all I want to thank my supervisor Dr Sandra O’Neill for her expert guidance 
and advice in all aspect during my PhD, especially her efforts to teach me how to 
write scientific papers. 
· I would like to thank everybody who worked with me in our research group Paul 
Adams, Allison Aldridge and Dr Alessandra Ravidà. They helped a lot during my 
experiments and we spent a great time together. I would also thank BRU for the 
technical assistance and help during the animal studies. I appreciate the efforts of the 
faculty and administrate staff at the School of Nursing and Human Sciences and 
School of Biotechnology whose backup support has made this work possible. 
· Many thanks for all my friends at DCU whose are not mentioned by name and all the 
members of T3 group especially Dr Christine Loscher and Dr Neil Lemon to their 
help during my PhD. Thanks a million to Dr Arman Rahman to teach me how to 
use the Facs machine. 
· Thanks Dr Phill Cummins and his lab for access to the qPCR machine and Keith 
Rochfort to teach me how to use the qPCR machine. 
· Thanks for Prof. Marcus Maurer and Dr Martin Metz and the members of their 
laboratory at Cherite Universitätmedizin Medicine Berlin for introducing me into the 
world of mast cells, I have spent an unforgettable time in their lab. 
· Enormous thank my husband, Dr Tamás Visnovitz for supporting me during my 
PhD. He helped me with his advices and critical review during my microscopic and 
qPCR studies. He was always with me when I was despondent and felt that I never 
will finish. 
iii 
 
· This work is funded under the Programme for Research in Third Level Institutions 
(PRTLI) Cycle 4. The PRTLI is co-funded through the European Regional 
Development Fund (ERDF), part of the European Union Structural Funds 
Programme 2007-2013. 
· …és végül de nem utolsó sorban köszönöm a támogatást családomnak akik végig 
mellettem álltak és elviselték, hogy Írországban éltem és doktoráltam. 
 
  
iv 
 
Table of Contents 
Declaration .................................................................................................................... i 
Acknowledgement........................................................................................................ ii 
Table of Contents ........................................................................................................ iv 
List of Figures ............................................................................................................ xii 
List of Tables............................................................................................................ xvii 
Abstract .................................................................................................................. xviii 
1 Chapter 1 – Introduction ...................................................................................... 1 
1.1 Characteristics of helminth infections ....................................................... 2 
1.2 Immunology of helminths ......................................................................... 6 
1.3 Receptors in helminth infection .............................................................. 10 
1.3.1 TLR signalling ................................................................................. 11 
1.3.2 Regulation of TLR signalling........................................................... 12 
1.3.3 C-type lectins ................................................................................... 15 
1.3.4 C-type lectin receptors in immune responses against helminths ..... 15 
1.3.5 C-type lectin receptors in immune responses against bacteria......... 18 
1.4 Fasciola hepatica .................................................................................... 18 
1.5 Antigens from Fasciola hepatica ............................................................ 22 
1.6 FhTeg ...................................................................................................... 24 
1.7 Mast cells................................................................................................. 28 
1.8 Mast cells in parasitic infections ............................................................. 28 
v 
 
1.8.1 C-type lectin receptors on mast cells ............................................... 29 
1.9 Mast cells in autoimmune diseases ......................................................... 30 
1.10 Mast cells in bacterial infections ............................................................. 30 
1.11 Mast cell - T-cell cross talk ..................................................................... 31 
1.12 Summary ................................................................................................. 33 
1.13 Aims of the project: ................................................................................. 34 
2 Chapter 2 – Material and Methods ..................................................................... 35 
2.1 Materials .................................................................................................. 35 
2.1.1 Reagents ........................................................................................... 35 
2.1.2 Equipment ........................................................................................ 39 
2.2 Methods ................................................................................................... 41 
2.2.1 Animals ............................................................................................ 41 
2.2.2 IL-3 preparation ............................................................................... 41 
2.2.3 FhTeg/FhES preparation .................................................................. 41 
2.2.4 Fasciola hepatica infection and treatment of mice with F. hepatica 
antigens 42 
2.2.5 Trypan blue and Kimura staining ..................................................... 43 
2.2.6 Passive Cutaneous and Systemic Anaphylaxis model ..................... 44 
2.2.7 Histological studies .......................................................................... 44 
2.2.8 Bone marrow-derived mast cells ...................................................... 46 
2.2.9 Peritoneum-derived cultured mast cells ........................................... 47 
vi 
 
2.2.10 Generation of bone marrow-derived dendritic cells (BMDC) ......... 48 
2.2.11 BMDC stimulation ........................................................................... 49 
2.2.12 BMMC and PCMC activation and measurement of cytokine 
secretion 50 
2.2.13 SOCS3 blocking experiments .......................................................... 51 
2.2.14 Measurement of β-hexosaminidase release from BMMCs and 
PCMCs 51 
2.2.15 Preparing serum samples for β-hexosaminidase assay .................... 53 
2.2.16 Proliferation...................................................................................... 53 
2.2.17 Chemotaxis assay ............................................................................. 53 
2.2.18 Flow cytometric analysis.................................................................. 54 
2.2.19 Co-culture of BMMCs or PCMCs with CD+ T-cells: ...................... 55 
2.2.20 Protein extraction ............................................................................. 56 
2.2.21 Sodium dodecyl sulphate polyacrylamide gel electrophoresis ........ 57 
2.2.22 Western blot analysis ....................................................................... 58 
2.2.23 RNA extraction and reverse-transcriptase polymerase chain reaction 
(RT-PCR) 59 
2.2.24 Quantitative RT-PCR analysis ......................................................... 62 
2.2.25 Isolation of Bordetella pertussis Lipooligosaccharide (LOS) ......... 64 
2.2.26 Statistics ........................................................................................... 65 
3 Chapter 3 – Fasciola hepatica tegumental antigens enhance mast cell numbers 
in vivo in a STAT6 independent manner.................................................................... 67 
vii 
 
3.1 Introduction ............................................................................................. 67 
3.2 Experimental design ................................................................................ 70 
3.3 Results ..................................................................................................... 72 
3.3.1 Mast cell numbers are significantly enhanced during F. hepatica 
infection and this is mimicked by intraperitoneal injection of FhTeg. .............. 72 
3.3.2 Mast cells treated with FhTeg do not degranulate and exhibit 
reduced FceRI expression but this does not alter IgE mediated activation of 
mast cells in vivo or in vitro. .............................................................................. 74 
3.3.3 FhTeg treated mast cells do not produce Th2 cytokines or promote a 
Th2 immune response in CD4+ cells. ................................................................. 76 
3.3.4 Enhancement of mast cell numbers in vivo is not dependent upon 
STAT6. 78 
3.3.5 Mast cells treated with FhTeg exhibit decreased expression of c-kit 
and this is associated with reduced cell proliferation in response to stem cell 
factor. 79 
3.3.6 Mast cell migration is induced by FhTeg stimulated dendritic cells 
but not mast cells. ............................................................................................... 81 
3.4 Discussion ............................................................................................... 84 
4 Chapter 4 - Fasciola hepatica tegumental coat antigens supress Th1 immune 
responses in mast cells ............................................................................................... 89 
4.1 Introduction ............................................................................................. 89 
4.2 Experimental design ................................................................................ 91 
4.3 Results ..................................................................................................... 93 
viii 
 
4.3.1 FhTeg inhibits TNF-α expression in mast cells in vivo. .................. 93 
4.3.2 FhTeg suppresses cytokine secretion from LPS or BP stimulated 
mast cells. 94 
4.3.3 Mast cells activation by BP and LPS is dependent upon STAT6, 
however this had no role to play in the suppressive effect of FhTeg. ................ 95 
4.3.4 CD4+ T-cells co-cultured with FhTeg treated mast cells secrete less 
IL-10, IFN-g and IL-5. ....................................................................................... 96 
4.3.5 ICAM1 is important in mast cell - T-cell communication and the 
expression of this receptor is suppressed by FhTeg. .......................................... 98 
4.3.6 FhTeg suppresses phospho-ERK and NF-kB p65 expression in BP 
and LPS stimulated mast cells.......................................................................... 100 
4.3.7 FhTeg suppressive effect is not specific to NF-kB p65 expression as 
it inhibits MAPK activation in dendritic cells.................................................. 102 
4.3.8 The primers for qPCR analysis of TLR4 signalling showed adequate 
specificity and efficiency in traditional and qPCR analysis............................. 104 
4.3.9 FhTeg up-regulates the transcription and expression SOCS3........ 106 
4.3.10 SOCS3 transcription and expression is up-regulated by FhTeg. ... 109 
4.3.11 SOCS3 transcription and expression is up-regulated in mast cells as 
well by FhTeg. ................................................................................................. 111 
4.3.12 FhTeg suppresses cytokine induced cell surface marker up-
regulation in dendritic cells. ............................................................................. 112 
4.4 Discussion ............................................................................................. 115 
ix 
 
5 Chapter 5 – C-type lectin receptors of mast cells are up-regulated by Fasciola 
hepatica infection, although blocking of these C-type lectins does not reverse the 
inhibitory effect of FhTeg ........................................................................................ 123 
5.1 Introduction ........................................................................................... 123 
5.2 Experimental design .............................................................................. 126 
5.3 Results ................................................................................................... 127 
5.3.1 Fasciola hepatica infection or its FhTeg up-regulates C-type lectin 
receptor expression on mast cells in vivo. ........................................................ 127 
5.3.2 FhTeg up-regulates C-type lectin receptor expression on dendritic 
cells and mast cells in vitro. ............................................................................. 129 
5.3.3 Blocking of MR and MGL does not reverse FhTeg’s inhibition of 
LPS activated dendritic cells and mast cells. ................................................... 130 
5.3.4 Blocking of MGL suppresses FhTeg induced SOCS3 expression in 
dendritic cells, although it does not reverse FhTeg’s inhibition of LPS activated 
dendritic cells. .................................................................................................. 134 
5.4 Discussion ............................................................................................. 136 
6 Chapter 6 - Mannose receptor and macrophage galactose lectin are involved in 
Bordetella pertussis mast cells interaction ............................................................... 140 
6.1 Introduction ........................................................................................... 140 
6.2 Experimental design .............................................................................. 144 
6.3 Results ................................................................................................... 146 
6.3.1 MR and MGL are expressed by PCMCs and BP stimulation has no 
effect on this expression. .................................................................................. 146 
x 
 
6.3.2 Anti-MR and anti-MGL blocking antibodies suppress BP-induced 
TNF-α, IL-6 and IFN-γ secretion in mast cells. ............................................... 147 
6.3.3 Anti-MR and anti-MGL blocking antibodies reverse T-cell 
activation by BP-primed mast cells.................................................................. 148 
6.3.4 Anti-MR and anti-MGL blocking antibodies do not suppress BP 
induced up-regulation of ICAM1. .................................................................... 150 
6.3.5 Glycans (mannan, GalNac and laminarin) and EGTA suppress BP 
induced TNF-α and IL-6 secretion. .................................................................. 151 
6.3.6 Syk inhibition supresses TNF-α and enhances IL-6 secretion by BP-
stimulated mast cells. ....................................................................................... 152 
6.3.7 Blocking of MR and MGL has no effect on BP induced ERK 
phosphorylation. ............................................................................................... 153 
6.3.8 Neutralisation of MR and MGL suppresses LOS induced cytokine 
secretion in mast cells ...................................................................................... 154 
6.4 Discussion ............................................................................................. 155 
7 Chapter 7 - Final discussion ............................................................................. 161 
7.1 Mast cells are new players in Fasciola hepatica immune modulation . 161 
7.2 The role of mast cells in tissue repair during helminth infection .......... 167 
7.3 Advances in mast cells’ crosstalk with other immune cells .................. 168 
7.4 Functional classification of mast cells .................................................. 169 
7.5 New role of C-type lectin receptors on mast cells in immunity against 
pathogens.............................................................................................................. 174 
7.5.1 CTLs, mast cells and Fasciola hepatica ........................................ 174 
xi 
 
7.5.2 CLRs on mast cells in Bordetella pertussis infection .................... 176 
7.6 Summary ............................................................................................... 177 
8 Literature .......................................................................................................... 178 
9 Appendix .......................................................................................................... 219 
9.1 Appendix A – Optimization of methods ............................................... 219 
9.1.1 TLR ligands .................................................................................... 219 
9.1.2 Validation of LPS and BP administration ...................................... 220 
9.2 Appendix B – Tim edependence of increase in mast cells ratio in the 
peritoneal cavity after FhTeg treatment ............................................................... 221 
9.3 Appendix C – Experiment to inhibit SOCS3 in BMDCs and BMMCs by 
zoledronic acid ..................................................................................................... 222 
9.4 Appendix D ........................................................................................... 224 
9.5 Appendix E ............................................................................................ 232 
9.6 Appendix F ............................................................................................ 240 
9.7 Appendix G ........................................................................................... 250 
9.8 Appendix H ........................................................................................... 256 
 
  
xii 
 
List of Figures 
Figure 1.1. Principles in TLR signalling. ................................................................... 13 
Figure 1.2. Life cycle of Fasciola hepatica. ............................................................... 19 
Figure 2.1. The purity of bone marrow-derived cultured mast cells is over 95% after 
4 weeks of cultivation. ............................................................................................... 47 
Figure 2.2. The purity of peritoneal-derived cultured mast cells is over 95% after 9 
days of cultivation. ..................................................................................................... 48 
Figure 2.3. Mast cells usually show 50% of degranulation when stimulated with 
A23187. ...................................................................................................................... 52 
Figure 2.4. Determination of real-time PCR efficiencies of reference gene (GAPDH).
 .................................................................................................................................... 63 
Figure 2.5. Silver stained SDS-PAGE. ...................................................................... 65 
Figure 3.1. Mast cell number increased in the peritoneal cavity and in the liver after 
Fasciola infection. Injection of FhTeg but not ES mimicked the effect of Fasciolosis.
 .................................................................................................................................... 73 
Figure 3.2. Mast cells treated with FhTeg do not degranulate and exhibit reduced 
FceRI expression. ....................................................................................................... 75 
Figure 3.3. FhTeg does not alter IgE mediated activation of mast cells in vivo or in 
vitro. ........................................................................................................................... 75 
Figure 3.4. FhTeg treated mast cells do not produce cytokines. ................................ 77 
Figure 3.5. Mast cells stimulated with FhTeg do not promote Th1 or Th2 immune 
responses when co-cultured with anti-CD3 stimulated naïve CD4+ T-cells. ............ 78 
Figure 3.6. Mast cell numbers are significantly enhanced during F. hepatica 
infection and after FhTeg injection in a STAT6 independent manner....................... 79 
xiii 
 
Figure 3.7. Mast cells treated with FhTeg does not proliferate and exhibit decreased 
expression of c-kit. ..................................................................................................... 80 
Figure 3.8. FhTeg suppresses SCF induced mast cell proliferation. .......................... 81 
Figure 3.9. Chemotaxis of mast cells is induced by FhTeg activated dendritic cells, 
but not by IL-4, FhTeg or FhTeg treated mast cells or macrophages. ....................... 82 
Figure 3.10. Chemotaxis of mast cells is induced by FhTeg activated dendritic cells 
or their supernatant. .................................................................................................... 82 
Figure 4.1. FhTeg inhibit TNF-a expression in mast cells in vivo............................. 93 
Figure 4.2. FhTeg suppressed cytokine expression in TLR4 stimulated BMMCs and 
PCMCs. ...................................................................................................................... 94 
Figure 4.3. Mast cells activation by BP and LPS was dependent upon STAT6, 
however this had no role to play in the suppressive of FhTeg. .................................. 95 
Figure 4.4. FhTeg suppressed the activation of T-cells by LPS or BP stimulated mast 
cells. ........................................................................................................................... 97 
Figure 4.5. BMMCs express low levels of TLR4, CD28, OX40L and CD40L but 
high level of ICAM1. ................................................................................................. 98 
Figure 4.6. FhTeg suppress the up-regulation of ICAM1 expression on LPS/BP 
stimulated mast cells. ................................................................................................. 99 
Figure 4.7. Effect of FhTeg on TLR stimulated mast cells can be mimicked by anti-
ICAM1 antibody when mast cells are co-cultured with anti-CD3 stimulated naïve 
CD4+ cells. ................................................................................................................. 99 
Figure 4.8. BP and LPS stimulated ERK and NF-kB expression in BMMCs and 
PCMCs was suppressed by FhTeg. .......................................................................... 101 
Figure 4.9. FhTeg suppressed the phosphorylation of ERK, p38 and JNK in LPS 
stimulated dendritic cells.......................................................................................... 103 
xiv 
 
Figure 4.10. Determination of real-time PCR specificity and efficiencies of reference 
and target genes. ....................................................................................................... 105 
Figure 4.11. Time dependence of the expression of 8 target genes. ........................ 108 
Figure 4.12. SOCS3 up-regulation was confirmed on protein level. ....................... 109 
Figure 4.13. Pattern of SOCS3 expression was similar on RNA and protein level. 110 
Figure 4.14. SOCS3 transcription and expression was up-regulated by FhTeg in mast 
cells. ......................................................................................................................... 112 
Figure 4.15. FhTeg suppressed cytokine induced cell surface marker up-regulation in 
dendritic cells. .......................................................................................................... 114 
Figure 5.1. MGL and MR but not Dectin1 or SignR1 are up-regulated on peritoneal 
mast cells during Fasciola hepatica infection. ........................................................ 128 
Figure 5.2. MGL but not MR was up-regulated on peritoneal mast cells after FhTeg 
injection. ................................................................................................................... 129 
Figure 5.3. MGL and MR were up-regulated by FhTeg in vitro. ............................ 130 
Figure 5.4 Blocking of CLRs did not reverse the effect of FhTeg on BMDC 
activation. ................................................................................................................. 131 
Figure 5.5. Blocking of MR or MGL did not reverse the effect of FhTeg on BMMC 
activation. ................................................................................................................. 132 
Figure 5.6. Blocking of MR or MGL did not reverse the effect of FhTeg on T-cell 
activation. ................................................................................................................. 133 
Figure 5.7. Blocking of MGL but not MR inhibit FhTeg induced SOCS3 
transcription.............................................................................................................. 134 
Figure 6.1. MR and MGL are expressed by mast cells. Cell surface expression of 
MR (B) and MGL (C) were measured by three colour (FcεRI, c-kit and CLR) flow 
xv 
 
cytometry on PCMCs. On histogram (A) isotype control is indicated with grey, MR 
and MGL are indicated with normal and dashed lines, respectively. ...................... 146 
Figure 6.2. BP stimulation has no effect on MR and MGL expression. .................. 147 
Figure 6.3. Blocking of MR and MGL suppressed BP induced cytokine secretion in 
mast cells. ................................................................................................................. 148 
Figure 6.4. Anti-MR and anti-MGL blocking antibodies interfere with BP-induced 
T-cell activation by PCMCs. .................................................................................... 149 
Figure 6.5. Anti-MR and anti-MGL blocking antibodies did not suppress BP induced 
up-regulation of ICAM1. ......................................................................................... 150 
Figure 6.6. Carbohydrate treatment impaired BP induced cytokine secretion in mast 
cells. ......................................................................................................................... 151 
Figure 6.7. Inhibition of Syk suppressed BP-induced TNF-a secretion and enhances 
IL-6 secretion in mast cells. ..................................................................................... 152 
Figure 6.8. Neutralisation of MR and MGL did not interfere with BP induced ERK 
phosphorylation. ....................................................................................................... 153 
Figure 6.9. Neutralisation of MR and MGL suppressed LOS induced cytokine 
secretion in mast cells. ............................................................................................. 154 
Figure 7.1. Possible mechanism how FhTeg suppress LPS/BP induced cytokine 
secretion in mast cells. ............................................................................................. 163 
Figure 7.1. FhTeg directly modulates dendritic cells and mast cells by inhibiting 
their ability to drive Th1 immune responses ............................................................ 165 
Figure 7.3. Suggested functional classification of mast cells .................................. 173 
Figure 9.1. LPS and BP stimulated mast cells produced TNF-a and IL-6 but no β-
hexosaminidase. ....................................................................................................... 219 
Figure 9.2. Concentration and time dependence of LPS and BP treatment. ............ 220 
xvi 
 
Figure 9.3. Mast cell ratio increased in the peritoneal cavity of mice after FhTeg but 
not FhES treatment ................................................................................................... 221 
Figure 9.4. Zoledronic acid (ZA) impaired dendritic cell and mast cell function to 
secret cytokines after bacterial stimulation. ............................................................. 223 
 
  
xvii 
 
List of Tables 
Table 1.1. Some inhibitors of TLR4 signalling pathways ......................................... 14 
Table 1.2. C-type lectins, their ligands and function important in helminth infection 
(Modified table from Geijtenbeek and Gringhuis, 2009)........................................... 17 
Table 1.3. Major secreted molecules of Fasciola hepatica (Robinson et al., 2012a) . 23 
Table 2.1. Kimura staining ......................................................................................... 44 
Table 2.2. Sample preparation for histological studies and dyes ............................... 45 
Table 2.3. Contents of media used in cell culture ...................................................... 49 
Table 2.4. Components of buffers for β-Hexosaminidase assay ................................ 52 
Table 2.5. Contents of Facs buffer ............................................................................. 54 
Table 2.6. Antibodies used in flow cytometry ........................................................... 55 
Table 2.7. Different variations of media used in co-culture studies .......................... 56 
Table 2.8. RIPA buffer ............................................................................................... 56 
Table 2.9. Gel for SDS-PAGE ................................................................................... 57 
Table 2.10. Contents of solutions for SDS PAGE ..................................................... 57 
Table 2.11. Components of buffers for western blot ................................................. 58 
Table 2.12. Western blot staining protocol ................................................................ 58 
Table 2.13. Antibodies and their concentration ......................................................... 59 
Table 2.14. Primers .................................................................................................... 61 
Table 2.15. Conventional PCR reaction ..................................................................... 62 
Table 2.16. Working solution for q-PCR ................................................................... 62 
Table 7.1 Effect of F. hepatica infection or FhTeg treatment on CLR expression of 
immune cells in vitro and in vivo ............................................................................. 175 
Table 8.1. List of stimulants, concentration and the type of TLR they bind to ....... 219 
 
xviii 
 
Krisztina V. Vukman: The immunomodulatory properties of helminth-derived 
antigens on inflammatory mast cells 
 
Abstract 
Mast cells are normally associated with T-helper (Th)2 driven IgE mediated immune 
responses in helminths infection, however it was recently shown that they have an 
important role to play in promoting Th1 immunity during infectious and non-
infectious diseases. Fasciola hepatica, a parasitic worm of humans and domestic 
animals, induces strong Th2/T-regulatory immune responses during infection while 
simultaneously suppressing Th1 immune responses that are associated with 
immunity. The Th1 suppressive properties of helminths can leave the host more 
susceptible to bystander bacterial and viral infections while protecting the host from 
developing Th1 mediated autoimmune diseases. It was previously shown that 
Fasciola tegumental antigen (FhTeg) directly targets dendritic cells impairing their 
ability to drive Th1 inflammatory responses. Here we show that F. hepatica infection 
and FhTeg enhance mast cell numbers in vivo in a STAT6 independent manner. The 
increased mast cell number is not the result of FhTeg induced proliferation; rather 
FhTeg indirectly induces mast cell migration by dendritic cell derived chemokines. 
FhTeg-activated mast cells do not produce Th2 cytokines, drive Th2 immune 
responses or inhibit IgE degranulation of mast cells. Instead FhTeg inhibits mast 
cells ability to drive Th1 immunity suppressing pro-inflammatory cytokines and 
ICAM1 expression in mast cells. FhTeg suppresses the activation of transcription 
factors in the TLR signalling pathway through the up-regulation of SOCS3 
inhibitory molecule which explains its suppressive effect. This study also 
demonstrated for the first time that the C-type lectin receptors, mannose receptor and 
macrophage galactose lectin, are expressed by mast cells and that they have an 
important role to play in the induction of SOCS3 by FhTeg and the promotion of 
mast cells inflammatory responses during Bordetella pertussis infection. This study 
advances our knowledge on mast cell biology, in particular the identification of 
potential targets on pathogenic mast cells. 
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1 Chapter 1 – Introduction 
Helminths are parasitic worms that cause a wide variety of infectious disease in 
animals and humans (McSorley and Maizels, 2012).  Helminths and the products 
they release exert strong anti-inflammatory T-helper (Th) 2/T regulatory (Treg) 
immune responses. Th2 immune response is important in allergy, against toxins and 
extracellular pathogens, such as helminths. It is characterised by increased number 
and activity of eosinophils (eosinophilia) and mast cells (mastocitosys) and high 
level of immunoglobulin (Ig)E (Anthony et al., 2007; Maizels and Yazdanbakhsh, 
2003). Parasitic worm infection is usually associated with a suppressive regulatory 
T-cells population that can switch off inflammatory and protective immune 
responses leading to increased worm survival (Anthony et al., 2007; Maizels et al., 
2004; Maizels and Yazdanbakhsh, 2003). 
 
Helminth infection also effects the incidence and progression of other diseases by 
suppressing protective pro-inflammatory (Th1) immune response to bystander 
bacterial, viral and protozoan infections, making individuals more susceptible to 
malaria (Nacher, 2011), HIV (Carod-Artal, 2008) and tuberculosis (Resende Co et 
al., 2007). In human populations helminths are also thought to prevent the initiation 
of inflammatory disorders like arthritis, multiple sclerosis and Crohn’s disease (Song 
et al., 2011). To this end we wish to understand the immune modulatory properties 
of helminths in order to understand host-pathogen interactions and to identify novel 
therapeutic targets to treat inflammatory conditions. 
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Studies examining the bystander effects of Fasciola hepatica (liver fluke) infection 
have predominantly examined the role of dendritic cells (Hamilton et al., 2009) and 
macrophages (Donnelly et al., 2009). However, recent studies have shown that mast 
cells have a critical role in the protection against microbes like Bordetella pertussis 
or Escherichia coli (Mielcarek et al., 2001; Wierzbicki and Brzezinska-Blaszczyk, 
2009). Mast cells were also shown to be involved in inflammatory disorders such as 
arthritis, multiple sclerosis and Crohn’s disease (De Winter et al., 2011; Theoharides 
and Kalogeromitros, 2006), as they are key players of the initiation and maintenance 
of the inflammation associated with these diseases. As helminth infection is thought 
to prevent the development of these diseases it is also important to study the 
immunomodulatory effect of F. hepatica and their products on mast cells. 
 
1.1 Characteristics of helminth infections 
The word helminth is originated from the Greek “helminqs”, which means worm. 
This term is used to describe various types of parasitic worms that cause a wide 
variety of infectious disease in animals and humans. Around third of world’s 
population (~3 billion people) are infected with helminths (Anthony et al., 2007). 
Helminths are responsible for many diseases in wild and domestic animals and cause 
significant economic losses. Helminth infection of cattle and sheep causes reduced 
grow-rates, weight loss, reproductive loss, and also can affect lactation (Bamaiyi, 
2012; Tisdell et al., 1999). Estimating the global economic impact of helminth 
infection is difficult, but for example in South America the loss in swine production 
because of porcine cysticercosis is about the half of the national investment and is 
responsible for a loss of more than $160 million every year (Murrell, 1991). Parasitic 
worms also can make sheep or cattle more susceptible to other bacterial or viral 
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infections like Salmonella dublin, or Mycobacterium tuberculosis (Aitken et al., 
1979; Barger, 1993), as they suppress protective immune responses normally 
controlling these infection. Liver fluke infection also has negative effect on the 
diagnosis of tuberculosis (Mycobacterium bovis) in cattle resulting in false negative 
results (Claridge et al., 2012). 
 
Although helminth infections are generally non-fatal in humans; they are associated 
with high rates of morbidity and chronic inflammation (Anthony et al., 2007). We 
can get more accurate picture of disease burden by estimating the disability-adjusted 
life year (DALY) lost due to helminth infection (WHO, 2012); the estimates of 
DALYs for soil transmitted helminth infections (Ascaris lumbricoides, Trichuris 
trichiura, Necator americanus, etc.) is between 4.7 and 39 million (Bethony et al., 
2006; Uneke, 2010) and for food-borne trematoidiases (Opisthorchis viverrini, 
Fasciola hepatica, Clonorchis sinensis, etc.) is 0.5-0.9 million (WHO, 2012). 
Gastrointestinal worm infection can cause vomiting, insomnia, weakness, stomach 
pains (Wang et al., 2008). In children heavy infections can result in growth 
retardation, apathy and learning difficulties (Levinger, 1992; Oberhelman et al., 
1998). In some rare cases blood helminths can cause granulomatous disease, which 
can lead to organ failure. Worms in the bile ducts can cause inflammation and 
oedema resulting in the atrophy of the liver parenchyma (Grimaud, 1987). 
 
Helminth infections generally do not cause severe disease relative to number of 
people infected; however, the suppression of the immune responses can make 
bystander bacterial, viral or other helminth infections more severe (Maizels and 
Yazdanbakhsh, 2003). Women with urinary or genital schistomiasis have an 
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increased risk of HIV (Carod-Artal, 2008; Ndhlovu et al., 2007), although the effect 
of schistosoma infection on HIV has not been studied. Patients with Mycobacterium 
tuberculosis infection developed more severe radiological pulmonary disease when 
co-infected with intestinal helminths (Resende Co et al., 2007).  Helminth infection 
can also be responsible for decreased effectiveness of vaccination such as tetanus 
and diphtheria in humans (Nookala et al., 2004). 
 
Studies in mouse model system showed that the number of Tuberculosis bacteria 
was higher in the lungs of mice infected with Nippostrongylus brasiliensis compared 
to the control group (Potian et al., 2011). Malaria parasitemias was significantly 
lower in mice infected with Plasmodium chabaudi only compared to mice with 
Schistosoma mansoni co-infection (Helmby et al., 1998) although in children 
Schistosoma hamatobium infection can be protective against malaria (Plasmodium 
falciparium) (Briand et al., 2005; Lyke et al., 2006; Lyke et al., 2005). 
 
Despite its morbidity worm infections have beneficial effects on the host suffering 
from diseases including allergy, which are linked to overactive immune system 
(Carvalho et al., 2006; Harnett and Harnett, 2008; Liu et al., 2009). There are 
increasing evidences that the lack of exposure to parasitic worms is responsible for 
the prevalence of certain diseases in developed countries where helminth infection is 
not widespread (“hygiene hypothesis”). Inflammatory disorders caused by infections 
can be less severe with helminth co-infection (Wilson and Maizels, 2004). The 
presence of helminth infection affects the likelihood of the development of Th1 
mediated immune disorders, like autoimmune disease, such as ulcerative colitis, 
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inflammatory bowel disease (IBD) or Crohn’s disease (Carvalho et al., 2006; 
MacDonald et al., 2002; Reddy and Fried, 2009). 
 
There are well defined animal model systems to study autoimmunity. Studies with 
helminths such as Schistosoma mansoni showed that parasitic worm infections can 
reduce incidence of autoimmune diseases by 50% (Wilson and Maizels, 2004) in 
mice. Gastrointestinal nematodes can suppress innate and adaptive pro-inflammatory 
immune responses and may be capable of suppressing unrelated inflammation in 
disorders such as IBD (Whelan et al., 2011). A tapeworm, Hymenolepsis diminuta 
was shown to have beneficial effect in a murine model of oxazolone-induced colitis 
(Reddy and Fried, 2009).  In mice Trichinella spiralis infection was shown to be 
protective against colitis following intrarectal challenge with dinitrobenzene sulphate 
(Ruyssers et al., 2008). 
 
There is increasing interest of parasitic worms as therapeutic agents (“helminthic 
therapy”). Within the past few years parasitic worms have been used in clinical trials 
against allergy, IBD, Crohn’s disease, rheumatoid arthritis or multiple sclerosis 
(Harnett and Harnett, 2008; Reddy and Fried, 2009; Ruyssers et al., 2008), however, 
there are only a few successful examples from human trials. For example, 
experimental hookworm infection in patients with allergic asthma did not improve 
bronchial responsiveness (Feary et al., 2009). While treatment with the porcine 
whipworm, Trichuris suis had beneficial effects on patients with Crohn’s disease or 
ulcerative colitis in clinical trials (Ruyssers et al., 2008). This worm seems to be a 
good candidate in IBD treatment, as it persists for limited period in the human host. 
However, treating patients with living helminths can have unpredicted pathological 
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effects like invasion into other tissues and development of serious diseases. 
Consideration must also be given that helminth therapy cannot be used in some 
patient groups such as children, elderly people, immunocompromised individuals or 
pregnant women (Johnston et al., 2009). 
 
Identification and characterisation of helminth-derived molecules could lead to new 
therapeutic approaches. Studies in different animal models investigated broad 
spectrums of immunomodulatory products of parasitic worms, for example, 
excretory-secretory products (ES) of Nippostrongylus brasiliensis was shown to 
prevent the development of asthma and Ascaris suum extracts (PAS1 and APAS3) 
inhibit lung inflammation in a mouse model for allergy (Harnett and Harnett, 2008). 
Brugia malay antigens can mimic mammalian anti-inflammatory cytokines, like the 
transforming growth factor (TGF)-b and may be used in chronic inflammatory 
diseases (Ruyssers et al., 2008). Dirofilaria immitis derived antigen was shown to 
prevent autoimmune diabetes (Imai et al., 2001) in mice. Using parasite antigens or 
synthetic analogues allows developing specific and more effective drugs to cure 
inflammatory disorders. Understanding how helminth antigens interact with host 
immunity will help us to identify immune modulatory products. 
 
1.2 Immunology of helminths 
Helminth infections are usually associated with polarized Th2/Treg immune 
responses (Anthony et al., 2007; Maizels and Yazdanbakhsh, 2003; Mulcahy et al., 
2004). The protective immune response against helminths has been referred as Th2 
immune response (Anthony et al., 2007) and is characterised by increased level of 
Th2 cytokines, IgE, eosinophilia and mastocytosis (Seidl et al., 2011; Svensson et 
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al., 2010). The major sources of Th2 cytokines (interleukin (IL)-4, IL-5, IL-9 and IL-
13) are CD4+ T-lymphocytes; these lymphocytes are involved in killing parasites and 
perpetuating immune responses. Innate immune cells (mast cells, granulocytes, 
macrophages and dendritic cells) are important in priming the adaptive immune 
response and also in the effector phase in the defence against helminth infection 
(Flynn et al., 2010). 
 
Mast cells and granulocytes (eosinophils, basophils and neutrophils) can react 
directly to the presence of helminths, but mainly became activated after the Th2 
immune response developed. Cytokines secreted by CD4
+
 T-cells direct B-cells to 
produce helminth specific IgE (Anthony et al., 2007; Erb, 2007). Mast cells and 
basophils express the high affinity FcεRI receptor, which in the presence of helminth 
antigens and the specific IgE antibody induce cell degranulation and the release of 
inflammatory mediators such as histamine, cytokines or chemokines. These 
mediators can promote Th2 immune responses (Melendez et al., 2007; Pearce, 2007) 
For example, Heligmosomoides polygyrus infection results in mast cell activation 
and induces tissue derived IL-25, IL-33 and TSLP cytokines (Hepworth et al., 
2012a), which drive Th2 cell priming by dendritic cells (Hepworth et al., 2012b). 
 
During helminth infection the number of eosinophils and basophils increases in the 
blood and they migrate to the site of infection. Eosinophils degranulate and release 
secondary granule proteins (ESGP) and may be involved in tissue remodelling and 
wound healing (Lee and Lee, 2005). With basophils, eosinophils also contribute to 
the secretion of IL-4 and IL-13 in the early stages of infection (Anthony et al., 2007). 
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Eosonophils also can act as antigen presenting cells (APC) to T-cells (Padigel et al., 
2006). 
 
Although Th2 immune responses are usually associated with eosonophils and mast 
cells, the number of alternatively activated macrophages (M2) also increases during 
Th2 type response against helminth parasites (Allen and Maizels, 2011). They 
express high level of arginase1 and IL-4 receptor but no iNOS (inducible isoform of 
nitric oxide synthase, usually associated with classically activated macrophages, M1) 
and important in regulation of the immune response, wound healing and resistance 
against helminth invasion (Anthony et al., 2007; Flynn et al., 2007). 
 
Dendritic cells are orchestrated to Th2/Treg immune responses during worm 
infection and their pro-inflammatory function is down-regulated (Anthony et al., 
2007; Jackson et al., 2009). They are important antigen representing cells and are 
involved in CD4
+
 T-cell activation and regulation (Mulcahy et al., 2004). They can 
interpret helminth signals to T-cells and induce Th2 responses. For example Th2 
immune responses can be induced by exposing dendritic cells to helminth products 
and inject them into recipients (Balic et al., 2004). Helminths and their products were 
also shown to inhibit dendritic cell maturation by bacterial ligands (Carvalho et al., 
2009; Kane et al., 2004). 
 
Interaction of helminths with the host immune system is the result of a co-evolution. 
As a part of the adaptation to a parasitic life, helminths had to develop a strategy to 
deal with the host’s immune system (MacDonald et al., 2002). The intension of the 
host is to clear the parasite and reduce its harmful effects and the helminth wants to 
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be invisible to the immune system and live in the host as long as possible without 
killing it (Allen and Maizels, 2011). There are various mechanisms for helminth 
immunomodulation resulting in down-regulation of pro-inflammatory Th1 immune 
responses, like intense stimulation of Th2/Treg immune responses, secretion of anti-
effector molecules, inhibition of effector cells or complement components and 
inhibition of immune cell proliferation (Allen and Maizels, 2011; Mulcahy et al., 
2004).  
 
Helminth infection is usually associated with the presence of a parasite-specific 
suppressive T-cell population in a regulated environment (Maizels and 
Yazdanbakhsh, 2003). These regulatory T-cells (Treg) secrete regulatory cytokines, 
IL-10 and TGF-b and can switch off inflammatory and protective immune responses 
(Flynn and Mulcahy, 2008; Maizels et al., 2004). This immunosuppression can lead 
to increased worm survival (Anthony et al., 2007) and also important in the 
suppression of potentially pathogenic immune responses. For example the mortality 
of IL-10 knockout mice are higher during Trichinella muris (Schopf et al., 2002) or 
Schistosoma mansoni (Wynn et al., 1998) infection compared to wild type mice with 
intact Treg immune responses. Dendritic cells and macrophages also play role in 
regulatory immune responses. As antigen presenting cells they are important in the 
polarisation of T-cells, and alternatively activated macrophages (M2) can prevent T-
cell proliferation and Th2 differentiation (Maizels and Yazdanbakhsh, 2003). 
 
Th1 immune responses are characterised by the secretion of interferon (IFN)-g and 
associated with Th1 CD4+ T-cells, cytotoxic CD8+ T-cells, neutrophils and 
classically activated macrophages (M1). This type of immune response is typically 
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evoked by microbial infections including viruses and bacteria. Unrestricted Th1 
immune response is harmful for the helminth and can cause pathology in the host as 
well, and it is down-regulated by helminth parasites (Anthony et al., 2007). In some 
cases host can develop Th1 immune responses against parasites, such as Schistosoma 
mansoni, which provoke Th1 associated pro-inflammatory cytokine secretion in the 
early larval stages of infection and induce Th2 immune response latter when the 
parasite starts to produce eggs (Stadecker et al., 2004). 
 
1.3 Receptors in helminth infection 
Pathogens share similar conserved structures known as pathogen-associated 
molecular patterns (PAMP). Immune cells express many pattern recognition 
receptors (PRR), which enable them to recognise PAMPs. PRRs include TLRs, 
intracellular nucleotide-binding domain and leucine-rich-repeat-containing family 
(NLR), retinoic acid-inducible gene I (RIG-I)-like receptors and c-type lectin 
receptors (CLR) (Geijtenbeek and Gringhuis, 2009). The complexity and crosstalk 
between the different PRR pathways allows cells to recognised wide range of 
pathogens and their ligands. 
 
Helminth parasites can elicit immune response through TLRs (Venugopal et al., 
2009). Schistosome mansoni was shown to activate dendritic cells through TLR2 and 
TLR3 (Ludwig-Portugall and Layland, 2012; Semnani et al., 2008), although its egg 
antigen act independently of these receptors (Kane et al., 2008). Brigia malayi alter 
the expression of TLR3 TLR5 and TLR7 on innate immune cells (Venugopal et al., 
2009).  TLR2 and TLR4 was shown to contribute to host immune response during 
Schistosoma japonicum infection (Zhang et al., 2011) 
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1.3.1 TLR signalling 
TLR4 can be activated by gram negative bacterial ligand such as LPS and Bordetella 
pertussis (Lu et al., 2008; Mann et al., 2005; Wolfe et al., 2009). Upon activation 
with the contribution of the CD14 co-stimulatory molecule TLR4 undergoes 
oligomerization. The downstream signalling pathway divides into two distinct 
pathways, the MyD88 independent and dependent pathway (Figure 1.1). Based on 
studies using MyD88 macrophages it is known that MyD88-dependent pathway 
mediates pro-inflammatory cytokine expression, while MyD88-independent pathway 
is responsible for the production of Type I interferon (Lu et al., 2008).  The Myd88-
independent pathway involve the activation of three molecules: TIR-domain-
containing adapter-inducing interferon-β (TRIF) and two IKK-related  kinases, 
TRAF family member-associated NF-kB activator (TANK)-binding kinase (TBK1) 
and IKKe (IkB kinase-e), and terminated in the phosphorylation and translocation of 
interferon regulatory factor (IRF) 3 (Mogensen, 2009) and the late-phase activation 
of NF-kB and mitogen-activated protein kinases (MAPK) (Lu et al., 2008). Studies 
on bone marrow mast cells reported the absence of the activation MyD88-
independent pathway after LPS stimulation (Keck et al., 2011), which may be due to 
the low expression of cell surface CD14 (Sandig and Bulfone-Paus, 2012). 
 
The MyD88-dependent signalling is activated by all TLRs except TLR3 (Takeda and 
Akira, 2004). Upon activation MyD88 associates with the cytoplasmic part of the 
TLR and recruits members of the IL-1-receptor-associated kinase (IRAK) family. 
IRAK4 and IRAK1/2 undergo phosphorylation and IRAK1 associates with an 
ubiquitin protein ligase, TRAF6 (TNF receptor associated factor 6), that leads to the 
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activation of a transforming growth factor-activated protein kinase, TAK1. TAK1 
then stimulates two distinct pathways IKK involving NF-kB and the MAPK pathway 
(Mogensen, 2009). IKKα, IKKb and IKKg form a complex to phosphorylate IkB 
proteins. IkB degrades which leads to the subsequent translocation of NF-kB. 
MAPK pathways activation resulted in the induction of another transcription factor, 
AP-1 through the phosphorylation of ERK (extracellular signal-regulated kinase), 
JNK (c-JUN N-terminal kinase) and p38 (Guha and Mackman, 2001). Activation of 
both transcription factors induces the expression of pro-inflammatory cytokines and 
other inflammation related gens. In addition to NF-kB and MAPK, IkBz and IRF5 
are two important factors downstream of MyD88 and could be activated through 
unknown mechanism (Lu et al., 2008). 
 
1.3.2 Regulation of TLR signalling 
Proper immune responses are crucial in the clearance of pathogen infection, although 
extensive or inappropriate inflammation may be harmful and result in 
immunopathology or autoimmunity (Lu et al., 2008). The innate immune system 
needs to be able to control and down-regulate the signalling after the infection has 
been resolved. So the pathogen induced signalling pathways such as TLR4 signalling 
is highly regulated. The innate immune system has numerous molecules involved in 
these regulatory processes and TLR4 signalling can be regulated in multiple levels 
(Lu et al., 2008; Mogensen, 2009). Some of the most important inhibitory molecules 
of TLR4 signalling pathway are listed in Table 1.3. 
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Figure 1.1. Principles in TLR signalling. TLR4 activates both the MyD88-dependent and MyD88-
independent, TRIF-dependent pathways. The MyD88-dependent pathway is responsible for early-
phase NF-κB and MAPK activation, which control the induction of pro-inflammatory cytokines. The 
MyD88-independent, TRIF-dependent pathway activates IRF3, which is required for the induction of 
IFN-β- and IFN-inducible genes. In addition, this pathway mediates late-phase NF-κB as well as 
MAPK activation, also contributing to inflammatory responses (Mogensen, 2009). ASM authorizes an 
advanced degree candidate to republish the requested material in his/her doctoral thesis or 
dissertation. 
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Table 1.1. Some inhibitors of TLR4 signalling pathways 
Inhibitor Function Ref 
SARM Inhibition of TRIF dependent signalling. The mechanism is unknown 1 
CYLD Denaturation of TRAF6 2 
TRIM30a Degradation of TAB2/3 (required for TAK1 activation) 3, 4 
IkB Auto-regulation of NF-kB 4 
RP105 Associates with MD/2 homologue MD/1 and inhibits the association 
between LPS and TLR4/MD-2 
5,6 
ST2, ST2L, 
IL1R1 
Homologue of IL-1 receptor. Interacts with MyD88 and TIRAP and 
inhibits their function by sequestration 
6, 7 
SIGIRR Inhibit TLR4 interaction with MyD88 8 
TRIAD3A E3 ubiquitin protein ligase. Interacts with TIR domain (TIRAP, TRIF, 
RIP1) what leads to the degradation of these proteins 
6, 9 
SOCS E3 ubiquitin protein ligase. Ubiquitination of TIRAP1. Inhibit 
Jak/STAT signalling pathway as well 
6, 10 
IRAK/M Belongs to IRAK family but without kinase activity. Prevents 
dissociation of IRAKs from MyD88 
4, 11 
IRAK2C Variant of IRAK-2, but without functional domain 4 
MyD88s Variant of MyD88. Binds to IRAK4 and inhibit IRAK1/2 
phosphorylation 
4 
TRAF1 
TRAF4 
Belong to TRAF family. After caspase cleavage, interact with TRIF 
and TRAF6 
6 
 
A20 De-ubiquitinating enzyme. Removes ubiquitin moieties from TRAF6 6 
Ref: 1(Peng et al., 2010); 2(Into et al., 2008); 3(Shi et al., 2008); 4(Mogensen, 2009); 5(Divanovic et 
al., 2007); 6(Lu et al., 2008); 7(Brint et al., 2004); 8(Gong et al., 2010); 9(Chuang and Ulevitch, 2004); 
10(Yoshimura et al., 2012); 11(Takeda and Akira, 2004) 
 
SOCS (suppressor of cytokine signalling) molecule family is one the main inhibitory 
groups that plays important role in auto-regulation of pathogen induced 
inflammatory responses (Yoshimura et al., 2012). SOCS was first described to 
interfere with the cytokine induced Jak/STAT pathway, and now it is known that it is 
inducible by both cytokines and TLR signals resulted in down-regulation of TRAF6 
activation and inhibition of both JAK/STAT and TLR pathways. The mechanism of 
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SOCS action is not clearly defined yet. It could be both a paracrine effect IFN-b or 
direct inhibition of the TLR pathway (Mogensen, 2009). 
 
1.3.3 C-type lectins 
CLRs as an important member of the PRR family are involved in the specific 
induction of gene expression in response to pathogens. They can modulate TLR 
signalling or can directly induce gene expression. CLRs are expressed by most cell 
types including macrophages and dendritic cell (Geijtenbeek and Gringhuis, 2009). 
They have conserved carbohydrate-recognition domains (CRD) and they can bind 
carbohydrates in a calcium dependent manner. The CRD is a compact structural 
module which determines the specificity of the receptor. 
 
1.3.4 C-type lectin receptors in immune responses against helminths 
Helminths express glycans, glycoproteins and glycolipids on their surfaces and on 
their excretory/secretory products (van Die and Cummings, 2009). Most antibodies 
isolated from Schistosoma infected murine host’s serum recognised carbohydrate 
epitopes (Levis
x
-containing structure) (Thomas and Harn, 2004). The glycans from 
helminths can be host-like glycans and pathogen-associated glycans (van Die and 
Cummings, 2009). There is increasing number of evidences that these glycans have 
key role in the induction of Th2-type (van Die and Cummings, 2006) and anti-
inflammatory immune responses (Harn et al., 2009; Thomas and Harn, 2004; van 
Die and Cummings, 2010).  
 
Glycans from helminth parasites were shown to be important in the induction of 
alternatively activated M2 macrophages and in dendritic cell’s maturation and 
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activation (Thomas and Harn, 2004). Dendritic cell function can be modulated by 
carbohydrates from S. mansoni and its soluble egg antigen. These glycans were 
shown to bind to CLRs like DC-SIGN (homologue in mouse: SignR1), mannose 
receptor (MR) and macrophage galactose lectin (MGL), which can contribute to the 
suppression of LPS induced activation (Kuijk et al., 2012; Kuijk and van Die, 2010; 
van Liempt et al., 2006; van Liempt et al., 2007). Although most of the studies are 
investigating the carbohydrates from Schistosoma species (Klabunde et al., 2000; 
Paveley et al., 2011; Thomas and Harn, 2004; van Vliet et al., 2005) information is 
available about other parasites, like Ascaris suum, Trichuris suis (Kuijk et al., 2012) 
or F. hepatica (Guasconi et al., 2011) and their immunomodulatory properties by 
their glycans (Table 1.2). 
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Table 1.2. C-type lectins, their ligands and function important in helminth 
infection (Modified table from Geijtenbeek and Gringhuis, 2009) 
CLR Glycan 
PAMPs 
Expression Helminths Function Ref 
DC-SIGN 
(CD209, 
mouse: 
SignR1) 
high 
mannose 
and 
fucose 
(Lex, Ley, 
LeA, LeB) 
Mieloid DCs D. viviparous, 
S. Japonicum, 
S. mansoni,  
↑ TLR-induced IL-10 
production; 
↑ Th1, Th2, Th17 and 
Treg T-cell 
differentiation; 
↓ Th1 cell 
differentiation; 
↑ Treg T-cells; 
antigen presentation 
1, 2, 
3, 4 
MGL 
(CLEC10A, 
CD301) 
Terminal 
GlcNAc 
Myeloid DCs 
and 
macrophages 
T. spiralis 
S. japonicum 
S. mansoni 
T. canis 
F. hepatica 
E. granulosus 
M. vogae 
↓ TLR induced DC 
activation 
1, 3, 
4, 5 
Dectin 1 
(CLEC7A) 
b-1.3-
glucan 
Myeloid DCs, 
monocytes, 
macrophages, 
B cells 
S. mansoni ↑ Th1 and Th17 cell 
differentiation; 
↑ TNF-α and CXCL2 
production, 
phagocytosis 
1, 3, 
6  
MR 
(CD206) 
high 
mannose, 
fucose 
and 
sulphated 
sugars 
(sLex) 
Myeloid DCs 
and 
macrophages 
T. spiralis 
A. suum 
A. vitae 
S mansoni 
F. hepatica 
Phagocytosis and 
antigen presentation 
1, 3, 
4, 7 
Ref: 1(Geijtenbeek and Gringhuis, 2009); 2(Saunders et al., 2010); 3(van Liempt et al., 2007); 4(Kuijk 
and van Die, 2010); 5(van Vliet et al., 2007); 6(Guasconi et al., 2011); 7(Paveley et al., 2011) 
 
Our model helminth, F. hepatica was also shown to express wide range of glycans 
and glycoproteins on their surface and in their FhES (Wilson et al., 2011; Wuhrer 
and Geyer, 2006) with possible immunomodulatory effects. It was shown that FhES 
failed to induce alternative activation of macrophages in the presence of mannan, 
laminarin or the blocking antibodies of MR or Dectin1, suggesting that these CLRs 
are important in the recognition of F. hepatica and their products (Guasconi et al., 
2011). However, it was shown that TLR2 is also involved in the inhibition of 
Mycobacterium bovis activated macrophages by FhES (Flynn and Mulcahy, 2008). 
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The major components of FhTeg are carbohydrates, so CLRs may be important in its 
immunomodulatory effect on immune cells (Wilson and Maizels, 2004; Wilson et 
al., 2011; Wuhrer and Geyer, 2006). 
 
1.3.5 C-type lectin receptors in immune responses against bacteria 
CLRs are not only important in helminth host interaction, but they also play role in 
immunity against bacterial and fungal infections. Bacterial carbohydrate CLR 
interactions have important roles in innate immunity as they are involved in 
pathogen recognition and in the cellular interactions that lead to the modulation of 
immune responses (Weis et al., 1998). On the bacterial surface there are complex 
oligosaccharide structures, and as CLRs have specificity for glycans (like mannos, 
Lewis, GalNAc and b-glucan) they can mediate specific interactions with pathogens 
(Lloyd et al., 2007).  Some pathogens can interact with more than one CLR and cells 
express different CLRs on their surfaces that can contribute to their different 
function at different locations. CLRs play role in antigen internalization and 
presentation onto major histocompatibility complex (MHC) molecule. As CLRs 
possess signalling properties they can modify TLR mediated immune reactions (van 
Vliet et al., 2005). 
 
1.4  Fasciola hepatica 
Our model helminth, Fasciola hepatica (liver fluke) is a parasitic worm causing liver 
disease (fascioliasis) in mammals, including cattle and sheep. Heavy liver fluke 
infection can cause weight loss, anaemia, wool break or even sudden death in 
domestic animals (Behm and Sangster, 1999; Taylor, 2012). It is an important 
zoonotic disease in human with approximately 2.4 million people infected 
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worldwide (McManus and Dalton, 2006). The life cycle of the parasite in the 
mammalian host is complex. The definitive host is infected following ingestion of 
metacercariae shed from snails (Lymnaeidae). These metacercariae excyst in the 
duodenum to form newly excysted juvenile flukes, those penetrate of the intestinal 
wall. They migrate through the abdominal cavity and liver for several weeks and 
then finally the adult worm resides in the bile ducts releasing eggs (Figure 1.2). 
Penetration of the small intestine generally not associated with clinical disease, as 
only a few cells are disrupted. But migration through the peritoneal cavity into the 
liver can cause haemorrhage or fibrosis. Also the larvae occasionally penetrate other 
organs than liver, including lymph nodes, lung or pancreas (Andrews, 1999; Behm 
and Sangster, 1999). 
 
 
Figure 1.2. Life cycle of Fasciola hepatica. Immature eggs are discharged in the biliary ducts and in 
the stool .  Eggs become embryonated in water , eggs release miracidia , which invade a 
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suitable snail intermediate host , including the genera Galba, Fossaria and Pseudosuccinea.  In the 
snail the parasites undergo several developmental stages (sporocysts , rediae , and cercariae ).  
The cercariae are released from the snail  and encyst as metacercariae on aquatic vegetation or 
other surfaces.  Mammals acquire the infection by eating vegetation containing metacercariae.  
Humans can become infected by ingesting metacercariae-containing freshwater plants, especially 
watercress .  After ingestion, the metacercariae excyst in the duodenum  and migrate through the 
intestinal wall, the peritoneal cavity, and the liver parenchyma into the biliary ducts, where they 
develop into adults .  In humans, maturation from metacercariae into adult flukes takes 
approximately 3 to 4 months.  The adult flukes (Fasciola hepatica: up to 30 mm by 13 mm) reside in 
the large biliary ducts of the mammalian host.  Fasciola hepatica infects various animal species, 
mostly herbivores (Public Health Image Library, http://www.dpd.cdc.gov/dpdx). 
 
Fasciola hepatica is able to survive in the liver bile duct for many years, although it 
is exposed to the immune system. The fluke promotes strong Th2/Treg T-cell 
mediated immune responses and induce the production of IL-4, IL-5 and IL-10 
(Miller et al., 2009; O'Neill et al., 2000). Innate and adaptive immune responses are 
both important in the defence against F. hepatica. The number of eosinophils 
increases during liver fluke infection in cattle (Bossaert et al., 2000) and sheep 
(Zhang et al., 2005). Fasciola hepatica antigens were shown to cause apoptosis of 
these cells (Serradell et al., 2007). The fluke is capable of inducing alternatively 
activated macrophages (M2) with up-regulated arginase1 expression and activity 
(Donnelly et al., 2005). These macrophages are involved in priming Th2 T-cell 
differentiation and also has inhibitory effect as they secrete the regulatory cytokine, 
IL-10 (Flynn and Mulcahy, 2008; Hacariz et al., 2010). Macrophages and dendritic 
cells act as antigen presenting cells and has role in the activation of Th2 T-cells 
(Flynn et al., 2010; Wynn, 2009). Adaptive B-cells are responsible for the generation 
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of parasite-specific antibodies during F. hepatica infection (Clery et al., 1996; 
O'Neill et al., 2000). 
 
In order for F. hepatica to survive within its host it must suppress Th1 inflammatory 
responses as immunity against Fasciola infection requires strong Th1 immunity 
(Moreau and Chauvin, 2010). IL-4 knockout mice, which were predisposed towards 
a Th1 immune response, are less susceptible to F. hepatica infection than IFN-g 
receptor knockout mice with only Th2 immune responses (O'Neill et al., 2000). 
Studies in mouse (O'Neill et al., 2000) cattle (Flynn and Mulcahy, 2008) and sheep 
(Moreau et al., 1998) suggest that early Th1 immune responses (characterised by 
IFN-g secretion) change to Th2 (characterised by IL-4 production) as infection 
established. Treg cells (secreting IL-10 and TGF-b) are capable of suppressing these 
Th1 and Th2 immune responses (Flynn et al., 2010). 
 
Liver fluke is known to suppress the protective Th1 immune response against 
bacterial infections. It was shown that cattle with fascioliasis had delayed immune 
response against Mycobacterium bovis (Flynn et al., 2009). In mouse model, F. 
hepatica infection reduced Bordetella pertussis-specific IFN-g production (O'Neill et 
al., 2001). Liver fluke infection could also prevent the development of Th1 
autoimmune diseases. It was showed to suppress antigen specific Th1 and Th2 
immune responses that mediate experimental autoimmune encephalomyelitis (Walsh 
et al., 2009).   
 
22 
 
1.5 Antigens from Fasciola hepatica 
Molecules secreted or shed by Fasciola hepatica play central role in manipulating 
the host’s immune system (Caffrey, 2012). There are three groups of antigens 
derived from F. hepatica: the excretory/secretory products (FhES), the whole liver 
fluke homogenate (LFH) and the tegumental coat antigen (FhTeg). The most 
intensively studied molecule group is the excretory/secretory product of the fluke 
(FhES). It can be isolated from the media F. hepatica is maintained (Robinson et al., 
2012a). There are secretory vesicles in the gastrodermal cells of the fluke; FhES is 
secreted into the lumen of the helminth’s gut and then externally into the host tissues 
(Collins et al., 2004). The major secreted molecules and their immunomodulatory 
effects are listed in Table 1.3 (Robinson et al., 2012a). 
 
Two protein fractions of FhES can be separated by gel permeation chromatography, 
PI and PII. PI contain peroxiredoxin (FhPrx) and helminth defence molecule-1 
(FhHDM-1) and can induce antigen-specific Th2 responses in vivo in mice, while PII 
fraction consist of cathepsin L cysteine protease (FhCL) and does not induce Th2 
immune responses but suppresses Th1 cytokine production in T-cells (Donnelly et 
al., 2008; Robinson et al., 2011; Robinson et al., 2010). These molecules have 
immune-therapeutic potential (Robinson et al., 2012b). 
 
23 
 
Table 1.3. Major secreted molecules of Fasciola hepatica (Robinson et al., 2012a) 
Molecule Effect on the immune system 
Cathepsin L1 and L2 Degrades endosomal TLR3 
Cleaves hinge region of IgG 
Inhibits the differentiation of Th17 cells by dendritic cells 
Cleaves hinge region of IgG 
 
Peroxiredoxin Induces M2 macrophages 
 
Helminth defence molecule Modulates LPS-mediated response in macrophages 
 
Leucine aminopeptidase Unknown 
 
Glutathione S-transferase Inhibits proliferation of spleen cells and production of nitric oxide 
by macrophages 
Inhibits differentiation of Th17 cells by dendritic cells 
 
Fatty acid-binding protein Unknown 
 
Peroxiredoxin is not only important in reducing oxidative stress on flukes (Caffrey, 
2012), but also induce M2 alternative activated macrophages, associated with Th2 
cytokines in parasitic inflammation. These macrophages are involved in controlling 
Th1 type immune responses (Donnelly et al., 2009; Donnelly et al., 2008) and in 
murine model of human auto-inflammatory disease these M2 macrophages were 
shown to suppress the progression EAE (Mikita et al., 2011).  
 
Cathepsin L Cysteine peptidases are the major components of FhES and play role in 
the nutrition of the parasite by degrading host proteins into peptides (Robinson et al., 
2012b) These enzymes do not induce Th2 immune responses rather prevent the 
development of protective Th1 immune responses. FhCL inhibits the release of 
inflammatory mediators, such as IL-6, IL-12, TNF or nitric oxide from macrophages 
and also suppress IL-23 secretion from dendritic cells and enhances co-stimulatory 
molecule expression (Dowling et al., 2009). FhCL treatment was shown to suppress 
Bordetella pertussis induced IFN-g production in mice (O'Neill et al., 2001). 
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F. hepatica also secretes molecules which can mimic the function of the host defence 
peptides (cathelicidin-like helminth defence molecule, FhHDM) (Robinson et al., 
2011). They act as antimicrobial peptides but also important in the activation of 
wound healing and angiogenesis. These molecules can modulate innate cell 
activation by TLR ligands like LPS. They can bind to LPS preventing its interaction 
with macrophages (Robinson et al., 2011). They might be important in the survival 
of the host and therefore of the parasite as well (Robinson et al., 2012a; Robinson et 
al., 2012b). FhHDM can protect mice against LPS-induced inflammation by 
reducing the release of inflammatory mediators from macrophages (Robinson et al., 
2011). 
 
There are few studies examining the immunomodulatory effect of the whole liver 
fluke antigen. LFH is a complex mixture of antigens that has shown cross reactivity 
with proteins in FhES or components of FhTeg (Falcon et al., 2012), but also 
contains proteins that are unique for this preparation. LFH was studied in vaccine 
trials in different animal models (Cervi et al., 2004; McCole et al., 1999). In vitro in 
dendritic cells and in vivo in mice it was shown to induce the production of Th2 and 
anti-inflammatory cytokines, but suppress pro-inflammatory responses (Carranza et 
al., 2012; Falcon et al., 2012). 
 
1.6 FhTeg 
A major interface between the parasite and its environment is the tegument. It is a 
syncytial cytoplasmic layer bounded by plasma membrane and covered by 
glycocalyx (Wilson et al., 2011) and connected by cytoplasmatic strands to nucleated 
cell bodies located in the parenchyma below the muscle layers (Threadgold, 1963). 
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In the cytoplasm there are mitochondria and secretory bodies. There are three types 
of secretory bodies: T0, T1 and T2, produced by T1 and T2 cells (species specific). 
The content of secretory bodies is age dependent and they are important in the 
adaption to the environment. T0 type secretory bodies build the glycocalix during 
invasion while T1 and T2 type antigens are less immunogenic than the juvenile 
antigens (Sobhon et al., 2000). In the adult fluke the tegument is 15-20 mm thick and 
the surface is increased by intuckings of the plasma membrane (apical invagination). 
The apical membrane is covered by thick (30+25 nm) glycocalix (Fairweather et al., 
1999). The glycocalix contains oligosaccharides with negative charge and may 
provide the first line of defence, as it is thick and insoluble (Sobhon et al., 2000).  
 
The tegument has multiple functions like absorption of exogenous nutrients, 
synthesis and secretion of various substances, osmoregulation and protection against 
enzymes, the bile and host’s immune responses (Dalton, 1999; Halton, 2004). The 
tegument is in interaction with the immune system during the migration from the gut 
to the peritoneal cavity and from the peritoneal cavity to the bile duct. The tegument 
is shed every 3 hours and it is in direct contact with the host’s immune cells. An 
intact glycocalix and syncytium is essential to the survival of the fluke in the host 
(Fairweather et al., 1999). 
 
The most successful anthelminthics drugs (benzimidazoles) usually target the 
tegument in order to kill the fluke. The effect of triclabendazole (TCBZ), the most 
popular and effective drug of this group, on the tegument is well investigated in vitro 
and in vivo as well. They disrupt the tegumental coat within 96 hours, and by that 
time the flukes are usually dead (Toner et al., 2010a; Toner et al., 2010b; Toner et 
26 
 
al., 2010c). Other benzimidasole drugs like albendazole or mebendazole act in a 
similar way (Keiser and Morson, 2008). 
 
Isolation of tegumental antigen has difficulties, because it contains different proteins 
and an insoluble glycocalix (Hillyer, 1980; Wilson et al., 2011). Use of detergents 
like Nonidet P40 is required. Most of the isolated proteins from FhTeg (Hacariz et 
al., 2012; Morphew et al., 2012; Wilson et al., 2011) and the contents of the 
glycocalix (Wuhrer and Geyer, 2006) are identified. Over 50 different proteins are 
present in the preparation and the biological active component(s) of FhTeg has yet to 
be identified. While FhES mainly consist of proteins, and has extensive enzyme 
activity, FhTeg contain more carbohydrates than proteins without much enzyme 
activity (Wilson et al., 2011; Wuhrer and Geyer, 2006). 
 
It was demonstrated before that the isolated tegumental antigen of F. hepatica 
suppresses the secretion of pro-inflammatory cytokines (IFN-g and IL-12p70) in vivo 
in the mouse model of septic shock (Hamilton et al., 2009). Dendritic cells play 
central role in driving Th1 inflammatory responses. They mature and became 
activated by conserved microbial molecules, such as lipopolysaccharide (LPS) of E. 
coli, and express co-stimulatory molecules on their surface (CD40, CD80 and CD86) 
and secrete pro-inflammatory cytokines as IL-12p70 and TNF-a (Murphy, 2011). 
FhTeg impairs dendritic cell maturation and function in vitro by inhibiting IL-6, 
tumour necrosis factor (TNF)-a, IL-10 and IL-12 production and CD80, CD86 and 
CD40 cell surface marker expression in Toll-like receptor (TLR)4 stimulated 
dendritic cells. 
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FhTeg also targeted other TLR and non-TLR signalling pathways, as peptidoglycan 
(PGN - TLR2), flagellin (TLR5), polyinosinic-polycytidylic acid (poli(I:C) - TLR3), 
dinucleotide from bacterial DNA (CpG - TLR9), zymozan (TLR6) and phorbol-
myrsitate-acetate (PMA - non-TLR) induced Th1-type cytokine secretion and cell 
surface marker up-regulation was also inhibited by FhTeg in these cells. FhTeg 
impaired dendritic cell function by inhibiting its phagocytic capacity and its ability to 
prime T-cells. It was shown that FhTeg suppress cytokine production through the 
inhibition of the phosphorylation of nuclear factor kappa-light-enhancer of activated 
B-cells (NF-kB) p65, transcription factor in the TLR signalling pathway (Hamilton 
et al., 2009). 
 
Although there are numerous studies of the interaction of the tegumental antigen of 
Schistosoma sp. and different cell types (Braschi et al., 2006; Caldas et al., 2000; 
Duraes et al., 2009) there is less to know about the effect of FhTeg on immune cells 
like macrophages and mast cells. Tegumental extraction of F. hepatica was shown to 
up-regulate arginase1 transcription in macrophages in vitro. Arginase1 activity is 
usually associated with M2 macrophages, although other M2 markers were not tested 
in this study (Hacariz et al., 2010). To our best knowledge, there is only one study 
about mast cell - tegumental coat antigen interaction; rat peritoneal mast cells were 
shown to produce histamine upon the stimulation with synthesized short peptides 
with homologue sequences as found in tegument of F. hepatica (Trudgett et al., 
2003). As mast cells have a key role in the immune system, it is important to involve 
these cells in FhTeg research. 
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1.7 Mast cells 
Mast cells are bone marrow derived haematopoietic immune cells. They are resident 
in tissues, but most common at sites which exposed to the environment like skin, 
intestine or airways (Galli and Tsai, 2010). Mast cells are a major component of 
protective immunity against microbial infections as bacteria and parasites, such as 
helminths. Mast cells are intensively studied in the context of Th2 immune 
responses. They express high affinity receptors on their surface like FcεRI, which 
allows these cells to be activated by IgE specific antigens and secrete various 
mediators like histamine, cytokines or chemokines and mediate Th2 immune 
responses (Melendez et al., 2007; Pearce, 2007). Mast cells also play key role in the 
development of Th1 immune responses and they are involved in Th1 immune 
disorders (Marshall et al., 2003). 
 
1.8 Mast cells in parasitic infections 
Parasitic infections are often associated with increased mast cell numbers and 
redistribution (Weller et al., 2011), although the importance of these cells in the 
clearance of helminth infections vary greatly (Anthony et al., 2007). During 
intestinal helminth infection the role of mast cells is well defined. Nematode 
fecundity is higher in mast cell-deficient mice when infected with Heligmosomoides 
polygyrus compared to normal or mast cell-reconstituted mice (Hashimoto et al., 
2009). Studies in mouse and rat models showed that the clearance of Strongloides 
ratti, Trichinella spiralis, N. brasiliensis and Strongyloides ratti is mast cell number 
dependent (Abe and Nawa, 1988; Marshall, 2004; McDermott et al., 2003). 
Although mast cells do not seem to be crucial in the clearance of Trichuris muris, as 
ablation of mast cells in murine model has no effect on the development of immune 
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response (Betts and Else, 1999). The activation of mast cells during infection is 
usually dependent on Th2 cytokines secreted by CD4+ T-cells (Anthony et al., 2007; 
Erb, 2007). Activated mast cells secrete serine proteases, chymase, tryptase and can 
directly protect against parasites (Metz and Maurer, 2007). They also contribute to 
the expulsion of nematodes by increasing intestinal permeability and inducing 
neutrophil influx (McDermott et al., 2003). Mast cells are important in tissue 
remodelling as they induce fibronectin turn-over and angiogenesis in order to protect 
the host from trauma caused by helminths (Maurer et al., 2003). While mast cells are 
mostly crucial in the clearance of gut helminths, they do not appear to a have key 
role in the clearance of other tissue dwelling helminths such as schistosomiasis, 
although they are present in the early stages of Schistosoma infection (Gerken et al., 
1990). 
 
1.8.1 C-type lectin receptors on mast cells 
There are only few studies about CLRs on mast cell surface. They express an 
identical CLR, mast cells function associated antigen (MAFA) (Guthmann et al., 
1995a; Guthmann et al., 1995b). The activation of MAFA leads to the inhibition of 
FceRI-induced activation of mast cells (Abramson et al., 2002). This protein was 
found on mouse natural killer (NK) cells and human basophils (Katz, 2002). Mincle 
and Dectin 1 were also shown to be expressed by mast cells, although the expression 
level is very low (Ribbing et al., 2011). Upon mast cell activation by the fungal 
antigen zymosan the Dectin1 level increases and zymosan induced leukotriene 
production seems to be Dectin1 dependent (Yang and Marshall, 2009). 
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1.9 Mast cells in autoimmune diseases 
Mast cells are thought to have protective role during sepsis and are associated with 
many Th1-mediated inflammatory disorders such as autoimmune disease and cancer 
where TNF-a secreting mast cells contribute to pathology (Metz and Maurer, 2007; 
Sutherland et al., 2011; Weller et al., 2011). Evidences have been published that 
mast cells play key role in IBD, the inflammatory autoimmune disorder of the gut. 
Experiments in animal models and in human studies showed that IBD is associated 
with high number of mast cells in the intestine and these cells degranulated and 
secrete histamine and pro-inflammatory cytokines like IL-6 and TNF-a (De Winter 
et al., 2011). Mast cell inhibitors have therapeutic potential in the treatment of IBD 
(He, 2004). Studies in mast cell-deficient mice (Kit-/-) showed that mast cells derived 
pro-inflammatory cytokines, such as TNF-α are important in the development of 
EAE (the murine model for multiple sclerosis) (Christy et al., 2012; Costanza et al., 
2012).  As helminth derived molecules can prevent the initiation of Th1 mediated 
inflammatory diseases, it is important to investigate FhTeg and mast cells 
interactions. 
 
1.10 Mast cells in bacterial infections 
Similar to dendritic cells and macrophages, mast cells express pathogen recognition 
receptor such as TLRs (TLR2, TLR3, TLR4, TLR6, TLR7 and TLR9) that recognise 
invading pathogens (Marshall et al., 2003). Mast cells in response to bacterial 
ligands express co-stimulatory molecules and secrete cytokines that promote pro-
inflammatory Th1 immune responses (Abraham and St John, 2010; Dawicki and 
Marshall, 2007; Galli and Tsai, 2010; Metcalfe et al., 1997; Weller et al., 2011). 
They secrete TNF-a, IL-5, IL-6 and IL-13 but not IL-1b after TLR2 activation with 
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bacterial peptidoglycan (Supajatura et al., 2001). TLR4 dependent stimulation with 
lipopolysaccharide (LPS) induces TNF-α, IL-1b, IL-6 and IL-13 but not IL-4 or IL-5 
secretion (Supajatura et al., 2002). 
 
Mast cell induced Th1 immune response is crucial in the clearance of protozoan and 
bacterial infection, such as Escherichia coli (Wierzbicki and Brzezinska-Blaszczyk, 
2009), Leishmania major (Maurer et al., 2006) or Pseudomonas aeruginosa 
(Siebenhaar et al., 2007) infections. Bordetella pertussis is a highly infectious 
respiratory pathogen which causes whooping cough. Mast cells together with 
dendritic cells and macrophages are supposed to play role in the mediation of 
bacterial clearance from the lung. In vitro B. pertussis induces IL-6 and TNF-a 
release from mast cells and in vivo the early TNF-a production is delayed in mast 
cell depleted, B. pertussis infected mice (Mielcarek et al., 2001). TLR4 was shown to 
be critical in the recognition of this pathogen (Mann et al., 2005).  
 
1.11 Mast cell - T-cell cross talk  
CD4+ T-cell dependent mast cell activation is well investigated during T-cell 
mediated inflammatory responses. T lymphocytes can induce degranulation, 
secretion of β-hexosaminidase, several inflammatory cytokines (TNF-α, IL-4 and IL-
6) and chemokines (CXCL2, CCL5) following direct contact with mast cells (Gri et 
al., 2012). Mast cell-secreted mediators also can activate B and T-cells and are 
known to have immune-regulatory and immune modulatory effect on T-cell-
dependent responses (Metcalfe et al., 1997). Mast cells can act as APCs and can 
process T-cell activation. They can be found in most of the tissues, also in the 
secondary lymphoid organs, so have potential to prime naïve T-cells or directly alter 
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T-cell function (Brown et al., 2008) via cell surface molecules or secreted mediators. 
In some studies, mast cell-deficient mice show delayed type hypersensitivity 
(Metcalfe et al., 1997), although in these mouse models the lack of c-kit signalling 
may have impact on T-cell development (Brown et al., 2008). 
 
Mast cells express cell surface markers, adhesion molecules, co-stimulatory and co-
inhibitory molecules which allows them to interact with other immune cells. MHC 
class I and II play central role in antigen presentation. Mast cells express high levels 
of MHCI but very low levels of MHCII, although this can be up-regulated during 
pathogen infection, LPS or IFN-g stimulation (Kambayashi et al., 2009). Expression 
of intracellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule 
(VCAM)-1, OX40L, CD40L, LFA-1 and many other molecules suggest broad ability 
to directly mediate T-cell activation, although the mechanism is unclear yet 
(Kashiwakura et al., 2004; Sayed and Brown, 2007).  
 
Mast cells secrete cytokines and chemokines which can be important in cell to cell 
communication (Galli and Tsai, 2010). Mast cell derived IL-4 was shown to be 
important in Th2 immune responses (Sayed and Brown, 2007), while IL-12 and 
TNF-a induce Th1 polarisation and TGF-b and IL-6 are important in Th17 immune 
responses (Brown et al., 2008; Nakae et al., 2006). In a rodent model of multiple 
sclerosis, T-cell activation (IFN-g production, CD44 and CD11a up-regulation) was 
shown to be mast cell dependent (Gregory et al., 2005). Bacterial and viral infections 
can induce cytokine secretion and adhesion molecule up-regulation in mast cells that 
leads to the activation of protective Th1 immune responses. Mast cells can regulate 
T-cell migration directly by producing chemotactic factors (IL-16, CCL2/MCP-1, 
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CCL3/MIP-1a, CCL4/MIP-1b or TGF-b). Exosomes may also be involved in mast 
cell T-cell communication. They were shown to contain molecules, like MHCII, 
CD86, CD40L, LFA-1, and ICAM-1 during infection (Galli et al., 2005). Mast cells 
mediate the up-regulation of the expression of surface adhesion molecules on 
endothelial cells and induce T-cell activation indirectly (Galli et al., 2005). 
 
Mast cells communicate with other cells types like dendritic cells or B-cells. Mast 
cell-derived IL-4 initiates the allergic response by inducing IgE production by B-
cells (Metcalfe et al., 1997; Sayed and Brown, 2007). CD40 and CD40L co-
stimulatory molecule interaction was shown to be involved in mast cell induced IgE 
production by B-cells (Galli et al., 2005; Sayed and Brown, 2007). There are many 
evidences that mast cells can regulate dendritic cells migration, regulation and 
function by the production of TNF-a, IL-1, IL-16, IL-18 or PGD2 (Galli et al., 
2005). Mast cell - dendritic cell interactions can be important in the APC function of 
dendritic cells (Bryce et al., 2004; Mazzoni et al., 2006). Both soluble mediators and 
direct cross-talk are important in these processes (Gri et al., 2012). Mast cells were 
also shown to induce natural killer cell, eosinophil and neutrophil accumulation and 
activation in different animal models for bacterial infection, allergy and autoimmune 
disease (Gri et al., 2012). 
 
1.12 Summary 
Helminths and the products they release exert strong Th2/Treg immune responses 
(Anthony et al., 2007) that can suppress the Th1 driven immune response to 
bystander infections making malaria (Nacher, 2011) and HIV (Carod-Artal, 2008) 
infections more severe. Helminths are also thought to prevent the initiation of Th1 
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mediated inflammatory disorders like arthritis, multiple sclerosis and Crohn’s 
disease (Song et al., 2011). Studies examining the bystander effects of helminths 
have predominantly examined the role of dendritic cells (Carvalho et al., 2006; 
Carvalho et al., 2009; Kane et al., 2004) and macrophages (Allen and Maizels, 
2011), however, recent studies have shown that mast cells have a critical role in Th1 
mediated immune responses against microbes, such as E. coli (Marshall, 2004) and 
in inflammatory disorders, such as arthritis, multiple sclerosis and Crohn’s disease 
(Metz and Maurer, 2007; Sutherland et al., 2011; Weller et al., 2011). In this study 
we examine the interaction of the tegumental coat antigen of F. hepatica with mast 
cells.  Better understanding the mechanism involved in the immunomodulation by F. 
hepatica may lead to potential identification of novel anti-inflammatory therapeutic 
targets. 
 
1.13 Aims of the project: 
The aim of the project is to understand interactions of mast cells with F. hepatica 
infection antigens derived from the tegumental coat (FhTeg) by answering the 
following questions:  
· Are mast cells observed during F. hepatica infection and also following 
treatment with FhTeg? 
· Are mast cells involved in FhTeg driven Th2 immune responses?  
· Does FhTeg suppress Th1 mediated immune responses in mast cells? 
· Can FhTeg treated mast cells modulate T-cells in vitro? 
· What immune modulatory mechanisms does FhTeg use to modulate innate 
immune cells? 
· Are C-type lectin receptors involved in FhTeg - mast cell interactions? 
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2 Chapter 2 – Material and Methods 
2.1 Materials 
2.1.1 Reagents 
2.1.1.1 Animals and cell lines 
Name Catalog # Company 
BALB/C mice (female) 
 
Harlan UK Ltd (UK) / Charles 
River (Ireland) 
C57BL/6 mice (female) 
 
Harlan UK Ltd (UK) / Charles 
River (Ireland) 
STAT6
-/-
 mice (female)  Charles River (Ireland) 
Liver flukes (Fasciola 
hepatica) 
 
abattoir in Ballyjamesduff, Ireland 
Metacercariae (F. hepatica)  Baldwin Aquatics Ltd, USA 
MC/9 CRL-8309 LGC Standards, Teddington, UK 
RAW 264.7 
ATCC: TIB-
71 LGC Standards, Teddington, UK 
WEHI-3 
ATCC: TIB-
68 LGC Standards, Teddington, UK 
 
2.1.1.2 Cell culture 
Product Catalog # Company 
Foetal Calf Serum (FCS) 10270-106 Gibco, Invitrogen, Paisley, UK 
IL-3 
407631 
Calbiochem, Merck, Darmstadt, 
Germany 
IMDM 12440-048 Gibco, Invitrogen, Paisley, UK 
L-Glutamine G7513 Sigma-Aldrich, Dublin, Ireland 
Phosphate Buffer Saline (PBS) 14190 Gibco, Invitrogen, Paisley, UK 
Penicillin/Streptomycin 1570-063 Gibco, Invitrogen, Paisley, UK 
RPMI 1640 31870-074 Invitrogen, Paisley, UK 
Stem Cell Factor S9915 Sigma-Aldrich, Wicklow, Ireland 
Trypan blue T8154 Sigma-Aldrich, Wicklow, Ireland 
X VIVO 15 BE04-48Q Lonza, Walkersville, USA 
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2.1.1.3 Stimulants and blocking antibodies 
Product Catalog # Company 
Anti- mouse ICAM1 ab25375 Abcam, Cambridge, UK 
Anti-mouse mannose receptor ab8918 Abcam, Cambridge, UK 
Anti-mouse MGL 
HM1081 
Hycult biotech, Uden, The 
Netherlands 
Anti-mouse SignR1 AF1836 R&D, Abingdon, UK 
Mannan (from Saccharomyces 
cerevisae) 
M7504 Sigma-Aldrich, Wicklow, Ireland 
Laminarin (from Laminaria 
digitata) 
L9634 Sigma-Aldrich, Wicklow, Ireland 
N-Acetil-D-galactosamine 
(GalNac) 
A2795 Sigma-Aldrich, Wicklow, Ireland 
Bordetella pertussis antigen kind gift of Bernie Mahon 
Calcium ionophore (A23187) C7522 Sigma-Aldrich, Wicklow, Ireland 
Flagellin (S. typhimurium) tlrl-stfla InvivoGen, CA, USA 
Lipopolysaccharide (LPS) (E. 
coli) 
ALX-581-
007 
Alexis Biochemicals, Lausanne, 
Switzerland 
CpG ODN 1826 tlrl-modn InvivoGen, CA, USA 
Peptidoglycan (PGN) (S. 
aureus) 
tlrl-pgnsa 
InvivoGen, CA, USA 
Phorbal myristate acetate 
(PMA) 
P8139 
Sigma-Aldrich, Wicklow, Ireland 
Piceatannol (Syk inhibitor) 
ALX-270-
2002-M001 Enzo Life Sciences, Exeter, UK 
Poli (I:C) tlrl-pic InvivoGen, CA, USA 
Zoledronic acid SML0223 Sigma-Aldrich, Wicklow, Ireland 
Zymosan (S. cerevisiae) Z4250 Sigma-Aldrich, Wicklow, Ireland 
 
2.1.1.4 Kits 
Product Catalog # Company 
Annexin V-FITC apoptosis 
detection kit 
556547 
BD pharmingen, Oxford, UK 
BCA protein kit 23288, 23224 Promega, Medison, USA 
CD4+ Isolation kit 130-095-248 Milltenyi Biotech, UK 
Cell Growth Determination 
Kit, MTT based 
CG-D1 
Sigma-Aldrich, Wicklow, Ireland 
DNase kit 18068-015 Invitrogen, Paisley, UK 
Greiss reagent system (nitric 
oxide) 
G2930 
Promega, Madison, USA 
Maxima SYBR Green/ROX 
qPCR Master Mix (2x) 
K0221 
Fermentas, Fisher, Dublin, Ireland 
Mouse IFN-g ELISA Set 555138 BD Biosciences, Oxford, UK 
Mouse IL-10 ELISA Set 555252 BD Biosciences, Oxford, UK 
Mouse IL-3 ELISA 432101 Biolegend, Cambridge, UK 
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Mouse IL-4 ELISA Set 555232 BD Biosciences, Oxford, UK 
Mouse IL-5 ELISA Set 555236 BD Biosciences, Oxford, UK 
Mouse IL-6 ELISA Set 555240 BD Biosciences, Oxford, UK 
Mouse TNF-a ELISA Set 558534 BD Biosciences, Oxford, UK 
PCR Mastermix + DNAse free 
water 
M7505 
Promega, Madison, USA 
PGD2 EIA kit CAY512031 Cayman Chemical. USA 
Pyrogene Recombinant Factor 
C Endotoxin Detection System 
50-658U 
Lonza, Walkersville, USA 
rt-PCR kit A5001 Promega, Madison, USA 
TGF-β Platinum ELISA BMS608/3 eBiosciences, Hatfield, UK 
Trypan blue T8154 Sigma-Aldrich, Wicklow, Ireland 
 
2.1.1.5 Reagents 
Product Catalog # Company 
2-Mercaptoethanol  63689 Sigma-Aldrich, Wicklow, Ireland 
2-Propanol  24137 Sigma-Aldrich, Wicklow, Ireland 
3,3′,5,5′-Tetramethylbenzidine 
dihydrochloride hydrate  
T8768  
Sigma-Aldrich, Wicklow, Ireland 
Acetone 27023 VWR, East Grinstead, UK 
Acrylamide/Bis-acrylamide, 
30% solution  
A3699  
Sigma-Aldrich, Wicklow, Ireland 
Agarose BIO-4125 Bioline, London, UK 
Albumin from bovine serum  A7030  Sigma-Aldrich, Wicklow, Ireland 
Alcian blue A5268 Sigma-Aldrich, Wicklow, Ireland 
Ammonium persulfate A7460 Sigma-Aldrich, Wicklow, Ireland 
Bovine serum albumin (BSA) A7906 Sigma-Aldrich, Wicklow, Ireland 
Bromophenol Blue 18030 Sigma-Aldrich, Wicklow, Ireland 
Buffer solution pH 10.0 
(20 °C) 
33668 
Sigma-Aldrich, Wicklow, Ireland 
Buffer solution pH 4.0 (20 °C) 33665 Sigma-Aldrich, Wicklow, Ireland 
Buffer solution pH 7.0 (20 °C) 33666 Sigma-Aldrich, Wicklow, Ireland 
Calcium chloride 383147 Sigma-Aldrich, Wicklow, Ireland 
Chloroform 3505 Fisher, Dublin, Ireland 
Citric Acid C1857 Sigma-Aldrich, Wicklow, Ireland 
Dimethyl sulfoxide  D2650  Sigma-Aldrich, Wicklow, Ireland 
DNAse I D0018 Sigma-Aldrich, Wicklow, Ireland 
DNP D198501 Sigma-Aldrich, Wicklow, Ireland 
Entellan 1079600500 Merck, Darmstadt, Germany 
Eosin E4009 Sigma-Aldrich, Wicklow, Ireland 
Ethanol E7023  Sigma-Aldrich, Wicklow, Ireland 
Ethylenediamine-tetraacetic 
acid (EDTA) 
E9884, 
E3889 Sigma-Aldrich, Wicklow, Ireland 
Ferric sulphate 215422 Sigma-Aldrich, Wicklow, Ireland 
Formaldehyde solution  F8775  Sigma-Aldrich, Wicklow, Ireland 
Glucose G8270 Sigma-Aldrich, Wicklow, Ireland 
Glycerol G8773 Sigma-Aldrich, Wicklow, Ireland 
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Glycine G/0800 Fisher, Dublin, Ireland 
Hematoxylin 98057-844 BDH, VWR, East Grinstead, UK 
HEPES H3375 Sigma-Aldrich, Wicklow, Ireland 
Hydrochloric acid H1758 Sigma-Aldrich, Wicklow, Ireland 
HyperLadder IV BIO33029 Bioline, London, UK 
Immobilon Western 
Chemiluminescent HRP 
Substrate 
WBKLS0100 
Millipore, MA, USA 
Indomethacin  I7378  Sigma-Aldrich, Wicklow, Ireland 
Magnesium chloride  M8266  Sigma-Aldrich, Wicklow, Ireland 
Mannan from Saccharomyces 
cerevisiae  
M7504 
Sigma-Aldrich, Wicklow, Ireland 
Methanol 65543 Sigma-Aldrich, Wicklow, Ireland 
N,N,N′,N′-
Tetramethylethylenediamine  
T9281  
Sigma-Aldrich, Wicklow, Ireland 
Neoclear 109843 Merck, Darmstadt, Germany 
Nonidet™ P 40 Substitute  74385 Sigma-Aldrich, Wicklow, Ireland 
Paraffin wax 107250 Merck, Darmstadt, Germany 
Odyssey molecular weight 
marker (9928-40000) 
3100 10899 
Li-Cor, Lincoln, USA 
Phosphatase Inhibitor Cocktail 
1  
P2850  
Sigma-Aldrich, Wicklow, Ireland 
Phosphatase Inhibitor Cocktail 
2  
P5726  
Sigma-Aldrich, Wicklow, Ireland 
Phosphatase Inhibitor Cocktail 
3  
P0044  
Sigma-Aldrich, Wicklow, Ireland 
Phosphate-Citrate Buffer with 
Sodium Perborate  
P4922  
Sigma-Aldrich, Wicklow, Ireland 
p-Nitrophenyl-N-acetyl-β-D-
glucosaminide (p-NAG) 
N9003 
Sigma-Aldrich, Wicklow, Ireland 
Potassium chloride P4504 Sigma-Aldrich, Wicklow, Ireland 
Potassium dihydrogen 
phosphate 
30407 
Riedel de Haën, Sigma-Aldrich, 
Wicklow, Irelnad 
Protease inhibitor Cocktail P8340 Sigma-Aldrich, Wicklow, Ireland 
Resazurin R7017 Sigma-Aldrich, Wicklow, Ireland 
RIPA Buffer  R0278 Sigma-Aldrich, Wicklow, Ireland 
Safranin S2255 Sigma-Aldrich, Wicklow, Ireland 
Saponin 47036 Sigma-Aldrich, Wicklow, Ireland 
SeeBlue Plus2 Prestained 
Standard 
LC592 
Invitrogen, Paisley, UK 
Skim Milk Powder 70166 Sigma-Aldrich, Wicklow, Ireland 
Sodium Acetate S2889 Sigma-Aldrich, Wicklow, Ireland 
Sodium azide  13412 Sigma-Aldrich, Wicklow, Ireland 
Sodium bicarbonate S5761 Sigma-Aldrich, Wicklow, Ireland 
Sodium carbonate S7795 Sigma-Aldrich, Wicklow, Ireland 
Sodium Chloride S/3160 Fisher, Dublin, Ireland 
Sodium dodecyl sulphate 
(SDS) 
L4390 
Sigma-Aldrich, Wicklow, Ireland 
Sodium hydroxide S5881 Sigma-Aldrich, Wicklow, Ireland 
Sodium phosphate S8282 Sigma-Aldrich, Wicklow, Ireland 
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Sodium pyrophosphate 106580 Merck, Darmstadt, Germany 
Sulphuric acid  435589 Sigma-Aldrich, Wicklow, Ireland 
SYBRSafe DNA gel stain S33102 Invitrogen, Paisley, UK 
TEMED T9281 Sigma-Aldrich, Wicklow, Ireland 
Tetramethylbenzidine (TMB) 
dihydrochloride (tablets) 
T3405 
Sigma-Aldrich, Wicklow, Ireland 
TMB Substrate Reagent Set 421101 Biolegend, Cambridge, UK 
Toluidine blue 89640 Sigma-Aldrich, Wicklow, Ireland 
Trizma base 93352 Sigma-Aldrich, Wicklow, Ireland 
Trisure BIO-38033 Bioline, London, UK 
Triton X-100 BDH306324 VWR, East Grinstead, UK 
Tween 20 P1379 Sigma-Aldrich, Wicklow, Ireland 
 
 
2.1.2 Equipment 
2.1.2.1 Equipment 
Product Catalog # Company 
Analogue Stirred Water bath NE4-22T VWR, East Grinstead, UK 
Benchtop microcentrifuge  4214 MSC Co. Ltd. Dublin, Ireland 
BIOQUEL Microflow Class II 
ABS Cabinet 
ABS1200F 
VWR, East Grinstead, UK 
Block Heater BBA series MSC Co. Ltd. Dublin, Ireland 
Consort nv electrophoresis 
power supply 
AE-6450 
Belgium 
Dual Mini Slab Kit-gel 
electrophoresis apparatus 
AE-6450 
ATTO Bio-Instrument, Bunkyo, 
Japan 
FacsAria flow cytometer  Becton Dickinson, Oxford, UK 
FacsCalibur flow cytometer  Becton Dickinson, Oxford, UK 
Fuji medical film processor FPM 100A Fuji photo film, Tokyo, Japan 
Fuji film cassette (18x24) EC-DW Fuji photo film, Tokyo, Japan 
G-Box Gel Imaging system  Syngene, Cambridge, UK 
Haemocytometer, Neubauer, 
Double cell 
 
MSC Co. Ltd. Dublin, Ireland 
Hotplate Stirrer AGB1000 Jenway, Stone, UK 
Leica Inverted microscope 
DMIL 
Leica Microsystems, Wetzlar, 
Germany 
MicroTec rotary microtome 
4060 
MicroTec Laborgeräte GmbH, 
Germany 
Midi horizontal electrophoresis 
unit 692 
Z338818 
Sigma-Aldrich, Wicklow, Ireland 
Mini horizontal electrophoresis 
unit 658 
Z338796 
Sigma-Aldrich, Wicklow, Ireland 
Nanodrop 1000 
 
Thermo Fischer Scientific, Dublin, 
Ireland 
Olympus transmitted-reflected BX60 Olympus, Hamburg, Germany 
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light microscope wit 
BF/DF/DIC/Polarised light 
Real time thermal cycler ABI7900FH Applied Biosciences, Paisley, UK 
Sigma 4K15 Benchtop 
Refrigerated Centrifuge 
10740 
Sigma Centrifuges, Merringtn, UK 
Stuart Scientific combined 
incubator and orbital shaker 
S150 
MSC Co. Ltd. Dublin, Ireland 
TECAN Genios Microplate 
Reader 
 
Tecan Group, Mannedorf, 
Switzerland 
TECAN Safire2 UV/VIS/IR 
and fluorescence plate reader 
 
MSC Co. Ltd. Dublin, Ireland 
Thermo Scientific CO2 Water 
Jacketed Incubator 
Model 3111 
MSC Co. Ltd. Dublin, Ireland 
Vortex mixer SA8 Stuart, Stone, UK 
West balance BL120S Sartons, Goettingen, Germany 
 
2.1.2.2 Software 
Product  Company 
Alpha View SA  Cell Bioscience Inc., St Clara, USA 
BD CellQuest Pro software  Becton Dickinson, Oxford, UK 
Cyflogic  CyFlo Ltd., Turku, Finland 
FlowJo  Tree Star, Ashland, USA 
imageJ  National Institute of Health, USA 
Origin 
 
Origin Lab Corp., Northampton, 
USA 
 
 
  
41 
 
2.2 Methods 
2.2.1 Animals 
BALB/C, C57BL/6 and STAT6-/- mice 6-8 weeks old were purchased from Harlan 
UK Ltd (Bicester, UK) and Charles River (Carrentrila, Ireland). Mice were kept 
under specific pathogen-free conditions at the Bioresource Unit, Faculty of Health 
and Science, Dublin City University, Ireland. All mice were maintained according to 
the guidelines of the Irish Department of Children and Health. Ethical approval for 
mice experiments was obtained from DCU ethics committee and the Irish 
Department of Children and Health. 
 
2.2.2 IL-3 preparation 
IL-3 was obtained from WEHI-3-conditioned medium following culture of WEHI-3 
cells (ATCC: TIB-68; LGC Standards, Teddington, United Kingdom) in Iscove’s 
Modified Dulbecco’s medium (IMDM; Invitrogen Ltd, Paisley, UK) supplemented 
with 10% foetal bovine serum (FCS; Invitrogen Ltd, Paisley, UK) 1% 
penicillin/streptomycin (Bio-Sciences, Dun Laoghaire, Ireland) at 37oC, supernatant 
was collected every 4
th
 day. The cell-free conditioned medium was used in bone 
marrow derived mast cell cultures or concentrated by ultrafiltration (cut off point 10 
kDa; Amicon ultra-15 centrifugal filter device, Millipore, Ireland). The concentration 
of IL-3 was determined by ELISA (BioLegend UK Ltd., Cambridge, UK). 
 
2.2.3 FhTeg/FhES preparation 
F. hepatica excretory-secretory products (FhES) and tegumental antigen (FhTeg) 
was prepared by adapting a previously published method (Hamilton et al., 2009). In 
brief, live worms were obtained from infected cattle and placed in RPMI (Roswell 
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Park Memorial Institute culture medium) supplemented with penicillin/streptomycin 
(100 u/ml) 2 mM L-glutamine and 10% FCS at 37oC and 5% CO2. Culture medium 
containing FhES was collected after 8 hours. Worms were washed in sterile 
phosphate-buffered saline (PBS), incubated in 1% Nonidet P-40 (NP-40) for 30 min 
at 37oC, and supernatant was collected. NP-40 was removed using Bio-BeadsTM 
(Bio-Rad, Herts, UK). Protein concentrations were measured using the bicinchoninic 
acid (BCA) protein assay kit (Thermo Scientific, Leicestershire, UK), and endotoxin 
levels were assessed using the Pyrogene endotoxin detection system (as described in 
manufacturer’s protocol, Cambrex, Lonza, Walkersville. USA). FhES and FhTeg 
gave endotoxin levels similar to background levels. Toxicity of antigen (0, 1, 5, 10, 
20 µg/ml) were tested on bone marrow-derived dendritic cells (section 2.2.10) with 
trypan blue staining (2.2.5) and resasurine (2.2.16). Viability of antigen treated (10 
µg/ml) cells were also tested with flow cytometer with Annexin V-FITC apoptosis 
test (2.2.18) 
 
2.2.4 Fasciola hepatica infection and treatment of mice with F. hepatica 
antigens 
BALB/C, C57BL/6 or STAT6-/- mice were infected with 20 F. hepatica 
metacercariae orally (metacercariae were purchased from Baldwin Aquatics Ltd, 
USA) and were sacrificed 2 weeks post infection. Peritoneal cells were obtained 
from the mice by injecting 10 ml PBS into the peritoneal cavity and livers were 
removed for histological studies (Section 2.2.7). 
 
BALB/C, C57BL/6 or STAT6
-/-
 mice were injected intraperitoneally (i.p.) three 
times per week for three weeks with PBS, FhTeg (10 µg) or FhES (20 µg) or 
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injected with BP in the presence of absence of FhTeg. Peritoneal cells were 
harvested on day 21 and used to measure intracellular TNF-a and membrane c-type 
lectin expression (Section 2.2.18). Cell numbers and viability were monitored using 
Trypan blue staining. Percentages of mast cells were measured by cell surface 
expression of c-kit and FcεRI (flow cytometry, Section 2.2.17) and by Kimura 
staining (Section 2.2.5). 
 
2.2.5 Trypan blue and Kimura staining 
Cell viability was measured by trypan blue staining. Cells were resuspended in 
trypan blue dye (Sigma, Wicklow, Ireland) and PBS (1:5) and examined with 
Olympus phase contrast light microscope (BX60, Olympus, Hamburg, Germany) 
immediately. Dead cells are stained blue while viable cells are white against the light 
blue background. 
 
Cells were incubated for 5 minutes at room temperature in 10 ml medium or PBS and 
10 ml Kimura dye (Table 2.1) than examined with Olympus light microscope (BX60, 
Olympus, Hamburg, Germany). Mast cells were identified by their ability to exhibit 
purple staining (Kimura et al., 1973). 
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Table 2.1. Kimura staining 
1. Toluidine blue solution 
Reagent Amount Concentration 
Toluidine blue 25 mg 0.5 mg/ml 
1.8% NaCl (18 g/L) 25 ml 9 g/L 
Ethanol (100%) 11 ml 22% 
Total 50 ml  
2. Saturated saponin 
Reagent Amount Concentration 
Saponin 200 mg 4 mg/ml 
Ethanol (50 %) 50 ml  
Total  50 ml Heat and vortex for 30 min 
3. NaH2PO4 solution 
Reagent Amount Concentration 
NaH2PO4 1.03 g 60 mM 
Total 100 ml (pH 6.4)  
Kimura staining 
Toluidine blue solution 50 ml  
Saturated saponin 2.27 ml  
NaH2PO4 solution 22.7 ml  
 
2.2.6 Passive Cutaneous and Systemic Anaphylaxis model 
Passive Cutaneous and Systemic Anaphylaxis experiments were done at Charité 
Univesitätmedizin in Berlin by Dr Sandra O’Neill. Briefly, C57BL/6 mice were 
injected with FhTeg (10 µg) three times before administering dinitrophenol (DNP)-
specific IgE prior to challenge with DNP either systemically in the Passive Systemic 
Anaphylaxis model (PSA) by intra venous (i.v.) injection or subcutaneously in the 
Passive Cutaneous Anaphylaxis model (PCA) by injecting DNP into the ear 
(Siebenhaar et al., 2007). In the PSA rectal temperature was recorded every 10 
minutes for two hours. In the PCA model ear swelling was measured by micrometer 
for 1, 2, 4 and 8 hours.  
 
2.2.7 Histological studies 
The livers were gently removed from sacrificed mice and fixed in 4% formalin and 
stored at room temperature. After dehydration by ethanol liver tissues were 
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embedded into paraffin wax and 5 µm thick sections were cut. Sections were 
rehydrated and stained with toluidine blue, alcian blue/safranin or standard 
hematoxylin/eosin staining (Table 2.2). After staining sections were washed in water 
and dehydrated, cleared in Neoclear and mounted in Entellan (Merck, Darmstadt, 
Germany). Mast cells were identified by their ability to exhibit metachromatic 
staining. Quantitative analysis of mast cell density was performed by counting the 
number of stained cells. Mast cell density was expressed as cells/mm2. 
 
Table 2.2. Sample preparation for histological studies and dyes 
 Solution Time / temperature 
1. Dehydration 30% Ethanol 1 h; RT 
50% Ethanol 1 h; RT 
70% Ethanol 1 h; RT 
90% Ethanol 1 h; RT 
96% Ethanol 1 h; RT 
ABS Ethanol 2x1 h; RT 
2. Clearing and embedding 
solution 
50% Ethanol, 50% Neoclear 1 h; RT 
100% Neoclear 1 1 h; RT 
100% Neoclear 2 1 h; RT 
Neoclear + wax 30 min; RT 
More wax 1 h; 65oC 
100% wax 1 h; 65oC 
Molding RT 
Sectioning 5 µm  
 On slides Overnight; 37oC 
3. Rehydrating, staining and 
dehydrating 
Neoclear A 10 min; RT 
Neoclear B 10 min; RT 
ABS Ethanol 5 min; RT 
96% Ethanol 5 min; RT 
70% Ethanol 2 min; RT 
Running tap water 5 min; RT 
Dye*  
Running tap water 5 min; RT 
70% Ethanol 2x1 sec; RT 
96% Ethanol 4x1 sec; RT 
ABS Ethanol 1 5 min; RT 
ABS Ethanol 2 5 min; RT 
50% ABS Ethanol 50% 
Neoclear 
5 min; RT 
Neoclear C 5 min; RT 
Neoclear D 5 min; RT 
4. Mounting Entellan Cover with cover slip 
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* Dyes: 
 Ragent concentration 
5. Toluidine staining Toloudine blue 0.5% 
HCl 0.5 N 
Incubation: 30 sec; RT 
Washing with running tap water 5 min; RT 
Eozin 1% 
Incubation: 1 min; RT 
6. Alcian blue/Safranin 
staining 
Alcian blue 0.36% 
Safranin 0.012% 
Ferric sulphate 0.48% 
Sodium acetate 0.2 M 
Incubation: 20 min 
7. Hematoxilin/Eosin 
staining 
Hematoxilin 1% 
Incubation: 15 min; RT 
 Washing with running tap water 5 min; RT 
Eosin 1% 
 Incubation: 1 min; RT 
 
2.2.8 Bone marrow-derived mast cells 
Bone marrow-derived cultured mast cells (BMMCs) were generated from the 
femoral bone marrow cells of C57BL⁄6 mice and maintained in complete IMDM 
(Table 2.3) in the presence of 10% heat-inactivated FCS, 100 u/ml 
penicillin⁄streptomycin, L-Glutamine (2 mM) and 30% WEHI-3 conditioned IMDM-
medium (ATTC TIB-68) as a source of the murine growth-factor IL-3 for 4 weeks 
(Mrabet-Dahbi et al., 2009). >95% of the total cells were identified as mast cells on 
the basis of c-kit and FceRI cell surface expression or Kimura staining (Kimura et 
al., 1973). Cell number and viability were monitored using trypan blue staining 
(Section 2.2.5) (Figure 2.1). 
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Figure 2.1. The purity of bone marrow-derived cultured mast cells is over 95% after 4 weeks of 
cultivation. Bone marrow cells from C57BL/6 mouse were cultured for 4 weeks in IMDM (with 10% 
FCS, 100 u/ml penicillin/streptomycin and 50 µM 2-mercaptoethanol) in the presence of 30% WEHI-
3 conditioned medium. Cell number (A) and purity (B) was determined by every passage, twice a 
week with trypan blue and Kimura staining. Data are presented as the mean ± SD of nine independent 
experiments. 
 
2.2.9 Peritoneum-derived cultured mast cells 
Peritoneal cells were obtained from C57BL/6 mice after i.p. injection of 10 ml sterile 
PBS and then cultured in RPMI 1640 medium supplemented with 10% FCS and 100 
u/ml penicillin⁄streptomycin, L-glutamine (2 mM) 10 ng⁄ml recombinant mouse IL-3 
(Calbiochem, Merck, Darmstadt, Germany) and 30 ng⁄ml recombinant mouse stem 
cell factor (SCF) at 37oC as previously described (Mrabet-Dahbi et al., 2009) (Table 
2.3). 48 h later, non-adherent cells were removed and replaced by fresh culture 
medium for a further 7 days. >95% of the total cells were identified as mast cells on 
the basis of c-kit and FceRI cell surface expression or Kimura staining. Cells 
expressing low level of c-kit on their surface are supposed to be immature mast cells. 
Cell number and viability were monitored using trypan blue staining (Section 2.2.5) 
(Figure 2.2). 
 
48 
 
With this method from one mouse only 1-2 million PCMCs can be obtained. We 
tried to develop a method to reduce the number of animal required. Mice were 
injected i.p. with the growth factor IL-3 for 5 days with 2 injections per day prior to 
the peritoneal lavage. Although the mast cell number increased in the IL-3 treated 
group the mast cells’ ability to respond for bacterial stimulation was impaired. Our 
finding are summarised in an article (Appendix D) 
 
 
Figure 2.2. The purity of peritoneal-derived cultured mast cells is over 95% after 9 days of 
cultivation. Peritoneal cells were cultured for 9 days in complete RPMI medium in the presence of 10 
ng/ml IL-3 and 30 ng/ml SCF. Purity was assessed on the basis of c-kit and FcεRI cell surface 
expression measured by flow cytometry. A: unstained control; B: double stained sample 
 
2.2.10 Generation of bone marrow-derived dendritic cells (BMDC) 
BMDCs were prepared using a modified protocol originally described by (Lutz et al., 
1999). Bone marrow was harvested from the femurs and tibias of female BALB/C 
mice. Cells were seeded at 2x105 cells/ml density in RPMI supplemented with 10% 
FCS, 1% L-glutamine, 100 u/ml penicillin/streptomycin, 50 mM 2-mercaptoethanol 
and 20 ng/ml granulocyte macrophage colony-stimulating factor (GM-CSF) (Table 
2.3). GM-CSF was obtained from a GM-CSF producing cell line, a kind gift from 
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Prof. Ton Rolink, University of Basel, Switzerland. Cells were fed with fresh media 
at every second day. Cells were harvested at day 10 giving >95% pure BMDC 
population. Cell number was monitored by trypan blue staining (Section 2.2.5) and 
purity was determined on the basis of CD11c expression measured by flow 
cytometry (Section 2.2.18). 
 
Table 2.3. Contents of media used in cell culture 
Complete RPMI 
Reagent Amount Concentration 
RPMI 1640 500 ml  
FCS 50 ml 10% 
Penicillin/Streptomycin 5 ml 100 u/ml; 100 µg/ml 
L-Glutamine 5 ml 2 mM 
2-mercaptoethanol (1 M) 25 µl 50 µM 
Complete IMDM   
Reagent Amount Concentration 
IMDM 1000 ml  
FCS 100 ml 10% 
Penicillin/Streptomycin 10 ml 100 U/ml; 100 µg/ml 
2-mercaptoethanol (1 M) 50 µl 50 µM 
Complete ex vivo media   
Reagent Amount Concentration 
X vivo 15 50 ml  
2-mercaptoethanol (1 M) 50 µl 1 mM 
L-glutamine 0.5 ml 2 mM 
Growth factors   
Reagent Amount Concentration 
Mouse SCF  30 µg/ml 
Mouse IL-3  10 µg/ml 
 
2.2.11 BMDC stimulation 
For cytokine stimulation experiments BMDC were stimulated with or without 10 
mg/ml FhTeg 2.5 h before stimulation with PBS, recombinant IL-6, TNF-a (5, 10, 
50, 100 pg/ml)  or IFN-g (50, 100, 500, 1000 pg/ml). Supernatant and cells were 
harvested after 18 h. Supernatant were analysed for IL-12 p70 and TNF-a with 
commercial ELISA (BD, Bioscience, Oxford, UK) and nitrite level were determined 
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by Griess reagent system (Promega, Madison, USA). Cells were analysed by two 
colour flow cytometry for CD80, CD86, CD40 and CD11c expression (Section 
2.2.18). 
 
2.2.12 BMMC and PCMC activation and measurement of cytokine secretion 
To find good candidates to activate mast cells and promote Th1 but not Th2 immune 
response we tried a panel of TLR-ligands (Appendix A) and we found that 
lipopolysaccharide (LPS) (100 ng/ml; Alexis, San Diego United States) and heat 
inactivated Bordetella pertussis whole cell antigen (BP; was a kind gift from Dr 
Bernie Mahon, NUI, Maynooth, Ireland) (100 bacteria/cell) gave the strongest 
response. 
 
BMMCs and PCMCs were stimulated with LPS (100 ng/ml) heat inactivated BP 
(100 bacteria/cell), phorbol myristate acetate (PMA; 25 ng/ml), A23187 (1 µM), 
FhTeg (10 µg/ml) or PBS at 37
o
C for 24 hours. Cells were also treated with FhTeg 
(10 µg/ml) 2.5 hour before stimulation with BP or LPS. Supernatants assessed for 
levels of TNF-α, IL-6, IL-4, IL-5, IL-10 and IFN-γ by commercial ELISA (BD 
Biosciences, Oxford, UK). 
 
For TGF-β and prostaglandin D2 (PGD2) measurements mast cells were treated with 
10 µg/ml FhTeg or PBS for 6 or 24 hours. Supernatant was collected and used 
immediately or stored at -80oC until ELISAs were performed. 
 
In c-type lectin experiments mannose receptor, MGL, SignR1 and Dectin1 was 
blocked using neutralizing antibodies (α-MR, 1 mg/ml; α-MGL 1 mg/ml, α-SignR1 1 
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mg/ml, mannan 50 mg/ml, GalNac 50 mM, laminarin 100 mg/ml and EDTA 10mM) 
and Syk was blocked by Piceatannaol 30 min prior to stimulation. Neutralizing 
antibodies were used in concentrations recommended by manufacturer. Integrity and 
specificity was tested with flow cytometer following staining of BMMCs with anti-
MR, anti-MGL, anti-Dectin1 and anti-SignR1 (2.2.18). All tested antibodies fully 
blocked the binding of the labelled antibodies only on their target CLR. Piceatannaol 
concentration (1, 10, 20 µM) was validated using TNF-a/IFN-γ treated BMDCs 
(2.2.11). 10 µM of Pinceatannaol was used in blocking experiments as it showed the 
strongest suppression on CD40 and CD80 up-regulation by the cytokine treatment. 
In SOCS3 blocking experiments cells were treated with zoledranic acid (0.5, 1 or 5 
mg/ml) for 5 days prior to stimulation with FhTeg and bacterial ligands. 
 
2.2.13 SOCS3 blocking experiments 
SOCS3 inhibiting experiments were performed by a modification of a previously 
described method (Bringmann et al., 2007). BMDCs and BCMCs were cultured with 
0.5 mg/ml zoledronic acid (Sigma, Wicklow, Ireland). Zoledronic acid was added 
every other day for one week before experiments. 
 
2.2.14 Measurement of β-hexosaminidase release from BMMCs and PCMCs 
BMMCs or PCMCs were washed twice with PBS, resuspended in tyrodes buffer 
(Table 2.4) and seeded in a 96-well round-bottom plate at a density of 4 x 
105cells/200 µl followed by stimulation with stimulants, A23187 (1 µM) or PBS for 
1 hour at 37oC. Cell pellets were solubilised in tyrodes buffer supplemented with 1% 
Triton-X, and cell lysates and supernatants were incubated separately with p-
nitrophenyl-N-acetil-b-D-glucosamide (p-NAG) substrate (Table 2.4) for 1 h at 
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37
o
C. The production of b-hexosaminidase-mediated p-nitrophenol was terminated 
by adding 150 µl 0.2 M glycine (pH10.7) and quantified by absorbance at 405 nm 
with an ELISA plate reader (Tecan Genios, Mannedorf, Switzerland). The 
percentage of β-hexosaminidase release indicating the extent of degranulation was 
calculated as the ratio of p-nitrophenol absorbance in the supernatants and the sum of 
absorbance in the supernatant and cell lysates (Figure 2.3). Degranulation was 
measured following stimulation of mast cells with various antigens or with 
DNP/anti-DNP immunoglobulin (Ig)E in the presence or absence of FhTeg. 
 
Figure 2.3. Mast cells usually show 50% of degranulation when stimulated with A23187. Mast 
cells were stimulated with 1 µM A23187 for 1 h and β-hexosaminidase release was measured. Graph 
shows the percentages of degranulation of the cells. Data are represented as the mean ± SD of three 
independent experiments. 
 
Table 2.4. Components of buffers for β-Hexosaminidase assay 
Tyrodes buffer 
Reagent Amount Concentration 
1 M HEPES (238.3 g/L; pH7.4) 10 ml 10 mM 
NaCl 7.54 g 130 mM 
KCl 0.37 g 5 mM 
CaCl2 (•2H2O) 0.206 g 1.4 mM 
MgCl2 (•6H2O) 0.203 g 1 mM 
Glucose 1.008 g 5.6 mM 
BSA 1 g 1 mg/ml 
Total 1000 ml  
p-Nitrophenyl-N-acetyl-β-D-glucosaminide (p-NAG) substrate 
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Reagent Amount Concentration 
0.2 M Na2HPO4 (28.4 g/L) 70 ml 0.2 M 
Citric acid (84.1 g/L) 20 ml 0.4 M 
p-NAG 300 mg 1.3 mg/ml 
Total 225 ml pH4.5  
 
2.2.15 Preparing serum samples for β-hexosaminidase assay 
F. hepatica infected and control BALB/C mice were sacrificed after 3 weeks of 
infection by cervical dislocation. The abdominal cavity was opened and the vena 
cava posterior was cut. Using a 1 ml syringe with a pipette tip approximately 1 ml 
blood was collected from each mouse. Blood samples were incubated for 1 h at room 
temperature and centrifuged for 15 min at 1500 g at 4
o
C. Serum (the top yellow 
phase) was collected and stored at -20oC until tested without dilution on BMMCs in 
β-hexosaminidase assay. 
 
2.2.16 Proliferation 
Proliferation was measured by MTT (3-[4,5-dimethylthiazol-2yl]-2,5-diphenyl-
tetrazolium bromide) test (as described in manufacturer’s protocol, Sigma Aldrich, 
Wicklow, Ireland) or 0.9 mM resazurin. SCF (10 ng/ml) was used as positive 
control.  
 
2.2.17 Chemotaxis assay 
Mast cell migration was measured in 8 µm trans-well migration plates. BMMCs and 
PCMCs were plated in the upper wells in density of 1 million cells in 200 µl in the 
presence of 10 ng/ml IL-3. For controls FhTeg (10 µg/ml), SCF (10 ng/ml) was used 
in the bottom wells. RAW macrophages, BMMCs and BMDCs were stimulated with 
FhTeg or PBS for 18 hours prior transfer to trans-well plates with density of 0.6 
million cells in 600 µl. In some experiments cells were centrifuged and only 
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supernatants were used. Total cell number and mast cell number was monitored with 
trypan blue and Kimura staining in the first 3 hours taking samples in every hour 
from the bottom wells. After 3 hours cell numbers were determined by flow 
cytometry. Mast cells were identified on the basis of c-kit cell surface expression. 
 
2.2.18 Flow cytometric analysis 
Cells were harvested, washed twice in Facs buffer (Table 2.5) and pre-incubated for 
15 min with CD16/CD32 (FcγIII/II, BD Biosciences, Oxford, UK) to block FcR. 
After washing, 0.25 x 106 cells were incubated with the appropriate antibodies 
(Table 2.6) or the appropriate immunoglobuline (IgG) isotype control for 30 min at 
4°C in the dark. In multicolour experiments unstained, single stained and 
fluorescence minus one (FMO) controls were also used. After washing twice the 
monoclonal antibody (mAb) binding was analysed by flow cytometry (FACSAria 
and FACSCalibur, BD, Oxford, UK), in the presence of DNase to avoid aggregation, 
using FacsDiva (BD, Oxford, UK) and FlowJo Software (Tree Star, Ashland, USA). 
 
For intracellular staining cells were fixed in 4% formaldehyde in Facs buffer for 5 
min at room temperature and membranes were permeabilize with 0.5% Tween20® in 
Facs buffer for 15 min. 
Table 2.5. Contents of Facs buffer 
Facs buffer 
Reagent Amount Concentration 
PBS 100 ml  
FCS 2 ml 2% 
NaH3 0.05 g 0.05% 
EDTA 0.019 g 1 mM 
DNAse (1u/µl) Add prior to use 10 u/ml 
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Table 2.6. Antibodies used in flow cytometry 
Name Fluorochrome Clone Catalog # Company 
FcεRI PE MAR1 12-5898 Ebioscience, UK 
FcεRI FITC MAR1 11-5898 Ebioscience, UK 
CD117 (c-kit) PE 2B8 12-1171 Ebioscience, UK 
CD117 (c-kit) FITC 2B8 11-1171 Ebioscience, UK 
CD117 (c-kit) APC 2B8 17-1171 Ebioscience, UK 
CD282 (TLR2) FITC 6C2 11-9021 Ebioscience, UK 
CD54 (ICAM1) PE YN1/1.7.4 12-0541 Ebioscience, UK 
CD252 (OX40L) PE MRI 12-5905 Ebioscience, UK 
CD40L PE MRI 12-1541 Ebioscience, UK 
CD28 PE 37.51 553297 BD Bioscience, UK 
TLR4/MD-2 PE MTS510 12-9924 Ebioscience, UK 
TNF-α APC MP6-XT22 17-7321 Ebioscience, UK 
CD206(MMR) Alexa fluor 488 MR5D3 123005 Biolegend, UK 
MGL Alexa fluor 488 ER-MP23 MCA2392A AbD serotec, UK 
Dectin1 Alexa fluor 488 GE2 MCA4661A AbD serotec, UK 
SignR1 Alexa fluor 688  eBio22D1 51-2093 Ebioscience, UK 
PE: phycoerythrin; FITC: fluorescein isothyocyanin; APC: allophycocyanin 
 
2.2.19 Co-culture of BMMCs or PCMCs with CD
+
 T-cells: 
CD4+ T-cells were isolated using MACS CD4+ T-Cell Isolation Kit (Miltenyi Biotec, 
Surrey, UK) and were used if the purity were 95% or above as determined by flow 
cytometry (FITC conjugated CD4, clone L3T4, BD Biosciences, Oxford, UK).  
BMMCs and PCMCs were cultured in appropriate medium (Table 2.7) the presence 
of FhTeg (10 µg/ml) 2.5 hour before stimulation LPS (100 ng/ml) or BP (100 
bacteria/cell) for 24 hours. In c-type lectin blocking experiments cells were treated 
with α-SignR1, α-MR or α-MGL (1 mg/ml) neutralizing antibodies 30 min prior to 
stimulation.  Washed BMMCs and PCMCs or supernatant was added to CD4+ T-
cells (1:1) in plates coated with anti CD3 (1 µg/ml; BD Biosciences, Oxford, UK) 
for 72 hours and supernatants were tested for IFN-γ, IL-4, IL-5 and IL-10 by 
commercial ELISA (BD Biosciences, Oxford, UK). In some experiments 
intracellular adhesion molecule 1 (ICAM-1) blocking antibody (clone YN1/1.4; 
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Abcam, Cambridge, UK) was given to mast cells 30 min before co-culturing with 
CD4+ cells. 
Table 2.7. Different variations of media used in co-culture studies 
Media Result 
100 % X vivo Mast cells died 
100 % c. RPMI Too high background in ELISA 
50-50% X vivo and c. RPMI Used in PCMC studies 
100 % c. IMDM Used in BMMC studies 
 
 
2.2.20 Protein extraction 
BMDCs, BMMCs and PCMCs were stimulated with LPS (100 ng/ml) or BP (100 
bacteria/cell) for 5, 15, 30, 60 or 120 minutes with and without FhTeg (10 µg/ml) 
treatment. In c-type lectin blocking experiments cells were treated with α-MR or α-
MGL (1 mg/ml) neutralizing antibodies 30 min prior to stimulation. Cells were 
washed in PBS twice and total protein was extracted from cell lysates by use of 
radioimmunoprecipitation (RIPA) buffer (100 µl/1 million cells) containing protease 
and phosphatase inhibitor cocktails (1%; Table 2.8). 
Table 2.8. RIPA buffer 
Reagent Amount Concentration 
RIPA 1 ml 100 µl/cell 
Protease inhibitor cocktail 2 ml 1% 
Phosphatase inhibitor cocktail 
1/3 
0.05 g 1% 
Phosphatase inhibitor cocktail 2 0.019 g 1% 
 
Samples were incubated at least 5 minutes on ice and lysates were cleared by 
centrifugation at 8000xg for 10 minutes. Supernatants were transferred to new tubes 
and protein concentrations were determined using the BCA protein assay kit (Pierce, 
Thermo Scientific, Leicestershire, UK) following the protocol provided by the 
company. 
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2.2.21 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed based on a previously established method (Laemmli, 1970) using a mini-
gel system (ATTO Bio-Instrument, Bunkyo, Japan). 10 % acrylamide resolving gels 
with 5 % stacking gels were prepared (Table 2.9).  
Table 2.9. Gel for SDS-PAGE 
10% Separating gel (2 gels) 5% Stacking gels (2 gels) 
Reagent Volume (ml) Reagent Volume (ml) 
40 % acrylamide 3.8 40 % acrylamide 0.625 
1M Tris-HCl, pH 8.8 5.6 1M Tris-HCl, pH 6.8 0.625 
d. H2O 5.4 d. H2O 3.625 
10 % SDS 0.15 10 % SDS 0.05 
10 % APS (fresh) 0.075 10 % APS (fresh) 0.05 
TEMED 0.025 TEMED 0.025 
Total 15 Total 5 
 
Protein samples were prepared in SDS-PAGE reducing dye, boiled for 2 min on a 
heating plate and then incubated on room temperature for at least 5 min. Samples 
and pre-stained protein markers (See Blue Plus 2, Invitrogen) were loaded on the 
gels and electrophoresis was performed between 150-200 V for 1 hour in ice cold 
SDS running buffer (Table 2.10). 
Table 2.10. Contents of solutions for SDS PAGE 
 Reagent Amount Concentration 
Running buffer Tris 3 g 25 mM 
Glycine 14.4 g 192 mM 
SDS 1 g 0.2 % 
Total 1000 ml, pH 8.3  
Reducing dye (5x) Tris 0.7571 g 0.625 M 
Glycerol 5 ml 50 % 
SDS 1 g 10% 
Bromphenol blue 0.01 g 0.1% 
2-mercaptoethanol 0.5 ml 5% 
Total 10 ml; pH6.8  
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2.2.22 Western blot analysis 
Protein samples (10 to 40 µg) were separated by SDS-PAGE and blotted onto 0.45-
µm Immobilon-P polyvinylidene fluoride membranes (Millipore, Carrigtwohill, 
Ireland) using Semi-dry blotter (Z340502, Sigma-Aldrich) with fresh ice cold 
transfer buffer (Table 2.11).  
Table 2.11. Components of buffers for western blot 
 Reagent Amount Concentration 
1. Transfer buffer Tris 6.06 g 25 mM 
Glycine 28.8 g 192 mM 
Methanol 400 ml 20 % 
Total 2000 ml, pH 8.3  
2. Tris buffer saline 
(PBS) 
Tris 2.4228 g 20 mM 
NaCl 8.766 g 150 mM 
Total 1000 ml, pH 7.5  
3. Washing buffer 
(TBS-T) 
Tween 20® 0.5 ml 0.05 % 
TBS 1000 ml  
4. Blocking/Antibody 
buffer 
Marvel (skim) 0.5 g 5 % 
TBS-T 10 ml  
 
Membranes were stained using standard western blot protocol (Table 2.12) with 
antibodies listed in Table 2.13. Proteins were visualized with a Chemiluminescent 
HRP substrate (Millipore, Carrigtwohill, Ireland), exposed to film (1-60 sec) and 
processed using an FPM 100A processor (Fuji Film). Protein bands were quantified 
using ImageJ analysis software (imagej.nih.gov). Levels of proteins were normalized 
to total protein controls or β-actin and expressed in arbitrary units as percentage 
increases over the medium control levels. 
Table 2.12. Western blot staining protocol 
Solution Incubation time Temperature 
Blocking buffer 1 h RT 
1st Antibody (in Ab buffer) overnight 4oC 
Washing buffer 30 min RT 
2nd Antibody (in Ab buffer) 1 h RT 
Washing buffer 1 h RT 
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Table 2.13. Antibodies and their concentration 
Primary Antibody Concentration Catalog # Company 
Phospho-ERK 1:1000 9106 Cell Signalling, USA 
Total-ERK 1:1000 9107 Cell Signalling, USA 
NF-κB (p65) 1:2500 ST1047/3375 Millipore, USA 
Phospho-p38 1:1000 9211 Cell Signalling, USA 
Total-p38 1:1000 9212 Cell Signalling, USA 
Phospho-JNK 1:1000 4668 Cell Signalling, USA 
Total-JNK 1:1000 9252 Cell Signalling, USA 
Phospho-IRF3 1:1000 4947 Cell Signalling, USA 
Total-IRF3 1:1000 4302 Cell Signalling, USA 
Phospho-cFos 1:1000 5348 Cell Signalling, USA 
Total-cFos 1:1000 2250 Cell Signalling, USA 
SOCS3 1:1000 2932 Cell Signalling, USA 
β-actin 1:500 643802 Biolegend, UK 
Secondary Antibody Concentration Catalog # Company 
Anti-Rabbit IgG 1:2500 A1949 Sigma-Aldrich, 
Ireland 
 
2.2.23 RNA extraction and reverse-transcriptase polymerase chain reaction 
(RT-PCR) 
BMDCs/BMMCs were stimulated with or without FhTeg (10 mg/ml) prior to 
stimulation with LPS or PBS. Cells were harvested and washed after 5, 15, 30, 60 
min, 6 and 18 hours. Total RNA was extracted from homogenised samples by using 
TRISure (Bioline, London, UK), and following the manufacturer’s instructions. 
RNA quality and quantity were monitored by Nanodrop® (Thermo Fischer 
Scientific, Dublin, Ireland). To eliminate genomic DNA contamination, RNA 
samples were treated with RNase free DNase (Invitrogen, Paisley, UK) 0.4 µg 
DNase treated total RNA was reverse-transcribed using the reverse transcriptase kit 
(Promega, Madison, USA) according to manufacturer protocol. 
 
Sequences of target DNAs were selected from the database of the National Center 
for Biotechnology Information (www.ncbi.nih.gow). Primers were designed using 
Primer3 program (frodo.wi.mit.edu) with the criteria that the product must be less 
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than 250 basis pairs and the melting temperature has to be around 60-61
o
C. Primers 
were tested in silico by the free online program Oligo Analyser (eu.idtdna.com) if 
there was any hairpin, self-dimer or hetero-dimer which could form a secondary 
product during the PCR analysis. Finally primer specificity was checked using 
BLAST (blast.ncbi.nlm.nih.gov). 
 
Prior to quantitative PCR (qPCR) analysis primers (Table 2.14.) were tested in 
conventional PCR reaction with the same settings as were used in qPCR using 20 ng 
cDNA templates. PCR was performed using GoTaq PCR master mix (Promega, 
Madison, USA) in Thermo-Hybrid PCR express PCR thermocycler (MSC, Dublin, 
Ireland) (Table 2.15). PCR products were separated on 1% agarose gels in 0.5 
strength TRIS base boric acid EDTA (TBA) buffer containing SYBRSafe 
(Invitrogen, Paisley, UK) and acquired under UV light (G-Box Gel imaging system, 
Syngene, Cambridge, UK). Primers were excluded from further experiments if they 
gave more than one single band when PCR products were run on 1% agarose gel or 
if they form primer dimers. In addition melting curves analysis was performed by a 
real time thermal cycler ABI7900FH (Applied Biosciences, Paisley, UK) to check 
product size and homogeneity. 
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Table 2.14. Primers 
Name Sequence Product size (bp) Tm (
o
C) 
b-actin AGTCCCTCACCCTCCCAAA 266 61.83 
CTGCCTCAACACCTCAACC 
 
 59.25 
GAPDH CAAGAAGGTGGTGAAGCAG 112 56.92 
GAAGGTGGAAGAGTGGGAGTT 
 
 59.59 
Gusb ACCAGCCACTATCCCTACTCA 200 58.68 
GCCACAGACCACATCACAAC 
 
 60.01 
TRAF6 CGGGTTGTGTGTGTCTGTGT 58 60.54 
CCTTCTTCTGGCTTTCGTG 
 
 58.58 
MyD88 AAATACAAGGCGATGAAGAAGG 279 59.63 
TGGGAGGAAAGGCAGTC 
 
 57.07 
TLR4 GAGCCGTTGGTGTATCTTTGA 274 60.13 
TGCCGTTTCTTGTTCTTCCT 
 
 59.85 
RelA 
(NFkB) 
CCCTCATCTTTCCCTCA 155 54.14 
TGTCTTGGTGGTATCTGTGCT 
 
 59.66 
SOCS1 GAGTGGTTGTGGAGGGTGAG 61 60.56 
 TGAGAGGTGGGATGAGGTC 
 
 58.51 
SOCS2 GCTGAAGGAGGGAAAGACC 159 58.80 
 GCATAAGACGAGGGATAAATACAAG 
 
 59.49 
SOCS3 GGTTCTGCTTTGTCTCTCCTATGT 95 60.19 
TGTGTTTGGCTCCTTGTGTG 
 
 60.79 
SOCS4 GCCCTTCCCATTCCTTC 115 57.91 
 TTCTAACCTCTCCGCATCACT 
 
 58.95 
SOCS5 CGAGAACCAGTCAAAGCAAA 222 59.05 
 TCACAGCCCACCGAACA 
 
 60.87 
PIAS1 ACGAGCAAAGGGAATAAGGAA 174 60.08 
 TGAAGGTGGGAGCAGGTAAG 
 
 60.25 
PIAS3 AACAAGAGTGGGCGGAAAC 159 60.10 
 GGGCAAAGAAAGCAAGGAG 
 
 59.94 
PIAS4 TCGGCAGGTGGAGATGA 235 59.83 
 GAGGTGGGTAAGGTTGATGG  59.26 
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Table 2.15. Conventional PCR reaction 
Temperature Time Cycle number 
95oC 30 sec  
95oC 30 sec 
x 35 
60oC 60 sec 
72oC 120 sec  
 
2.2.24 Quantitative RT-PCR analysis 
The qPCR expression analysis was carried out on a real time thermal cycler 
ABI7900FH (Applied Biosciences Paisley, UK), using Maxima SYBRgreen master 
mix according to manufacturer’s protocol (Table 2.16.) (Fermentas, Fischer 
Scientific, Dublin, Ireland) in triplicate on 96 well Microamp optical plates (Applied 
Biosystems, Paisley, UK). Three internal standards were used: b-actin 
(NM_007393.3), GAPDH (NM_008084.2), Gusb (β-glucuronidase) (NM_010368.1) 
(Table 2.14.). 
 
Table 2.16. Working solution for q-PCR 
Reagent Amount 
SYBRgreen 12 ml 
Forward primer (10 mM) 1 ml 
Reverse primer (10 mM) 1 ml 
Template cDNA 20 ng 
Total 25 ml 
 
Samples were maintained for 10 s at 95°C as initial step, then 15 s at 95°C and 60 s 
at 60°C through 40 cycles. After amplification, melting curves were recorded (from 
50 to 95oC) to check product size and homogeneity. Pfaffl’s method was used to 
calculate relative changes in gene expression determined from real-time quantitative 
revers transcription PCR experiments (Pfaffl, 2001). Real-time PCR efficiencies 
were calculated from the given and averaged Ct values of the dilution series for each 
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primers determined with RQ Manager 1.2 software (Applied Biosystems, Paisley, 
UK). The corresponding real time PCR efficiency (E) was calculated according to 
the equation: E=10(-1/slope). The investigated range was from 0.3 to 20 ng total cDNA 
input (n = 3) using 8 step dilution series (Figure 2.4.). 
 
Figure 2.4. Determination of real-time PCR efficiencies of reference gene (GAPDH). Ct cycles 
versus cDNA concentration input were plotted to calculate the slope (mean ± SD; n=3). The 
corresponding real time PCR efficiency (E) was calculated according to the equation: E=10(-1/slope). 
The investigated range was from 0.3 to 20 ng total cDNA input (n = 3) using 8 step dilution series. 
 
To determine the relative quantification of a target gene in comparison to a reference 
gene a mathematical model was used described by (Pfaffl, 2001). The relative 
expression ratio of a target gene was calculated based on the efficiency (E) and the 
Ct deviation of a treated sample versus a control, and expressed in comparison to a 
reference gene. 
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Etarget: real-time PCR efficiency of a target gene transcript 
Eref: real-time PCR efficiency of a reference gene transcript 
DCttarget: Ct deviation of control – sample of target gene transcript 
DCtreference: Ct deviation of control – sample of reference gene transcript 
 
2.2.25 Isolation of Bordetella pertussis Lipooligosaccharide (LOS) 
Isolation of BP LOS was performed according to a previously described protocol 
(Schaeffer et al., 2004) and performed by Dr Alessandra Ravidà (DCU, Dublin, 
Ireland). Briefly, 1x1011 cells of heat inactivated BP were suspended in 3 ml of 0.1 
mg/ml proteinase K (Roche, Manheim, Germany) in PBS and incubated for 1.5 h at 
56°C. After incubation the mixture was subjected to acetone precipitation and the 
pellet solubilised in 1 ml of sterile PBS. Reaction completion was evaluated by 16% 
SDS-PAGE followed by silver staining (Figure 2.5.A) (Kittelberger and Hilbink, 
1993). The contaminating presence of Proteinase K in the crude LOS preparation 
was removed by centrifugation (Inzana et al., 2002) (Avanti®J-26 XP centrifuge, 
Beckman Coulter, Fullerton, USA) at 40,000 x g for 4 h at 4°C in a fixed angle rotor 
(Beckman JA-20, Fullerton, USA). Both the LOS-containing pellet and the acetone 
precipitated supernatant were dissolved in 300 μl of sterile PBS. Purified LOS was 
separated on 16% SDS-PAGE and stained by the silver nitrate method (Figure 
2.5.B). 
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Figure 2.5. Silver stained SDS-PAGE. A, BP: Whole B. pertussis cell lysate (10 mg), Proteinase K 
(5 mg), B. pertussis LOS crude preparation (10 ml); B, B. pertussis LOS supernatant (SN), B. pertussis 
LOS pellet 
 
BMMCs were stimulated with blocking anti-MR and anti-MGL neutralisation 
antibodies (1 mg/ml) 30 min prior to stimulation with this LOS preparation (1 u/cell, 
equal to 100 bacteria/cell) for 24 h. Supernatant were tested for TNF-a and IL-6 
cytokines. Proteinase K was used as a control to see if it has any effect on cytokine 
secretion. 
 
2.2.26 Statistics 
All data were analysed for normality prior to statistical testing by Origin® 6.1 
(OriginLab Corporation) software (n ≥ 3, exact numbers of origin data points are 
indicated below each figures). Where multiple group comparisons were made, data 
were analysed using one-way ANOVA to asses if data belong to the same group. For 
comparisons between two groups, the Student’s t test was used. In all tests, p < 0.05 
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was deemed significant. All results (exept results from ELISA) were presented as the 
mean ± SD of at least three independent experiments. Flow cytometry and western 
blot results were normalised to isotype control or untreated control before statistic 
analysis. Figures from ELISA results are representatives of three independent 
experiments and presented as the mean ± SD of three replicate samples from the 
same experiment. 
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3 Chapter 3 – Fasciola hepatica tegumental antigens enhance mast cell 
numbers in vivo in a STAT6 independent manner 
 
3.1 Introduction 
Helminth infections are often associated with increased mast cell numbers 
(mastocytosis) and redistribution of these cells to the site of infection (McCole et al., 
1998; Maizels et al., 2004; Weller et al., 2011). Mast cells are associated with 
helminth induced Th2 immune responses (Dawicki and Marshall, 2007) where Th2 
cytokines secreted by CD4
+
 T-cells direct B-cells to produce helminth specific IgE 
(Anthony et al., 2007; Erb, 2007). Mast cells express the high affinity FcεRI 
receptor, which in the presence of helminth antigens and the specific IgE antibody 
induce mast cell degranulation and the release of inflammatory mediators such as 
histamine, cytokines or chemokines. These mediators can promote Th2 immune 
responses (Melendez et al., 2007; Pearce, 2007), for example during 
Heligmosomoides polygyrus infection results in mast cell activation and induces 
tissue derived IL-25, IL-33 and TSLP cytokines (Hepworth et al., 2012a) which 
drive Th2 cell priming by dendritic cells (Hepworth et al., 2012b). 
 
Mast cells contribute to the clearance of helminth infection by gut parasites 
(Anthony et al., 2007; Klementowicz et al., 2012). For example, studies in mouse 
and rat models demonstrated that the clearance of Trichuris muris, Nippostrogylus 
brasiliensis or Strongyloides ratti is mast cell dependent (Abe and Nawa, 1988; 
McDermott et al., 2003; Marshall, 2004). Nematode fecundity is higher in mast cell-
deficient mice when infected by Heligmosomoides polygyrus compared to normal or 
mast cell-reconstituted mice (Hashimoto et al., 2009), and mast cells were shown to 
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contribute to the development of Th2 responses towards this gastrointestinal 
helminths by activating other cells involved in Th2 immunity, like epithelial cells or 
dendritic cells (Hepworth et al., 2012b). While mast cells are crucial in the clearance 
of gut helminths, they do not appear to have a key role in the clearance of tissue 
dwelling helminths such as schistosomiasis, although they are present in the early 
stages of Schistosoma infection (Gerken et al., 1990). 
 
Fasciola hepatica causes a chronic liver infection (fascioliasis) in mammals, 
including cattle and sheep (Collins et al., 2004) and is an important zoonotic disease 
in humans with approximately 2.4 million people infected worldwide (McManus and 
Dalton, 2006). The life cycle of the parasite is complex with an intermediate snail 
host and definitive mammalian host. The definitive host is infected following 
ingestion of metacercariae shed from snails. These metacercariae excyst in the 
duodenum to form newly excysted juvenile flukes that penetrate the intestinal wall. 
They migrate through the peritoneal cavity and liver for several weeks and then 
finally the adult worm resides in the bile ducts releasing eggs for up to 30 years.  
 
Fasciola promotes strong Th2/Treg mediated immune responses characterised by 
production of IL-4, IL-5 and IL-10 (O'Neill et al., 2000; Miller et al., 2009). 
Previous studies have shown mast cell number to be increased in the liver of cattle 
and sheep infected with F. hepatica (Rahko, 1969; Ferreras et al., 2000). An increase 
in mast cell number was also reported in the Peyer’s patches (O'Brien et al., 2008) 
and mucosa of the small intestine (Charbon et al., 1991; Van Milligen et al., 1998) in 
F. hepatica infected rats. We know that injection of FhES mimics the Th2 immune 
response observed during Fasciola infection; however, it does not enhance mast cell 
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numbers in rats (Trudgett et al., 2003). Other studies have shown that F. hepatica 
derived peptides from the tegumental coat induce degranulation of rat peritoneal 
mast cells and histamine release (Trudgett et al., 2003). 
 
Fasciola tegumental coat is shed from the parasite every 2-3 hours and is in constant 
contact with host immune cells (Halton, 2004). The isolated tegumental antigen of F. 
hepatica (FhTeg) suppresses dendritic cell maturation and function by inhibiting IL-
6, tumour necrosis factor (TNF)-a, IL-10 and IL-12 production and CD80, CD86 
and CD40 cell surface marker expression in TLR4 stimulated dendritic cells. FhTeg 
also impaired dendritic cell function by inhibiting its phagocytic capacity and its 
ability to prime T-cells (Hamilton et al., 2009; Hacariz et al., 2010). In this study we 
examined the interaction between FhTeg and mast cells in order to help us to 
understand the function of mast cells in the immunity against F. hepatica. 
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3.2 Experimental design 
This chapter investigates the role of mast cells during Fasciola hepatica infection in 
mice and investigates if FhTeg can mimic these responses in vivo. FhTeg’s 
interaction with mast cells was also examined to determine if FhTeg can enhance or 
suppress Th2 immune responses. Firstly, BALB/C mice were infected with F. 
hepatica metacercariae (2.2.4) to determine if mast cells numbers increase in the 
peritoneal cavity (2.2.18) and liver (2.2.7) of mice infected with F. hepatica. The 
initial experiments used BALB/C mice as these are model mice for Th2 immune 
responses. Since STAT6 is important to the establishment of Th2 immune responses, 
STAT6
-/-
 mice and background C57BL/6 control mice were infected with F. 
hepatica metacecariae to determine if mast cell numbers were enhanced during 
infection in the absence of Th2 immune responses. We have previously established a 
model system were Fasciola antigens injected three time per week for three weeks 
can mimic the immune responses during F. hepatica infection. Using this system we 
determined if one of two fasciola antigen sources (FhES and FhTeg) could induce an 
increase in peritoneal mast cell number following treatment and the role of STAT6 
was also determined.  
 
Since FhTeg can induce mast cell numbers in vivo in a STA6 independent manner it 
was also determined if FhTeg can activate mast cells to promote Th2 immune 
responses. In vitro experiments were designed to determine if mast cells treated with 
FhTeg for 24 hours in vitro degranulate (2.2.14), produce Th2 promoting cytokines 
(2.2.12) or undergo proliferation (2.2.16). In these experiments BMMCs (2.2.8) were 
used for all experiments. However, PCMCs (2.2.9) are more mature and a better 
model to study mast cell – antigen interactions, although the isolation of these cells 
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require a substantial number of mice (1 mouse for 1 million cells) and therefore for 
ethical reasons only some positive results were confirmed with these cells. Cells 
were isolated from C57BL/6 mice as these mice are considered the model system for 
mast cell research. FhTeg treated BMMCs and PCMCs were also co-cultured with 
naïve T-cells (2.2.19) to determine if they can promote Th2 immune responses. 
Since IgE-dependent degranulaiton of mast cells is associated with helminth 
infection it was also tested if FhTeg can suppress IgE driven mast cell degranulation 
in two in vivo (PSA and PCA models, 2.2.6) and one in vitro (BMMCs, 2.2.14, 
2.2.15) model systems. 
 
Since FhTeg can enhance mast cells numbers in vivo it was investigated if FhTeg can 
induce proliferation and/or migration of mast cells. BMMCs and PCMCs were 
treated with FhTeg or FhTeg in the presence of stem cell factor which induces mast 
cell proliferation and proliferation measured after 24 hours (2.2.18). Migration of 
BMMCs and PCMCs were also tested on trans-well plates against FhTeg (10 µg/ml), 
IL-4, SCF (10 ng/ml) or FhTeg treated/untreated mast cells, macrophages and 
dendritic cells or their supernatants.  
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3.3 Results 
3.3.1 Mast cell numbers are significantly enhanced during F. hepatica 
infection and this is mimicked by intraperitoneal injection of FhTeg. 
BALB/C mice were infected with 20 F. hepatica metacecariae and after two weeks 
peritoneal exudate cells and whole livers were obtained to determine mast cell 
numbers. The ratio and number of mast cells increased in the peritoneal cavity from 
0.5 ± 0.2% ((0.89 ± 0.51) x 104) control mice) to 17.5 ± 9.1% (p ≤ 0.05) ((265.64 ± 
177.54) x 10
4
) infected mice) (Figure 3.1A) with similar increases observed in the 
liver; 1.5 ± 2.2/mm
2 (control mice) to 7.9 ± 6.6/mm2 (p ≤ 0.01) (infected mice) 
(Figure 3.1B, C, E). Hematoxylin/eosin staining showed tumour like cells in infected 
liver by the bile duct (Figure 3.1D, F). This is a symptom of fluke infection (Rahko, 
1969).  
 
It was previously shown that F. hepatica derived antigens when injected into 
BALB/C mice can mimic the immune response associated with F. hepatica infection 
(Donnelly et al., 2005). Using this model system we found that both FhTeg (19.6 ± 
3.5%; p ≤ 0.01; (35.39 ± 3.9) x 10
4
) and FhES (5.4 ± 2.2 %; p ≤ 0.05; (5.79 ± 3.5) x 
104) when injected into mice increased mast cell numbers in the peritoneal cavity 
(control, 0.6 ± 0.2% (0.31 ± 0.13) x 104)) (Figure 3.1A). However, the increase in 
mast cell ratio in response to FhTeg was significantly greater when compared to 
FhES (p ≤ 0.01) and was similar to that observed during natural infection. Given that 
the total cell number in the peritoneal cavity was higher during infection than after 
FhTeg injection, increase in mast cell number also appear to be higher in the infected 
group compared to FhTeg group, although the values are not significantly different 
(p = 0.1). 
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Figure 3.1. Mast cell number increased in the peritoneal cavity and in the liver after Fasciola 
infection. Injection of FhTeg but not ES mimicked the effect of Fasciolosis. Peritoneal exudate 
cells were harvested from un-infected (control), F. hepatica metacercariae (infected); PBS, FhES and 
FhTeg (10 µg) injected BALB/C mice. Percentages of mast cells were determined by two-colour flow 
cytometry for c-kit and FcεRI (A). Flow cytometry data were normalised to isotype controls and are 
presented as the mean ± SD of three independent experiments with 3 or 5 mice (n=9). *, p ≤ 0.05; **, 
p ≤ 0.01 compared to control group. 5 µm sections of liver from control and F. hepatica infected mice 
were stained with alcian blue/safranin dye (C, E) and mast cells were counted (**, p ≤ 0.05, B). 
Sections were also stained with standard hematoxiliyn/eosin dye (D, F). 
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3.3.2 Mast cells treated with FhTeg do not degranulate and exhibit reduced 
FceRI expression but this does not alter IgE mediated activation of mast cells in 
vivo or in vitro.  
As mast cell number in the peritoneal cavity increased after FhTeg injection mast 
cell – FhTeg interaction was investigated in more detail. Previous studies have 
shown that F. hepatica derived peptides induce degranulation of rat peritoneal mast 
cells and histamine release (Trudgett et al., 2003). In contrast, we found that bone 
marrow and peritoneum-derived mast cells do not degranulate in the presence of 
FhTeg (Figure 3.2A, B), even in the presence of sera from F. hepatica infected mice 
(Figure 3.3D). 
 
Mast cells treated with FhTeg exhibited consistent and significant decrease in FceRI 
expression (Figure 3.2C, D; p £ 0.01). FceRI is the receptor for IgE and is critical in 
IgE mediated degranulation of mast cells. We therefore investigated if FhTeg could 
alter IgE mediated degranulation in two in vivo model systems; passive systemic 
anaphylaxis model (PSA) or passive cutaneous anaphylaxis (PCA). We found that 
FhTeg does not markedly alter the IgE mediated responses in either model systems. 
However in the PCA model there was significant decrease in ear swelling at 4 and 6 
hours (Figure 3.3A, B; p £ 0.05). Similarly FhTeg did not alter DNP-specific IgE 
degranulation in BMMCs in vitro (Figure 3.3C). 
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Figure 3.2. Mast cells treated with FhTeg do not degranulate and exhibit reduced FceRI 
expression. BMMCs and PCMCs were treated with FhTeg (10 mg/ml) for 24 hours. Degranulation 
was tested by measuring b-hexosaminidase release (A, B). FceRI expression was measured by two 
colour flow cytometry (FceRI and c-kit) (C, D). Data are presented as the mean ± SD of at least three 
independent experiments (n=3). 
 
 
Figure 3.3. FhTeg does not alter IgE mediated activation of mast cells in vivo or in vitro. 
C57BL/6 mice were injected with FhTeg (10 µg/ml) three times before administering DNP-specific 
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IgE prior to challenge with DNP subcutaneously (A; Passive cutaneous anaphylaxis model – PCA) or 
systemically (B; Passive systemic anaphylaxis model – PSA). DNP-specific IgE mediated 
degranulation was measured by β-hexosaminidase assay in vitro on FhTeg treated and untreated 
BMMCs (C). Data are presented as the mean ± SD of three independent experiments (n=3). *, p ≤ 
0.05; **, p ≤ 0.01 compared to control group. These experiments (except D) were done at Charité 
Universitätmedizin in Berlin by Dr Sandra O’Neill. 
 
3.3.3 FhTeg treated mast cells do not produce Th2 cytokines or promote a 
Th2 immune response in CD4
+
 cells. 
Mast cells are potent source of pro-inflammatory mediators, such as IL-4, that play 
key role in the development of Th2 immune responses against helminth parasites 
(Maizels et al., 2004). We, therefore, assessed if FhTeg stimulated mast cells 
promote Th2 immune responses. BMMCs and PCMCs stimulated with different 
concentrations (5, 10, 20 mg/ml) of FhTeg for 6 (data not shown) or 24 hours did not 
release significant amounts of IL-6, TNF-α (Figure 3.4A-B), IFN-γ, IL-13, IL-10, 
IL-5 or IL-4 (data not shown). Given that PCMCs are more mature and were shown 
previously to give a different activation profile when stimulated with pathogen 
antigens (Mrabet-Dahbi et al., 2009) we repeated these experiments with PCMCs 
and a similar result were observed (Figure 3.4C-D). All positive control responded 
appropriately and responses were statistically significant (p ≤ 0.01). 
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Figure 3.4. FhTeg treated mast cells do not produce cytokines. BMMCs and PCMCs were 
stimulated with FhTeg (10 µg/ml) or PBS for 24 hours. TNF-α (A, C) and IL-6 (B, D) secretion was 
determined from supernatant using ELISA. A23187, or LPS was used as positive controls and 
responds appropriately and statistically significant (p≤0.01). Data are presented as the mean ± SD of 
at least three independent experiments (n=3). 
 
Previous studies have shown that BMMCs and PCMCs co-cultured with CD4+ T-
cells can promote cytokine secretion (Huels et al., 1995; Nakae et al., 2005) and this 
is enhanced when mast cells first exposed to TLR ligands (Nie et al., 2011). Co-
culturing of FhTeg treated mast cells with naïve CD4
+ T-cell did not promote Th1 or 
Th2/Treg responses in mast cells (Figure 3.5). Next we investigated if Th2 cytokines 
are involved in the increase of mast cell number during F. hepatica infection. 
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Figure 3.5. Mast cells stimulated with FhTeg do not promote Th1 or Th2 immune responses 
when co-cultured with anti-CD3 stimulated naïve CD4+ T-cells. BMMCs and PCMCs were 
stimulated with PBS, FhTeg (10 µg/ml) or LPS (100 ng/ml) for 24 hours. Cells were washed and co-
cultured with anti-CD3 stimulated naïve CD4+ cells (1:1) and after 72 hours supernatant were 
analysed for IFN-γ (A, E), IL-10 (B, F), IL-5 (C, G) and IL-4 (D, H) cytokines. T-cells cultured 
without mast cells were used as negative controls. Figures are representative of at least three 
independent experiments and presented as the mean ± SD of three replicate samples from the same 
experiment. 
 
3.3.4 Enhancement of mast cell numbers in vivo is not dependent upon 
STAT6. 
Since FhTeg stimulated mast cells did not promote Th2 immunity in vitro we wanted 
to determine if Th2 cytokines are involved in the increase in mast cells ratio and 
number during infection and following injection of FhTeg. STAT6 activation is 
critical in driving Th2 immune responses associated with helminth infection 
(Finkelman et al., 2004). When STAT6-/- mice were infected with F. hepatica 
metacercariae or injected with FhTeg, we found increases in mast cell numbers in 
control background  mice (C57BL/6, from uninfected 2.9 ± 1.4%; (1.53 ± 2.51) x 
10
4
   to infected 24.6 ± 11.3%; (385.07 ± 143.40) x 10
4
 (p ≤ 0.05)) to be similar to 
those in STAT6-/- mice (from uninfected 2.3 ± 0.8%; (1.87 ± 2.03) x 104 to infected 
19.2 ± 7%; (297.04 ± 149.37) x 10
4  (p ≤ 0.01)). STAT6-/- mice injected with FhTeg 
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also demonstrated a similar increase in mast cells numbers (from 5.3 ± 3.4%; (1.89 ± 
2.64) x 104 to 21.7 ± 6.7%; (45.81 ± 17.26) x 104 (p ≤ 0.05) as controls (C57BL/6: 
from 4.1 ± 2.9%; (1.46 ± 1.35) x 10
4 to 22.7 ± 1.9%; (31.26 ± 2.70) x 104 (p ≤ 0.01)) 
(Figure 3.6).  
 
 
Figure 3.6. Mast cell numbers are significantly enhanced during F. hepatica infection and after 
FhTeg injection in a STAT6 independent manner. Peritoneal cells were harvested from un-infected 
(control), F. hepatica infected (infected) (A); PBS and FhTeg injected (B) STAT6-/- or its control 
C57BL/6 mice Percentages and numbers (C, D) of mast cells were determined by two colour  flow 
cytometry for c-kit and FcεRI. Flow cytometry data were normalised to isotype controls and are 
presented as the mean ± SD of three independent experiments (A, C: n=10; B, D: n=8). *, p ≤ 0.05; **, 
p ≤ 0.01 compared to control group. 
 
3.3.5 Mast cells treated with FhTeg exhibit decreased expression of c-kit and 
this is associated with reduced cell proliferation in response to stem cell factor. 
To determine if FhTeg-induced mast cell hyperplasia is due to mast cell 
proliferation, peritoneal mast cells were treated with FhTeg and found that they do 
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not proliferate (5, 10, 20 µg/ml) (Figure 3.7A-B). However, these cells exhibited a 
consistent and significant decrease in c-kit expression (Figure 3.6C-D; p ≤ 0.01). 
When mast cells were stimulated with stem cells factor (that can induce proliferation 
in mast cells) in the presence of FhTeg a significant dose dependent decrease in 
proliferation was observed (Figure 3.8). 
 
 
Figure 3.7. Mast cells treated with FhTeg does not proliferate and exhibit decreased expression 
of c-kit. BMMCs and PCMCs were treated with FhTeg (10 mg/ml) for 24 hours. Proliferation was 
measured with MTT test (A, B) and c-kit expression was determined by two colour flow cytometry 
(c-kit and FceRI) (C, D). Flow cytometry results were normalised to isotype controls. Data are 
presented as the mean ± SD of three independent experiments (n=3). 
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Figure 3.8. FhTeg suppresses SCF induced mast cell proliferation. SCF (10 ng/ml) induced 
proliferation was measured by MTT test on BMMCs following FhTeg treatment. Concentrations of 
FhTeg are indicated on the graph. Figure is representative of three independent experiments (n=3). 
 
3.3.6 Mast cell migration is induced by FhTeg stimulated dendritic cells but 
not mast cells. 
Since mast cells do not proliferate in response to FhTeg we asked if mast cells, 
stimulated in vitro with FhTeg, can induce mast cell migration which could explain 
the increase of mast cells in vivo. FhTeg, IL-4 and FhTeg stimulated macrophages or 
mast cells did not induce mast cell migration (Figure 3.9). FhTeg treated dendritic 
cells or their supernatants induced increased migration rate of both BMMCs and 
PCMCs. Migration rate increased significantly compared to control PBS treated cells 
after 3 hours tested with trypan blue and Kimura staining (p £. 0.01). Results were 
confirmed with flow cytometry at 3 hour time point (p £. 0.05) (Figure 3.10). 
 
82 
 
 
Figure 3.9. Chemotaxis of mast cells is induced by FhTeg activated dendritic cells, but not by 
IL-4, FhTeg or FhTeg treated mast cells or macrophages. Cemothaxis was measured against IL-4, 
FhTeg or SCF for 3 hours (A). BMMCs (MC), RAW macrophages (MF) and BMDCs (DC) were 
treated with FhTeg (10 µg/ml) or PBS for 18/24 h. Chemotaxis of mast cells were measured for 3 
hours against the treated cells (B). Mast cell number was assessed by Kimura staining or by flow 
cytometric analysis on the basis of c-kit expression. Graphs are representative of two independent 
experiments. 
 
 
Figure 3.10. Chemotaxis of mast cells is induced by FhTeg activated dendritic cells or their 
supernatant. BMDCs were treated with FhTeg (10 µg/ml) or PBS for 18 h. Chemotaxis of PCMCs 
were measured against dendritic cells or their supernatants. Mast cell number was assessed by Kimura 
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staining at 0, 1, 2, and 3 h time points (A, B) or flow cytometric analysis on the basis of c-kit 
expression after 3 h (C, D). Flow cytometry data were normalised to isotype controls and 
data are presented as the mean ± SD. *p ≤ 0.05; **p ≤ 0.01. 
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3.4 Discussion 
Increased mast cell numbers in the liver is one of the key features of fascioliasis 
(Rahko, 1969; Ferreras et al., 2000), and increased mast cell numbers were observed 
in the gut mucosa of rats experimentally infected with F. hepatica (Van Milligen et 
al., 1998). To our knowledge this study is the first to demonstrate an increase in mast 
cell numbers in vivo in the liver and the peritoneal cavity of F. hepatica infected 
mice. We also show that this increase in mast cell numbers can be mimicked by 
treatment of mice with F. hepatica tegumental antigen (FhTeg). During F. hepatica 
infection the worm first migrates through the peritoneal cavity before residing in the 
bile ducts for many years. Increased mast cell numbers are first observed in the early 
stages of infection, which suggests that these cells may have an important role to 
play in shaping the adaptive immune response during infection.  
 
FhTeg stimulated mast cells do not secrete key Th2 promoting cytokines and fail to 
promote Th2 responses in naïve T-cells. This suggests that FhTeg interaction with 
mast cells may not be important in driving Th2 immunity. This is supported by our 
studies in STAT6 knockout mice as the increase in mast cell number in the 
peritoneal cavity following F. hepatica infection and FhTeg injection is STAT6 
independent. IL-13 and IL-4 signal through the STAT6 signalling pathway and 
activation of this pathway is important in Th2 immune responses (Finkelman et al., 
2004). Our finding contrasts other studies that demonstrate the involvement of mast 
cells in Th2 immune responses against multiple nematodes and other parasitic 
infections (Dawicki and Marshall, 2007). Activation of STAT6 signalling pathway is 
important in Th2 immune responses required for the protection against helminths 
like Trichinella spiralis (Bian et al., 2005; Finkelman et al., 2004) and N. 
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brasiliensis (Finkelman et al., 2004; Sakamoto et al., 2004) in murine models, 
although the mechanism is unclear (Urban et al., 2000). These studies suggest that 
mast cells react to the presence of helminths by generating cytokines like IL-4 that 
shapes the development of Th2 immune responses (Maizels et al., 2004; Allen and 
Maizels, 2011). 
 
During F. hepatica infection Th1 immune responses are more important for 
protection (O'Neill et al., 2000; Mulcahy et al., 2004; Moreau and Chauvin, 2010) as 
IL-4-/- mice, which are predisposed towards a Th1 immune response, are less 
susceptible to F. hepatica infection with reduced liver damage (O’Neill et al., 2000). 
Similar studies with Taenia crassiceps showed that STAT6-/- mice that exhibited 
polarized Th1-type responses were more effective in worm clearance (Rodriguez-
Sosa et al., 2002). Mast cells co-cultured with CD4+ T-cells can promote the 
secretion of IFN-γ (Huels et al., 1995; Nakae et al., 2005) and this is enhanced when 
mast cells are first exposed to TLR ligands (Nie et al., 2011). Mast cells are 
important in driving Th1 immunity; perhaps during F. hepatica infection mast cell 
contribute to Th1 immunity which is important for immune protection. This 
hypothesis requires further investigation.  
 
FhTeg does not induce mast cell proliferation but rather inhibits stem cell factor 
(SCF) driven proliferation of mast cells through the inhibition of c-kit expression, a 
pan marker for mast cells and a receptor for SCF (Metcalfe et al., 1997). This 
suggests that the increase in mast cell numbers in the peritoneal cavity may be the 
result of mast cell migration into the peritoneal cavity. This contrasts studies in N. 
brasiliensis and Strongyloides venezulensis infected rats where intensive 
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proliferation of these cells is observed in the intestinal mucosa, Peyer’s patches and 
mesenteric lymph nodes (Kasugai et al., 1995; Tegoshi et al., 1997). In another 
study, nematode-induced proliferation was reported in the gut but not in the 
peritoneal cavity, although mast cell numbers increased at both sites (Arizono et al., 
1994) suggesting that mast cell migration is also important. 
 
FhTeg stimulated mast cells did not induce mast cell migration in vitro, but FhTeg-
activated dendritic cells induced mast cell migration. In our laboratory it was shown 
previously that FhTeg stimulated dendritic cells secrete MIP2 (CXCL2) and MIP1a 
(CCL3) chemokines (Appendix F) and these cytokines might be involved in mast 
cell migration (Gilfillan et al., 2011; Kunii et al., 2011; Taub et al., 1995). MIP1a 
was shown to induce migration but not degranulation of BMMCs in vitro (Taub et 
al., 1995). Mast cells express chemokine receptors on their surface including CXCR2 
and CCR3, the receptors for MIP2 and MIP1a (Juremalm and Nilsson, 2005). This 
result is supported by other studies underlying the importance of mast cell – 
dendritic cell cross talk in the development of immune responses (Bryce et al., 2004; 
Galli et al., 2005; Mazzoni et al., 2006). Peritoneal mast cells and dendritic cell 
crosstalk was shown to cause dendritic cell maturation resulting in cytokine (IFN-g, 
IL-2, IL-6 and TGF-b) secretion that can modulate T-cells (Dudeck et al 2011). In 
contact hypersensitivity mouse models, activated dendritic cells bind to mast cells 
and promote Ca2+ influx and TNF-a production in these cells. These activated mast 
cells further promote additional activation of dendritic cells inducing migration 
(Otsuka et al., 2011). 
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In the early stages of infection, F. hepatica larvae penetrate trough the gut wall into 
the peritoneum and then into the liver, causing extensive tissue damage (Robinson et 
al., 2010). One explanation, for the increased mast cell number in the peritoneal 
cavity in the early stage of infection, may be that mast cells are involved in wound 
healing. Mast cells represent a heterogeneous population and have various functions 
(Metcalfe et al., 1997), and they play a key role in wound healing and tissue 
remodelling. In mast cell-deficient mice wound closure is significantly impaired 
compared to normal or mast cell reconstructed mice (Weller et al., 2006). Mast cells 
secrete mediators, such as histamine, serotonin, enzymes and cytokines that are 
important in inducing fibroblast proliferation, increased vascular permeability 
(marker for wound healing responses) and neutrophil recruitment (Maurer et al., 
2003; Weller et al., 2006). These findings suggest that mast cell functions at sites of 
infection may not be limited to promoting Th1 or Th2 immune responses and further 
studies are required to investigate this. 
 
Mast cells do not degranulate in response to FhTeg. Mast cells became activated by 
IgE through their high affinity FceRI receptor (Melendez et al., 2007; Pearce, 2007) 
in the presence of IgE-specific antibody. In our experiments FhTeg treated mast cells 
express lower level of FceRI compared to control cells. This down-regulation of 
FceRI by FhTeg does not have an impact on IgE dependent mast cell degranulation 
in vitro or in vivo, although there is a significant decrease in ear swelling at 4 and 6 
hours in the passive cutaneous anaphylaxis model. This is in keeping with FhTeg’s 
ability to suppress inflammatory responses in vivo. Previous studies have shown that 
mast cell-derived TNF-a is protective during septic peritonitis (Echtenacher et al., 
1996)  and  FhTeg can suppress the release of pro-inflammatory cytokines in a 
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mouse model of septic shock (Hamilton et al., 2009). Similarly, FhTeg can impair 
the release of inflammatory mediators from TLR activated dendritic cells (Hamilton 
et al., 2009). During anaphylaxis, mast cell degranulation and the immediate release 
of mediators, such as histamine and tryptase, is followed by a delayed phase (2-6 
hours) when mast cells generate cytokines like TNF-a (Finkelman, 2007; Metcalfe 
et al., 2009). As FhTeg suppresses TNF-a secretion in TLR activated immune cells, 
it may also suppress TNF-a secretion in mast cells in the passive cutaneous 
anaphylaxis model and this might be responsible for the decreased ear swelling in its 
late phase. Further investigation is warranted to identify the mechanism of 
suppression at later time points.  
 
In this study we showed that mast cells number increased in the peritoneal cavity and 
liver of F. hepatica infected mice, and this can be mimicked by injection of FhTeg. 
FhTeg activated mast cells express reduced levels of c-kit and FceR1 but do not 
secrete a panel of cytokines or drive Th2 or Treg immune responses. Our study 
suggests that the increase in mast cell numbers is not the result of FhTeg induced 
proliferation; rather FhTeg indirectly induces mast cell migration by dendritic cell 
derived chemokines. The increase in mast cells numbers occurs in the absence of 
Th2 cytokines and independent of STAT6 and our finding is that FhTeg interactions 
with mast cells do not drive Th2 or Treg immune responses. While it is clear that 
mast cells have role in the expulsion of gut dwelling helminths, our finding contrast 
studies examining the interaction of gut dwelling helminths with mast cells. This 
highlights the need to revisit the role of mast cells in tissue dwelling parasitic 
infections in order to advance our understanding of mast cells in host immunity. 
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4 Chapter 4 - Fasciola hepatica tegumental coat antigens supress Th1 
immune responses in mast cells 
 
4.1 Introduction 
Mast cells are associated with helminth infection but are mainly studied in the 
context of IgE mediated responses and Th2 immunity. Mast cells express pathogen 
recognition receptors such as TLRs and when activated with TLR ligands are a 
potent source of Th1 pro-inflammatory mediators, such as TNF-α and IFN-g. Mast 
cells promote Th1 driven host defence against bacterial and protozoan infections 
(Galli and Tsai, 2010; Marshall et al., 2003; Mielcarek et al., 2001; Wierzbicki and 
Brzezinska-Blaszczyk, 2009), and in the absence of mast cells these infections are 
significantly exacerbated (Maurer et al., 2006; Siebenhaar et al., 2007) 
demonstrating a critical role for mast cells. Mast cells are also associated with many 
Th1-mediated inflammatory disorders such as multiple sclerosis and Crohn’s disease 
where TNF-a secreting mast cells are important contributors to immune pathology 
(Metz and Maurer, 2007; Sutherland et al., 2011; Weller et al., 2011).  
 
Helminths and the products they release exert effects that impair Th1 immunity to 
bystander microbial infections, such as malaria and tuberculosis (Mulcahy et al., 
2004; Nacher, 2011) and this effect significantly impacts population in the 
developing world (Anthony et al., 2007). However they can prevent the initiation 
and perpetuation of many Th1 immune disorders such as arthritis and Crohn’s 
disease (De Winter et al., 2011; Song et al., 2011) in these populations. Helminth 
driven regulatory networks through the induction of regulatory cytokines, TGF-b 
and IL-10 can suppress these pro-inflammatory Th1 immune response (Song et al., 
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2011; Whelan et al., 2011) or helminths release molecules that directly impair the 
ability of innate immune cells to drive Th1/Th17 immune responses (Allen and 
Maizels, 2011; Mulcahy et al., 2004). Understanding these mechanisms could lead to 
the development of novel anti-inflammatory therapeutic targets and expand our 
understanding of helminth – microbial interactions in human population. 
 
Fasciola hepatica can suppress protective Th1 driven immunity against bystander 
infections such as tuberculosis and Bordetella pertussis (Brady et al., 1999; Claridge 
et al., 2012; Flynn et al., 2009). It can also attenuate experimental autoimmune 
encephalitis (EAE) through the suppression of Th17 and Th1 immune responses 
(Walsh et al., 2009). The isolated F. hepatica coat antigen (FhTeg) has suppressive 
effect in vivo by inhibiting the release of pro-inflammatory cytokines in the mouse 
model of septic shock (Hamilton et al., 2009) FhTeg alters the ability of dendritic 
cells to prime Th1 immune responses by rendering them hypo-responsive to TLR 
activation suppressing the production of a selected panel of inflammatory cytokines 
and co-stimulatory molecules. The suppressive effect is not mediated trough the 
common MAPKs found in the TLR pathway and is dependent of MyD88 and TLR4. 
FhTeg suppresses the transcription factor NF-kB p65 which is involved in the 
transcription of many Th1 promoting factors (Hamilton et al., 2009). This study 
examines FhTeg’s interaction with mast cells to determine if its modulatory effect 
can impair mast cell ability to promote Th1 immunity and the possible mechanism 
involved in this process will be examined. 
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4.2 Experimental design 
Since FhTeg does not enhance or suppress Th2 immune responses in mast cells this 
chapter investigates the effect of FhTeg on Th1 promoting mast cells. The effect of 
FhTeg on bacterial ligand-induced cytokine production of mast cells was tested in 
vivo and in vitro. In vivo C57BL/6 mice were treated with FhTeg prior to i.p. 
injection of Bordetella pertussis antigen (BP) (2.2.4) to determine if FhTeg treatment 
has any effect on BP-induced TNF-α expression in peritoneal mast cells (2.2.18). In 
this experiment C57BL/6 mice were used as these mice are good models to study 
Th1 immune responses. These in vivo results were confirmed in vitro with LPS or 
BP activated BMMCs (2.2.8) and with the more mature PCMCs (2.2.9, 2.2.12). 
Since it was shown that the mast cell number increase in the peritoneal cavity during 
F. hepatica infection is STAT6 independent, BMMCs from STAT6-/- mice was also 
investigated to determine the role of STAT-6 on FhTeg’s immunomodulatory effect. 
Since mast cells can activate T-cells in vitro FhTeg treated and LPS/BP stimulated 
BMMCs and PCMCs were co-cultured with naïve T-cells (2.2.19) to examine if 
FhTeg can suppress mast cell induced cytokine secretion (IFN-γ, IL-10, IL-5 and IL-
4) in T-cells. Involvement of ICAM1 in mast cell – T-cell communication was also 
examined (2.2.18-19). 
 
FhTeg – mast cell interaction was further examined to find a potential mechanism. 
LPS and BP are TLR4 ligands that induce transcription factors of TLR4 signalling 
pathway. The modulatory effect of FhTeg on this signalling pathway was 
investigated in BMMCs by western blot analysis. (2.2.20-22). These experiments 
required high amount of cells, so only some positive results were confirmed with the 
more mature PCMCs. Dendritic cells (BMDCs) (2.2.10) were also examined in this 
92 
 
study as the activation of transcription factors is restricted in mast cells compared to 
dendritic cells. FhTeg effect on the members and inhibitory molecules of the TLR4 
signalling pathway (RelA, MyD88, TLR4, TRAF6, PIAS1/3/4, SOCS1/2/3/4/5) 
were examined with qPCR (2.2.23-24) and western blot (2.2.20-22). It was also 
investigated if FhTeg can modulate cytokine secretion and cell surface marker up-
regulation by cytokine signalling pathways (TNF-α, IFN-γ or IL-10) in BMDCs 
(2.2.10-11, 2.2.18). 
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4.3 Results 
4.3.1 FhTeg inhibits TNF-α expression in mast cells in vivo. 
F. hepatica suppresses protective Th1 driven immunity against B. pertussis (Flynn et 
al., 2009) and since mast cells have an important role to play in protection against 
bacterial infection we wanted to determine if FhTeg can inhibit the production of 
pro-inflammatory cytokines by mast cells in vivo. Here we firstly demonstrated that 
B. pertussis antigen (BP) when injected into the peritoneal cavity of C57BL/6 mice 
induced high numbers of TNF-a expressing mast cells (Figure 4.1). When these 
mice were co-injected with FhTeg, mast cells expressed significantly less TNF-
a when compared to BP injected mice only, confirming that FhTeg can inhibit the 
production of pro-inflammatory cytokines by mast cells in vivo (Figure 4.1). 
 
 
Figure 4.1. FhTeg inhibit TNF-a expression in mast cells in vivo. C57BL/6 mice were injected 
with FhTeg (10 mg) or PBS prior to be immunised by BP (10 mg) 4 times for 10 days. Peritoneal mast 
cells were intracellular stained for flow cytometry with TNF-a. Mast cells were identified on the basis 
of c-kit and FcεRI expression. Data are presented as the mean ± SD of two independent experiments 
with 3-5 mice per group (n=8). *, p ≤ 0.05 compared to control group. 
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4.3.2 FhTeg suppresses cytokine secretion from LPS or BP stimulated mast 
cells. 
To confirm our in vivo findings we stimulated BMMCs and PCMCs in vitro with BP 
or LPS as a positive control in the presence of absence of FhTeg and cytokine 
secretion was measured in supernatant after 24 hours. Both BMMCs (IL-6 and TNF-
a) and PCMCs (IL-6, TNF-a, IL-10 and IFNg) secreted significant levels of 
cytokines however in the presence of FhTeg cytokine secretion was significantly 
suppressed (Figure 4.2; p ≤ 0.05 to p ≤ 0.001). 
 
 
Figure 4.2. FhTeg suppressed cytokine expression in TLR4 stimulated BMMCs and PCMCs. 
Mast cells were stimulated with and without FhTeg (10 µg/ml) for 2.5 hours following with PBS, LPS 
(100 ng/ml) or BP (100 bacteria/cell) for 24 hours. PMA (phorbal myristate acetate, 20 ng/ml) was 
used as positive control. Supernatants were tested for TNF-α (A, B), IFN-γ (C), IL-6 (D, E) and IL-10 
(F) ELISA. Figures are representatives of three independent experiments (n=3) and presented as the 
mean ± SD of three replicate samples from the same experiment.. +, p ≤ 0.05; ++, p ≤ 0.01 compared to 
vehicle (PBS) group; *, p ≤ 0.05; **, p ≤ 0.01 compared to LPS and BP group. 
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4.3.3 Mast cells activation by BP and LPS is dependent upon STAT6, however 
this had no role to play in the suppressive effect of FhTeg. 
To test if STAT6 pathway is involved in the inhibitory effect of FhTeg we cultured 
BMMCs from C57BL/6 (control) and STAT6-/- mice and stimulated them with LPS 
and BP with or without FhTeg treatment. The absence of STAT6 maintains FhTeg’s 
suppressive effect on TNF-α and IL-6 secretion and cell surface marker (c-kit and 
FceRI) expression of mast cells. However STAT6-/- mast cells secreted more Th1 
cytokines after BP stimulation (p ≤ 0.05, Figure 4.3). 
 
 
Figure 4.3. Mast cells activation by BP and LPS was dependent upon STAT6, however this had 
no role to play in the suppressive of FhTeg. BMMCs from STAT6-/- and control mice were 
stimulated with and without FhTeg (10 µg/ml) for 2.5 hours following with PBS, LPS (100 ng/ml) or 
BP (100 bacteria/cell) for 24 hours. Supernatants were tested for IL-6 (A) and TNF-α (B) ELISA. 
Figures are representatives of three independent experiments (n=3) and presented as the mean ± SD of 
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three replicate samples from the same experiment.; *, p ≤ 0.05; **, p ≤ 0.01 when FhTeg/LP and 
FhTeg/BP compared to LPS and BP group. +, p ≤ 0.05 when mast cells from STAT6-/- mice compared 
to control C57BL/6 group Cells were stained for cytometry with c-kit (C) and FcεRI (D). Results are 
represented on histograms: STAT6-/- BMMCs are indicated with dashed line and curves of FhTeg 
treated cells are tinted. 
 
4.3.4 CD4
+
 T-cells co-cultured with FhTeg treated mast cells secrete less IL-
10, IFN-g and IL-5. 
Mast cells when co-cultured with naïve CD4+ cells in the presence of anti-CD3 can 
promote Th1 immune responses and this can be enhanced when mast cells are pre-
treated with bacterial antigens or TLR ligands (Huels et al., 1995; Nakae et al., 2005; 
Nakae et al, 2006). BMMCs and PCMCs were stimulated with BP and LPS for 24 
hours to determine if mast cells ability to promote cytokine production from naïve T-
cell can be inhibited. After 24 hours supernatants were removed and cells were 
washed. Supernatant was added to CD4+ T-cells or CD4+ T-cells were co-cultured 
with washed mast cells. CD4+ T-cells co-cultured with BP- and LPS-stimulated 
BMMCs/PCMCs or when cultured with supernatant from these cells secreted 
significant levels of IFN-γ, IL-10 and IL-5 (Figure 4.4A, F, I, N) but not IL-4 (Figure 
4.4G, H, O, P). Significantly less IFN-γ, IL-10 and IL-5 cytokines were obtained 
when T-cells were co-cultured with BP- and LPS-stimulated BMMCs/PCMCs in the 
presence of FhTeg or when cultured with the supernatant from these cells (Figure 
4.4). BMMCs, PCMCs and T-cells alone were used as negative controls and levels 
of IFN-g, IL-10, IL-4 or IL-5 were not significantly higher than background and 
were significantly less than co-cultured samples when measured after 72 hours. 
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Figure 4.4. FhTeg suppressed the activation of T-cells by LPS or BP stimulated mast cells. BMMCs and PCMCs were stimulated with and without FhTeg (10 µg/ml) 
for 2.5 hours following with PBS, LPS (100 ng/ml) or BP (100 bacteria/cell) for 24 hours. anti-CD3 stimulated naïve CD4+ cells were co-cultured with the washed cells 
(A-H) (1:1) and with the supernatants (I-P) for 72 hours. Supernatants were collected and tested for IFN-γ (A-B, G-H), IL-10 (C-D, I-J), IL-5 (E-F, K-L) and IL-4 (G-H, 
O-P) ELISA. Figures are representatives of three independent experiments (n=3) and presented as the mean ± SD of three replicate samples from the same experiment.. *, 
p ≤ 0.05; **, p ≤ 0.01 compared to LPS and BP group. 
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4.3.5 ICAM1 is important in mast cell - T-cell communication and the 
expression of this receptor is suppressed by FhTeg. 
OX40L, CD40L, CD28 and ICAM1 are thought to have role in mast cell – T-cell 
communication (Nakae et al., 2006; Henz et al., 2001; Brill et al., 2004). BMMCs 
express low levels OX40L, CD40L and CD28 and this was not significantly 
enhanced in the presence of LPS and BP. In contrast ICAM1 was highly expressed 
on these cells and this was enhanced in the presence of LPS (Figure 4.5) or BP (data 
not shown). FhTeg did not enhance OX40L, CD40l, CD28 and ICAM1 expression 
on mast cells. 
 
Figure 4.5. BMMCs express low levels of TLR4, CD28, OX40L and CD40L but high level of 
ICAM1. BMMCs were stimulated with PBS of LPS (100 ng/ml) for 24 h and cell surface expression 
of TLR4, CD28, OX40L, CD40L and ICAM1 was measured by two colour (double stained with 
FcεRI) flow cytometry. Figure is representative of three independent experiments (n=3).  *, p ≤ 0.05; 
**, p ≤ 0.01 compared to control group. 
 
Since ICAM1 was highly expressed we stimulated mast cells with BP or LPS in the 
presence of FhTeg and demonstrated that FhTeg significantly inhibited ICAM1 
expression on BMMCs and PCMCs (Figure 4.6; p ≤ 0.05). We confirmed that 
ICAM1 is important in mast cells – CD4+ T-cells communication by adding anti-
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ICAM1 blocking antibody to activated mast cells half hour prior to washing and co-
culturing with CD4+ T-cells. Similar to FhTeg it caused significant decrease in IFN-
γ, IL-10 and IL-5 secretion (Figure 4.7). 
 
 
Figure 4.6. FhTeg suppress the up-regulation of ICAM1 expression on LPS/BP stimulated mast 
cells. PCMCs were stimulated with and without FhTeg (10 µg/ml) for 2.5 hours following activation 
with PBS, LPS (100 ng/ml) or BP (100 bacteria/cell) for 24 hours. ICAM1 expression was measured 
by Flow cytometry. Data are presented as the mean ± SD of three independent experiments (n=3). *, p 
≤ 0.05; compared to control group. 
 
 
Figure 4.7. Effect of FhTeg on TLR stimulated mast cells can be mimicked by anti-ICAM1 
antibody when mast cells are co-cultured with anti-CD3 stimulated naïve CD4
+
 cells. PCMCs 
were stimulated with and without FhTeg (10 µg/ml) for 2.5 hours following with PBS, LPS (100 
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ng/ml) or BP (100 bacteria/cell) for 24 hours. anti-ICAM1 antibody (1 µg/ml) was added to mast cells 
30 minutes before co-culturing. Then, washed cells were co-cultured with anti-CD3 stimulated naïve 
CD4+ cells (1:1) for 72 hours. Supernatants were tested for IFN-γ (A), IL-10 (B), IL-5 (C) and IL-4 
(D) ELISA. Figures are representatives of three independent experiments and presented as the mean ± 
SD of three replicate samples from the same experiment. 
 
4.3.6 FhTeg suppresses phospho-ERK and NF-kB p65 expression in BP and 
LPS stimulated mast cells. 
It was previously shown that FhTeg suppresses the activation of NF-kB in LPS 
stimulated dendritic cells (Hamilton et al., 2009) and this was examined in mast 
cells. Firstly we confirmed that BP can induce p-NF-kB p65 expression (at 15 and 
30 min) in BMMCs (Figure 4.8A, C). FhTeg suppressed the activation of NF-kB in 
LPS and BP stimulated mast cells (Figure 4.8A, C) and this was confirmed in 
PCMCs at 15 and 30 minutes (Figure 4.8D, F). 
 
To test if this effect was specific to NF-kB, the phosphorylation of ERK, JNK and 
p38 was measured. BP significantly enhanced  phospho-ERK but not phospho-JNK 
and p38. We also demonstrated that FhTeg suppressed the activation of phospho-
ERK in LPS and BP stimulated BMMCs at 5, 30 and 60 minutes (Figure 4.8A, B). 
These results were confirmed in PCMCs at 15 and 30 minutes (Figure 4.8D, E). 
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Figure 4.8. BP and LPS stimulated ERK and NF-kB expression in BMMCs and PCMCs was suppressed by FhTeg. PCMCs were stimulated with and 
without FhTeg (10 µg/ml) for 2.5 hours following with PBS, LPS (100 ng/ml) or BP (100 bacteria/cell) for 24 hours. Protein samples were analysed by western 
blot for phosphorylated-ERK (p-ERK), total-ERK (t-ERK), p-NF-κB p65 and β-actin expression (A, D). Values of p-ERK and p-NF-κB p65 were normalised to t-
ERK and β-actin and are expressed in arbitrary units as fold increases over PBS control (B-C, E-F). Densitometry data are presented as the mean ± SD of three 
independent experiments (n=3). *, p ≤ 0.05; **, p ≤ 0.01 compared to control group. 
 102 
 
4.3.7 FhTeg suppressive effect is not specific to NF-kB p65 expression as it 
inhibits MAPK activation in dendritic cells. 
Since we could not test if FhTeg has the same inhibitory effect on other members of 
the MAPK pathway (p38, JNK) we decided to involve dendritic cells in our study. 
Firstly we confirmed that FhTeg inhibitory effect is not limited to NF-kB we 
stimulated dendritic cells with LPS for 5, 15, 30, 60 min in the presence and absence 
of FhTeg. LPS can induce phospho-ERK, -JNK and -p38 expression in dendritic 
cells. We demonstrated that FhTeg suppressed the activation of these molecules. 
Phospho-ERK and phospho-p38 protein expression was suppressed in all time points 
(5, 15 and 30 min, p ≤ 0.01- p ≤ 0.05), although it was not significant after 60 
minutes (Figure 4.9A-C), while JNK was only activated at 30 min and it could be 
inhibited by FhTeg (p ≤ 0.05) (Figure 4.9A, D). 
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Figure 4.9. FhTeg suppressed the phosphorylation of ERK, p38 and JNK in LPS stimulated 
dendritic cells. BMDCs were stimulated with and without FhTeg (10 µg/ml) for 2.5 hours prior to 
stimulation with PBS or LPS (100 ng/ml) for 5, 15, 30, 60 min. Protein samples were analysed by 
western blot for phosphorylated-ERK (p-ERK), total-ERK (t-ERK), p-38, t-38, p-JNK, t-JNK, p-IRF, 
t-IRF and β-actin expression (A). Values of phosphorylated proteins were normalised to total target 
proteins and β-actin and are expressed in arbitrary units as percentage increases over PBS control 
value (B-D). Densitometry data are presented as the mean ± SD of three independent experiments 
(n=3). *, p ≤ 0.05; **, p ≤ 0.01 compared to control group. 
 
We included IRF-3 in our analysis as IRF-3 is the central protein of the alternative 
TLR4 signalling pathway. IRF-3 was only slightly activated after 60 min in LPS 
stimulated dendritic cells (Figure 4.9) and FhTeg did not suppress this activation 
(even in later time points after 2 and 4 h; data not shown). 
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4.3.8 The primers for qPCR analysis of TLR4 signalling showed adequate 
specificity and efficiency in traditional and qPCR analysis. 
As both NF-kB and MAPK pathway is suppressed by FhTeg we hypothesize that 
this antigen targets signalling molecules further up the TLR4 signalling pathway or 
FhTeg may induce negative regulators of the TLR pathway. Based on the western 
blot results we decided to use LPS activated dendritic cells as a model system to 
investigate FhTeg’s effect on TLR4 signalling and its inhibitors with qPCR before 
mast cell experiments. We chose 3 different genes as controls to use in qPCR 
analysis. In the literature the most intensively used control is b-actin, although 
studies suggest that it can only be used with some consideration as upon activation 
the RNA level may vary (Watson et al., 2007). The other two controls were Gusb 
(Glucuronidase) and GAPDH (glyceraldehyde-3-phosphate dehydrogenase), other 
housekeeping genes. As targets we chose 4 proteins from different level of the TLR4 
signalling (TLR4, MyD88, TRAF6 and RelA) and 7 inhibitors (SOCS1, SOCS2, 
SOCS3, SOCS4, SOCS5, PIAS1, PIAS3 and PIAS4). 
 
Primers were designed for qPCR analysis with product size lower than 250 bp and 
melting temperature around 60oC. Specificity and efficiency were tested with 
conventional PCR and with qPCR. All tested primers gave one single bend PCR 
products when run on agarose gel without primer dimers and gave one peak after 
melting curves analysis. Efficiency was calculated from Ct values of solution series 
for every primer according to the equation: E=10(-1/slope). All efficiency values were 
in the range of 1.8-2.2 so primers were used in further analysis (Figure 4.10). 
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 Figure 4.10. Determination of real-time PCR specificity and efficiencies of reference and target 
genes. Primers were tested in conventional PCR reaction using 20 ng cDNA templates and were 
excluded from latter experiments if they gave more than one single band when PCR products were 
run on 1% agarose gel or if they form primer dimers. Melting curves analysis was performed to check 
product size and homogeneity. Ct versus cDNA  (reverse transcripted total RNA) concentration input 
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were plotted to calculate the slope (mean ± SD, n=3). The corresponding real-time PCR efficiencies 
were calculated according to the equation: E = 10[-1/slope].    
 
4.3.9 FhTeg up-regulates the transcription and expression SOCS3. 
To test the effect of FhTeg on members of the TLR4 signalling pathways BMDCs 
were treated with FhTeg prior to LPS stimulation. As we did not know the optimal 
time point when the transcription is highly up- or down-regulated (that can be 
different for the tested genes) we tested 6 incubation times: 5, 15, 30, 60 minutes and 
6, 18 hours. 
 
During analysis we tested the integrity of the used control genes. Within the first 
hour all three control genes showed the same pattern within the samples, although in 
the last two time points (at 6 and 18 hours) b-actin and Gusb expression seemed to 
change upon LPS stimulation.  Later we used GAPDH as control by latter time 
points in further analysis of dendritic cells as it showed stable expression in all time 
points. 
 
First we tested the effect of FhTeg on 4 members of the TLR4 signalling pathway. 
TLR4 as the main receptor for LPS stimulation was one of our target. Interestingly 
TLR4 RNA transcription was up-regulated in FhTeg treated samples after 1 hour 
(Figure 4.11A). MyD88 was slightly down regulated by FhTeg in the first 30 
minutes and although it was up-regulated later by LPS, this up-regulation was 
supressed by FhTeg, but only at 1 hour (Figure 4.11B). TRAF6 was up-regulated by 
both FhTeg and LPS but only in later time points and there was no difference 
between LPS and LPS - FhTeg treated samples (Figure 4.11C). RelA (Nf-kB) is 
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known to be regulated on protein level and not on transcription level, so it was used 
as a negative control. Interestingly RelA was slightly up-regulated by FhTeg even in 
early time points and by LPS later after 6 hours (Figure 4.11D) although this 
transcription factor is known to be regulated on protein level by phosphorylation 
instead of by transcription/expression. 
 
We also tested some possible inhibitors of the TLR4 signalling pathway. The 
expression of suppressor of cytokine signalling (SOCS)2, SOCS4, protein inhibitor 
of activated STAT (PIAS)1 and PIAS4 did not change after FhTeg and LPS 
treatment so they seem to not play important role in FhTeg inhibition. SOCS1 
(Figure 4.11E) and PIAS3 (Figure 4.11G) was up-regulated only by LPS after 6 and 
18 h with no significant difference between LPS and LPS/FhTeg treated samples and 
FhTeg had no effect on this up-regulation. There was no increase in the transcription 
level of SOCS5 (Figure 4.11F). The most promising results came from the SOCS3 
analysis as it was highly up-regulated by FhTeg (10 fold after 5 min) and this up-
regulation was even higher after LPS stimulation (90 fold after 60 min) (Figure 
4.11H). 
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Figure 4.11. Time dependence of the expression of 8 target genes. BMDCs were stimulated with 
and without FhTeg (10 µg/ml) for 2.5 hours prior to stimulation with PBS or LPS (100 ng/ml) for 5, 
15, 30, 60 min, 6h or 18h.  Total RNA was extracted and after reverse transcription cDNA was 
analysed with qPCR for RelA, TLR4, TRAF6, MyD88, SOCS1, SOCS3, SOCS5 and PIAS3. RNA 
expression was normalized to GAPDH control gene expression and showed relative to PBS control. 
Figures are representative of two independent experiments. 
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4.3.10 SOCS3 transcription and expression is up-regulated by FhTeg. 
As SOCS3 was up-regulated by FhTeg in early time points and it is known to be one 
of the most important inhibitory molecules of the TLR4 signalling pathway, we 
confirmed the qPCR results with western blot analysis. We repeated the FhTeg/LPS 
treatment experiment and extracted the proteins in the first 4 time points (5, 15, 30, 
60 min), as FhTeg seems to act in early stage of LPS stimulation (Figure 4.12). 
SOCS3 up-regulation nicely correlated in RNA and protein levels at different time 
points (Figure 4.13). After 15 min LPS treated samples exhibited increased SOCS3 
expression although in FhTeg and FhTeg/LPS treated samples SOCS3 up-regulation 
was still higher (Figure 4.13). At 30 and 60 minutes both LPS and LPS/FhTeg 
treated samples showed increased SOCS3 RNA and protein levels (Figure 4.11H, 
Figure 4.12, Figure 4.13) 
 
Figure 4.12. SOCS3 up-regulation was confirmed on protein level. BMDCs were stimulated with 
and without FhTeg (10 µg/ml) for 2.5 hours prior to stimulation with PBS or LPS (100 ng/ml) for 5, 
15, 30, 60 min. Protein samples were analysed by western blot for SOCS3 and β-actin expression (A). 
Values of proteins were normalised to β-actin and are expressed in arbitrary units as percentage 
increases over PBS control value (B-D). Densitometry data are presented as the mean ± SD of three 
independent experiments (n=3).  *p ≤ 0.05 when compared to LPS control. 
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Figure 4.13. Pattern of SOCS3 expression was similar on RNA and protein level. BMDCs were 
stimulated with and without FhTeg (10 µg/ml) for 2.5 hours prior to stimulation with PBS or LPS 
(100 ng/ml) for 5, 15, 30 and 60 min.  Total RNA and proteins were extracted. After the reverse 
transcription of RNA cDNA was analysed with qPCR for SOCS3 expression. RNA expression was 
normalized to GAPDH control gene expression and showed relative to PBS control (A-D). RNA data 
are presented as the mean ± SD of three independent experiments (n=3). Protein samples were 
analysed by western blot for SOCS3 and β-actin expression. Values of proteins were normalised to β-
actin and are expressed in arbitrary units as percentage increases over PBS control value (E-H). 
Figures are representatives of three independent experiments. 
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4.3.11 SOCS3 transcription and expression is up-regulated in mast cells as well 
by FhTeg. 
We were interested in whether FhTeg has the same effect on SOCS3 transcription 
and expression in mast cells as in dendritic cells, so we repeated the qPCR analysis 
with BMMCs at 5, 15, 30 and 60 minutes as FhTeg seems to act in early stage of 
bacterial activation. SOCS3 RNA level was significantly higher at 5 and15 minutes 
after LPS stimulation and 5 minutes after BP stimulation in FhTeg treated BMMCs 
than in control cells (Figure 4.14A, B), although this up-regulation was much lower 
than was seen in dendritic cells. There is a reversal of FhTeg up-regulation at the 15 
min time point in both LPS and BP experiment although the decrease in SOCS3 
level is not significant. 
 
We confirmed the qPCR results with western blot analysis, so we repeated the 
experiment and extracted the proteins. Similarly to qPCR results, in the early time 
points SOCS3 was up-regulated in FhTeg treated samples and it was followed by 
LPS and BP induced SOCS3 expression in latter time points (Figure 4.14C). 
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Figure 4.14. SOCS3 transcription and expression was up-regulated by FhTeg in mast cells. 
BMMCs were stimulated with and without FhTeg (10 µg/ml) for 2.5 hours prior to stimulation with 
PBS (P), LPS (L; 100 ng/ml) or BP (B; 100 bacteria/cell) for 5, 15, 30 and 60 min.  Total RNA was 
extracted and after reverse transcription cDNA was analysed with qPCR for SOCS3 (A-B). RNA 
expression was normalized to GAPDH, b-actin and Gusb control gene expression and showed relative 
to PBS control using Pfaffl’s method. Protein samples were analysed by western blot for SOCS3 and 
β-actin expression (C). Values of proteins were normalised to β-actin and are expressed in arbitrary 
units as percentage increases over PBS control value. Densitometry data are presented as the mean ± 
SD of three independent experiments (n=3). *, p ≤ 0.05; **, p ≤ 0.01 compared to control group. 
 
4.3.12 FhTeg suppresses cytokine induced cell surface marker up-regulation in 
dendritic cells. 
In order to see if FhTeg has effect on other pathways than TLR4, we tried to develop 
a model system where we stimulated BMDCs with different cytokines (IL-6, IFN-γ 
or TNF-α). When we stimulated the cells with the individual cytokine we saw only 
nitrite secretion upon IFN-γ treatment and FhTeg did not inhibit rather it enhanced it 
in a dose dependent manner (data not shown). Cell surface expression of CD40, 
CD80 and CD86 were also measured (Figure 4.15). Although we got significant up-
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regulation of CD40 by TNF-α (p £ 0.05), FhTeg suppressed the cell surface 
expression of all markers in all groups (p £ 0.05 to p £ 0.01; Figure 4.15). We tried if 
the combination of IFN-γ and TNF-α induce dendritic cells stimulation and we found 
only nitrite secretion when the concentrations of the cytokines were 1000 times more 
than the recommended values (The ED50 values was determined by producer 
(Biolegend, Cambridge, UK) corresponding to a specific activity of 5-10 x 107 u/mg) 
and FhTeg had no effect on this up-regulation (data not shown). 
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Figure 4.15. FhTeg suppressed cytokine induced cell surface marker up-regulation in dendritic 
cells. BMDCs were treated with FhTeg (10 µg/ml) 2.5 h before stimulation with IL-6 (50 pg/ml or as 
indicated), TNF-α (20 pg/ml or as indicated) or IFN-γ (500 pg/ml or as indicated) for 18 h. TNF-α, 
IL-12 and nitrite secretion and CD40, CD80 and CD86 expression was measured with commercial 
ELISAs, Griess reagent system or flow cytometry. Figures are representatives of three independent 
experiments (n=3). *, p ≤ 0.05; **, p ≤ 0.01 compared to PBS (non-FhTeg) group. +, p ≤ 0.05 
compared to control PBS group  
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4.4 Discussion 
In the previous chapter we showed that FhTeg does not induce Th2/Treg immune 
responses in mast cells and our hypothesis is that mast cells are recruited during F. 
hepatica infection to promote a Th1 environment where F. hepatica tegumental 
antigen switches off the activity of these cells to influence this process.  Here we 
shed new light on the anti-inflammatory effects of helminth antigens on the Th1 pro-
inflammatory properties of mast cells. FhTeg impairs mast cells ability to drive Th1 
immune responses by inhibiting the release of key mediators such as, TNF-a, IL-6, 
IFN-g and IL-10. It also suppresses the expression of ICAM1, a cell surface 
molecule that has an important role in mast cell/T-cell crosstalk stabilizing cell to 
cell interaction and has function in signal transduction (Brill et al., 2004). While 
studies have shown the importance of ICAM1 expression on T-cells in mast cell/T-
cell communication here we show for the first time that ICAM1 expression on mast 
cells is also critical in this process. Our results suggest that in T-cell – mast cell 
communication both the mast cell derived cytokines and cell to cell contact are 
crucial to induce sufficient immune responses as we showed that the inhibition of 
cytokine secretion and cell surface molecule up-regulation by FhTeg both impaired 
mast cells ability to prime T-cells. This study supports previous findings 
demonstrating that FhTeg can suppress Th1 immunity in vivo by directly rendering 
innate immune cells such as dendritic cells hypo-responsive to TLR activation 
(Hamilton et al., 2009) a characteristic of helminth activated dendritic cells 
(MacDonald et al., 2002). 
 
The suppression of cytokine secretion by FhTeg was STAT6 independent, this 
supports our previous finding that FhTeg injection induced increase of mast cell 
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number in the peritoneal cavity was independent of STAT6. STAT6 signalling 
pathway is important in driving Th2 immune responses and promoting Th2 cytokine 
secretion (Finkelman et al., 2004), supporting our theory that FhTeg does not play 
role in the development of Th2 immune responses from mast cells. It also correlates 
with a study on STAT6-/- mice where the immunity against Taenia crassiceps was 
shown to be STAT6 independent (Rodriguez-Sosa et al., 2002).  
 
The suppression of Th1 immune response is critical for F. hepatica to survive within 
its host as immunity to Fasciola infection requires strong Th1 inflammatory 
responses (Moreau and Chauvin, 2010). IL-4
-/-
 mice, which are predisposed towards 
a Th1 immune response, are less susceptible to F. hepatica infection with reduced 
liver damage compared to IFN-gR-/- mice that elicited strong Th2 responses and are 
highly susceptible to infection (O'Neill et al., 2000). Vaccine efficacy using F. 
hepatica excretory-secretory molecules or using recombinant F. hepatica secretory 
enzymes is associated with enhanced lymphocyte proliferation and IFN-g expression 
(Mulcahy et al., 1999; Mulcahy et al., 2004).  
  
We know that F. hepatica infection is sufficiently potent to impact upon bystander 
microbial infections (Brady et al., 1999; Flynn et al., 2009) where in humans 
Fasciola infection is associated with susceptibility to Cryptosporidium and in cattle 
to increased incidence of Salmonella and Tuberculosis (Claridge et al., 2012; Flynn 
et al., 2009). Mice co-infected with Fasciola exhibit delayed clearance of Bordetella 
pertussis from their lungs which is associated with a decrease in antigen specific Th1 
immune responses (Brady et al., 1999). This was also observed in mice co-injected 
with B. pertussis and Fasciola antigens (O’Neill et al., 2000). Here we demonstrate 
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that FhTeg injected into mice suppresses B. pertussis induced TNF-α expression in 
mast cells, suggesting that mast cells may be targeted by helminth antigens during 
bystander infections. This could explain the failure of F. hepatica co-infected mice 
to clear B. pertussis infection since mast cells secrete pro-inflammatory mediators 
like TNF-α and IFN-g that mediate host defence against B. pertussis (Mielcarek et 
al., 2001; Wierzbicki and Brzezinska-Blaszczyk, 2009). Similarly mast cells have a 
critical role to play during experimental autoimmune encephalitis (EAE) as mast cell 
knockout mice are protected from developing this disease (Piconese et al., 2011) and 
this could explain how Fasciola could attenuate EAE in mice (Walsh et al., 2009). 
Further investigation is required to determine the role of mast cells in these processes 
which would shed further light on the impact of helminths on Th1 mediated 
autoimmune diseases. 
 
ERK and NF-κB are activated in mast cells after LPS and BP stimulation (Desai and 
Thurmond, 2011; Li et al., 2009) and here we found that FhTeg suppressed LPS 
induced NF-κB and MAPK pathway (ERK) activation in mast cells. It was shown in 
our laboratory that FhTeg suppresses LPS induced NF-κB activation in dendritic 
cells (Hamilton et al., 2009) and now we demonstrate that the MAPK pathway 
(ERK, JNK and p38) is also targeted by FhTeg in these cells. NF-kB and MAPKs 
are important signalling molecules in the expression of ICAM1 (Tsang et al., 2005) 
and secretion of pro-inflammatory cytokines. Our findings correlate with other 
studies in dendritic cells as S. mansoni egg antigens reduce LPS-stimulated 
phosphorylation of p38, JNK and ERK in murine dendritic cells (Kane et al., 2004). 
S. haematobium and Ascaris lumbricuides infection was shown to suppress the LPS 
induced p38 phosphorylation, but not ERK activation in dendritic cells (Everts et al., 
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2010a; van Riet et al., 2009). Studies demonstrate that NF-kB
-/-
 mice infected with 
Trichuris muris show increased susceptibility to infection with impaired Th2/Treg 
immune responses and the phosphorylation of NF-kB and ERK supposed to be 
crucial in helminth induced Th2 immune responses (Everts et al., 2010b; Mason et 
al., 2004). Given that FhTeg does not induce, rather suppresses the activation of 
these proteins supports our previous finding that FhTeg does not drive or suppress 
Th2 immunity (Figure 3.2, Figure 3.4, Figure 3.5), rather it has role in the 
suppression of Th1-type responses. As both Nf-kB and MAPK pathways are 
suppressed by FhTeg, the antigen should have its target further up in the TLR4 
signalling pathway. 
 
We decided to use dendritic cells to screen the possible targets of FhTeg by qPCR 
method. There was not much difference in the transcription level of the members of 
the TLR4 signalling pathway in early time points, suggesting that the suppression of 
immune response by FhTeg is not directly on the transcription of these proteins. 
Although in latter time points FhTeg alter the transcription of TLR4 and TRAF6, 
what correlates with a study where the expression of TLR4 is up-regulated in 
immune cells in mice with Heligmosomoides polygyrus infection (Ince et al., 2006). 
Innate immune cells have to respond quickly to bacterial infections; consequently the 
TLR pathway must be activated immediately after TLR4 activation. It takes time for 
the cells to make the proteins, so proteins downstream to TLR4 are activated on 
protein level by phosphorylation, ubiquitination or protein-protein interaction 
(Mogensen, 2009).  
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FhTeg induces negative regulators of the TLR pathway since FhTeg enhanced 
expression of SOCS3 in mast cells and in dendritic cells. SOCS3 is a member of a 
family of molecules that are one of the main inhibitory groups playing an important 
role in auto-regulation of pathogen induced inflammatory responses (Yoshimura et 
al., 2012). Previous studies showed increased SOCS3 RNA levels in blood cells 
from children with helminth (Ascaris sp, Trichuris sp. or Schistosoma haematobium) 
infection. They suggested that the higher level of SOCS3 might be responsible for 
the increased severity of bystander Plasmodium infection that requires Th1 immune 
responses (Hartgers et al., 2009). It is likely that F. hepatica has the same 
mechanism to suppress Th1 immune responses during bystander infection but further 
studies are required. 
 
FhTeg treated dendritic cells did not alter the expression of SOCS1 or SOCS2 which 
contrast studies with other helminths since during Brugia malay infection SOCS1 
up-regulation is important in the alternative activation of macrophages (Everts et al., 
2010b, Whyte et al., 2011), and SOCS2 was shown to be essential in the regulation 
of Th1 immune responses in dendritic cells (Dalpke et al., 2001; Posselt et al., 2011). 
Since the main inhibitors of TLR4 pathway are induced by the Janus kinase/signal 
transducer and activators of transcription (JAK/STAT) pathway the down-regulation 
of PIAS3 can result in increased transcription of SOCS3 and the inhibition of TLR4 
pathway. SOCS1 and PIAS3 were up-regulated by LPS in latter time points what is 
in conjunction with their auto-regulatory effect in TLR signalling during 
inflammation (Mogensen, 2009; Yagil et al., 2010). 
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The best way to prove that SOCS3 is responsible for the inhibition would be to block 
SOCS3 and see if FhTeg still keeps its effect. SOCS3-deficient mice die during 
embryotic development as a result of placental defect (Takahashi et al., 2006) and 
using zoledronic acid (ZA) (Scheller et al., 2011)., inhibitor of SOCS3, is not 
possible in our model system, as ZA impaired primary cell’s ability to be activated 
by bacterial ligands (Appendix C) (Bringmann et al., 2007; Fiore et al., 2007; Su et 
al., 2010). Other method to suppress gene expression would be to use small 
interfering (si)-RNA; it has also some difficulties in primery cells as it may influence 
cell development. Involving cell lines in this study could solve this problem, 
considering the differences between mast cells in their inflammatory responses based 
on their origin (Hochdorfer et al., 2011; Matsushima et al., 2004; McCurdy et al., 
2001; Supajatura et al., 2002). 
 
It is likely that FhTeg do not only target the TLR signalling pathways but has effect 
on other processes in immune cells. The JAK/STAT pathway is the principal 
signalling mechanism for a wide array of cytokines (like IL-6 or IFN-g) and growth 
factors (like TNF-a). The activation of this pathway can cause cell proliferation, 
differentiation, migration and apoptosis (Rawlings et al., 2004). This pathway can 
cross-talk with the TLR signalling pathway and cytokines were shown to alter TLR 
responses in macrophages in vitro (Hu et al., 2007) and in mice in vivo (Greenhill et 
al., 2011). In our study, although we did not manage to induce cytokine secretion 
from dendritic cells by cytokine treatment, we showed that FhTeg suppresses TNF-α 
induced cell surface marker up-regulation. 
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Mast cells were shown to contribute to the immune response against Strongloides 
ratti, Trichinella spiralis and Nippostrongylus brasiliensis in rats and mice models 
(Abe and Nawa, 1988; Marshall, 2004; McDermott et al., 2003). The fecundity of 
Heligneosomoides polygyrus was higher in mast cell-deficient mice than in the wild 
type controls (Hashimoto et al., 2009). These studies indicate that mast cell 
phenotype is important in driving Th2 immunity that is essential for clearing gut 
parasites (Pennock and Grencis, 2006). We previously showed that mast cell number 
increases markedly in the peritoneal cavity and liver of F. hepatica infected and 
FhTeg-injected mice, and that the interaction of FhTeg with mast cells does not 
promote Th2 immune response or suppress IgE mediated mast cell activation. Given 
that the Th1 immune responses are important in immune protection against Fasciola 
infection it is possible that in the early stages of infection mast cells are required to 
contribute to the overall Th1 milieu and this is inhibited by the release of FhTeg by 
Fasciola into the micro-environment. This is supported by FhTegs interaction with 
mast cells and dendritic cells as it directly inhibits their ability to drive Th1 immune 
responses. 
 
In summary, FhTeg impairs mast cell ability to drive Th1 immune responses which 
sheds new light on how helminths leave population susceptible to bystander 
infections while simultaneously protecting them against Th1-mediated autoimmune 
disorders. Further studies will help us to determine how FhTeg enhances SOCS3 
expression which may lead to potential identification of novel means by which 
helminths modulate innate immune cells. Since mast cells are involved in Th1 
immune disorders like autoimmune diseases, inflammatory bowel disease or Crohn’s 
disease where TNF-a secretion from these cells is critical to disease pathology 
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(Sutherland et al., 2011; Weller et al., 2011), it is therefore possible that the 
protective effect of helminths against autoimmunity may also be the result of its 
molecules direct blocking of pro-inflammatory cytokines from mast cells and 
dendritic cells. This finding might lead to the development of a therapeutic inhibitor 
for pathogenic cell phenotypes. 
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5 Chapter 5 – C-type lectin receptors of mast cells are up-regulated by 
Fasciola hepatica infection, although blocking of these C-type lectins 
does not reverse the inhibitory effect of FhTeg 
 
5.1 Introduction 
CLRs are important members of the pattern recognition receptor family and are 
important in the recognition of pathogen-associated molecular patterns (PAMPs). 
They can modulate TLR signalling or can directly induce gene expression. CLRs are 
expressed by most cell types including macrophages and dendritic cell (Geijtenbeek 
and Grinhuis, 2009; Ip et al., 2009). They have conserved carbohydrate-recognition 
domains (CRD) and they can bind carbohydrates in a calcium dependent manner. 
The CRD is a compact structural module which determines the specificity of the 
receptor (Geijtenbeek and Grinhuis, 2009). 
 
CLRs are activated by glycans and helminths express glycans, glycoproteins and 
glycolipids on their surfaces and these molecules were shown to have key role in the 
induction of Th2-type (van Die and Cummings, 2006) and anti-inflammatory 
immune responses (Harn et al., 2009; van Die and Cumings, 2010; Thomas and 
Harn, 2004). Glycans from helminths are important in the induction of alternatively 
activated (M2) macrophages and dendritic cell’s maturation and activation (Thomas 
and Harn, 2004). Fasciola hepatica expresses wide range of glycans and 
glycoproteins on its tegumental surface (Wilson et al 2011, Wuhrer and Geyer 2005) 
with possible immunomodulatory effects. 
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It was shown that F. hepatica antigens failed to induce alternative activation of 
macrophages in the presence of mannan, laminarin or the blocking antibodies of 
mannose receptor (MR) or Dectin1, suggesting that these CLRs are important in the 
recognition of F. hepatica and their products by immune cells (Guasconi et al 2011). 
In vivo, during F. hepatica infection the expression levels of macrophage galactose 
lectin (MGL) and MR are up-regulated on macrophages (Adams et al., unpublished 
data) suggesting that they are involved in the immunomodulatory effect of the fluke. 
 
Immune cells express DC-SIGN (homologue in mouse: SignR1), MR and MGL on 
their surface and helminth glycans can bind to these CLRs and this can lead to the 
suppression of LPS induced activation (Kuijk et al., 2010; Kuijk et al., 2012; van 
Liempt et al., 2006). Mast cells express an identical CLR, mast cell function 
associated antigen (MAFA) (Guthmann et al., 1995a; Guthmann et al., 1995b) and 
the activation of MAFA leads to the inhibition of FceRI-induced activation of mast 
cells (Abramson et al., 2002). This protein was subsequently found on mouse natural 
killer cells and human basophils (Katz, 2002). Mincle and Dectin 1 were also shown 
to be expressed by mast cells in low levels (Ribbing et al., 2011). Upon mast cell 
activation by the fungal antigen zymosan the Dectin1 level increases and zymosan 
induced leukotriene production seems to be Dectin 1 dependent (Yang and Marshall, 
2009). 
 
Schistosoma mansoni antigens were shown to bind to MR and Dectin1, and the 
blocking of these CLRs results in inhibition of immunomodulatory effect of the 
parasite (Guasconi et al., 2011) and decreased level of IL-4 secretion (Paveley et al., 
2011). Carbohydrate components of Trichinella spiralis larvae were shown to 
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activate macrophages leading to pro-inflammatory cytokine expression (Gruden-
Movsesijan et al., 2004). Helminth glycans have potential to interact with CLRs on 
dendritic cells. Schistosoma mansoni antigens were shown to bind to MGL (van 
Vliet et al., 2005), Dectin1 and DC-SIGN (van Kooyk et al., 2008) on dendritic cells 
and interfere with their APC function and impair T-cell polarisation (Kuijk et al., 
2010). Since FhTeg may suppress Th1 immune responses in dendritic cells 
(Hamilton et al., 2009) and mast cells, and SOCS3 is involved in this process, in this 
chapter we are investigating the role of CLRs in the immune modulation of dendritic 
cells and mast cells. 
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5.2 Experimental design 
Since C-type lectin receptors (CLR) have an important role to play during helminth 
infection, in this chapter we investigated if C-type lectin receptors are involved in 
FhTeg mast cell interaction. Firstly, BALB/C mice were infected with F. hepatica 
metacercariae (2.2.4) and CLR expression on mast cells from the peritoneal cavity 
was examined with flow cytometry. Since FhTeg treatment can mimic F. hepatica 
infection results were confirmed with mast cells from FhTeg treated mice (2.2.4). 
Dendritic cells represent a minor population in the peritoneal cavity, so CLR 
expression of these cells was measured in vitro. BMMCs and the more mature 
PCMCs were also examined in vitro to determine if FhTeg treatment can induce 
CLR up-regulation on these cells (2.2.12) by flow cytometry (2.2.18). 
 
Since MR and MGL were up-regulated by FhTeg in vitro and in vivo, we examined 
if these CLRs are involved in FhTeg – immune cell interaction. It was determined if 
blocking of MR or MGL can reverse the inhibition of bacterial ligand induced 
cytokine secretion by FhTeg using specific blocking antibodies prior to FhTeg 
treatment and LPS/BP stimulation (2.2.12). Blocking antibody treated, stimulated 
BMMCs were also co-cultured with naïve T-cells (2.2.19) to test if blocking of 
CLRs can reverse FhTeg’s inhibition on T-cell activation. Results were confirmed in 
dendritic cells (2.2.11-12). Involvement of MR and MGL in FhTeg induced SOCS3 
transcription was also examined in this model system (2.2.23-24). 
 
  
 127 
 
5.3 Results 
 
5.3.1 Fasciola hepatica infection or its FhTeg up-regulates C-type lectin 
receptor expression on mast cells in vivo. 
It was previously shown that F. hepatica infection and treatment of mice with F. 
hepatica antigen enhanced the expression of MR and MGL on murine peritoneal 
macrophages (Adams et al., unpublished data). In this study we examine if F. 
hepatica infection has the same effect on other immune cells. We investigated if 
Dectin1, MGL, MR and SignR1 are expressed by mast cells and if there is any 
change in the expression of these four CLRs during F. hepatica infection. Dendritic 
cells represent only a minor population in the peritoneal cavity, so we could not 
examine the expression of these CLRs on dendritic cells in vivo. The mice were 
orally infected with F. hepatica metacercariae and after 2 weeks of infection 
peritoneal exudate cells were collected and cell surface expression of CLRs on mast 
cells were measured by flow cytometry. After infection MR (to 125.0 ± 33.9%, p £ 
0.05) and MGL (to 774.6 ± 222.1%, p = 0.014) but not Dectin1 (p = 0.34) or SignR1 
(p = 0.77) was significantly upregulted (Figure 5.1). 
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Figure 5.1. MGL and MR but not Dectin1 or SignR1 are up-regulated on peritoneal mast cells 
during Fasciola hepatica infection. BALB/C mice were orally infected with Fasciola hepatica 
metacercariae and after 2 weeks of infection peritoneal exudate were collected and Dectin1 (A), MGL 
(B), MR (C) and SignR1 (D) expression was measured by three colour (FceRI, c-kit and CLRs) flow 
cytometry. Data are normalized to isotype controls and are presented as the mean ± SD of three 
independent experiments with 3-5 mice (n=13); *, p ≤ 0.05; compared to control group. 
 
Since the expression levels of MR and MGL, but not Dectin1 or SignR1 were up-
regulated during F. hepatica infection we exclude the latter two from further 
experiments. Treatment of mice with FhTeg induces mast cells in vivo and here 
BALB/C mice were treated with FhTeg and CLR expression on mast cells was 
measured by three colour flow cytometry (c-kit, FceRI and CLR). Mast cells from 
FhTeg treared mice exhibited significantly increased expression levels MGL (to 
412.6 ± 77.1%, p £ 0.01) (Figure 5.2A) although the increase of MR (to 138.5 ± 
43.5%, p = 0.21) was not significant (Figure 5.2B). 
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Figure 5.2. MGL but not MR was up-regulated on peritoneal mast cells after FhTeg injection. 
BALB/C mice were injected with FhTeg (10 mg) 5 times for 3 weeks After 3 weeks peritoneal 
exudate were collected and MGL (A) and MR (B) expression was measured by three colour flow 
cytometry (FcεRI, c-kit and CLR). Data are normalized to isotype controls and are presented as the 
mean ± SD of three independent experiments with three mice per group (n=9). *, p ≤ 0.05; **, p ≤ 
0.01 compared to control (PBS) group. 
 
5.3.2 FhTeg up-regulates C-type lectin receptor expression on dendritic cells 
and mast cells in vitro. 
To confirm our in vivo results, we wished to see if FhTeg can up-regulate CLR 
expression on dendritic cells and mast cells in vitro. First we confirmed by flow 
cytometry that MGL and MR are expressed by BMDCs, BMMCs and PCMCs. All 
examined cell populations expressed significant level of MR and MGL on their 
surface (p £ 0.01; Figure 5.3). BMDCs, BMMCs and PCMCs were stimulated with 
FhTeg (10 µg/ml) for 24 hours and MGL and MR cell surface expression was 
measured by flow cytometry. 
 
Expression level of MGL was down-regulated (to 67.45 ± 18.63% p £ 0.05) and MR 
was up-regulated (to 131.37 ± 3.49% p £ 0.01) in BMDCs after FhTeg treatment, 
(Figure 5.3A-B). In BMMCs the expression level of MR (to 160.7 ± 19.1%, p £ 
0.05) but not MGL (100.17 ± 23.27 p = 0.99) increased significantly after FhTeg 
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treatment compared to control group (Figure 5.3C-D). PCMCs showed higher 
expression of the tested CLRs and were more responsive when compared to the less 
mature BMMCs. In PCMCs all two tested CLRs (MGL: 155.6 ± 25.2%, p £ 0.01; 
and MR: 289.2 ± 37.7%, p £ 0.05) are significantly up-regulated by FhTeg (Figure 
5.3E-F). 
 
 
Figure 5.3. MGL and MR were up-regulated by FhTeg in vitro. BMDCS, BMMCs and PCMCs 
were treated with FhTeg (10 µg/ml) for 24 hours and MGL (A, C, E), and MR (B, D, F) membrane 
expression was measured by two colour (FceRI/CD11c and CLR) flow cytometry. Data are 
normalized to isotype controls and presented as the mean ± SD of three independent experiments with 
triplicates (n=9); ++, p ≤ 0.01 compared to isotype control *, p ≤ 0.05; **, p ≤ 0.01 compared to 
control (PBS) group. 
 
5.3.3 Blocking of MR and MGL does not reverse FhTeg’s inhibition of LPS 
activated dendritic cells and mast cells. 
MR and MGL are up-regulated in vivo during F. hepatica infection and after FhTeg 
treatment and there are commercially available neutralizing antibodies for these two 
CLRs. To see if the blocking of MR or MGL reverses the inhibitory effect of FhTeg 
on cytokine secretion of LPS stimulated dendritic cells BMDCs were treated with 
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anti-MR or anti-MGL blocking antibodies 30 min before FhTeg/LPS stimulation. 
Blocking antibody treatment had no effect on LPS stimulation and there was no 
significant difference between LPS/FhTeg treated groups either. Blocking of MR or 
MGL did not reverse the inhibitory effect of FhTeg on cytokine secretion (Figure 
5.4). 
 
Figure 5.4 Blocking of CLRs did not reverse the effect of FhTeg on BMDC activation. BMDCs 
were treated with anti-MR or anti-MGL blocking antibody 30 min before treated with FhTeg (10 
µg/ml) for 2.5 hours and after stimulated with LPS (100 ng/ml) for 18 hours. IL-12 (p70) was 
measured with commercial ELISA. Figure is representative of three independent experiments (n=3) 
and presented as the mean ± SD of three replicate samples from the same experiment; *, p ≤ 0.05; **, 
p ≤ 0.01 compared to control (PBS) group. 
 
The previous experiment in mast cells were repeated to see if we get the same results 
as in dendritic cells, and the blocking of MR or MGL did not reverse the inhibitory 
effect of FhTeg on BP-activated mast cells (Figure 5.5). In this experiment the less 
mature BMMCs were used so the LPS stimulation did not induce significant level of 
cytokines. There is an increase in cytokine output from controls by FhTeg but the 
difference is not significant and the levels are very low. Interestingly blocking of the 
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two CLRs impairs TNF-α secretion in BP activated mast cells (p £ 0.01). Mast cells 
were co-cultured with CD4+ naïve T-cells to see if the blocking of the CLRs has any 
effect on FhTeg inhibition and the blocking of CLRs did not reverse T-cell inhibition 
by FhTeg (Figure 5.6). In the case of IFN-g blocking of MR and MGL inhibited BP-
induced T-cell activation (p £ 0.01; Figure 5.6A) 
 
 
Figure 5.5. Blocking of MR or MGL did not reverse the effect of FhTeg on BMMC activation. 
BMMCs were treated with anti-MR and anti-MGL blocking antibody (1 mg/ml) 30 min before treated 
with FhTeg (10 µg/ml) for 2.5 hours and after stimulated with LPS (100 ng/ml) or BP (100 
bacteria/cell) for 24 hours. TNF-a (A) and IL-6 (B) secretion was measured with commercial ELISA. 
Figures are representatives of three independent experiments (n=3) and presented as the mean ± SD of 
three replicate samples from the same experiment. *, p ≤ 0.05; **, p ≤ 0.01 compared to control PBS 
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group. +, p ≤ 0.05; ++, p ≤ 0.01 compared to control (non-FhTeg) group. ‡, p ≤ 0.05; ‡‡, p ≤ 0.01 
compared to control LPS or BP treated group. 
 
 
 
Figure 5.6. Blocking of MR or MGL did not reverse the effect of FhTeg on T-cell activation. 
BMMCs were treated with, anti-MR and anti-MGL blocking antibody (1 mg/ml) 30 min before treated 
with FhTeg (10 mg/ml) for 2.5 hours and after stimulated with LPS (100 ng/ml) or BP (100 
bacteria/cell) for 24 hours. Cells were washed and co-cultured with anti CD3 activated naïve CD4+ T-
cells (1:1) for 72 h. IFN-γ (A) and IL-10 (B), secretion was measured with commercial ELISA. 
Figures are representatives of three independent experiments (n=3) and presented as the mean ± SD of 
three replicate samples from the same experiment. *, p ≤ 0.05; **, p ≤ 0.01 compared to control PBS 
group. +, p ≤ 0.05; ++, p ≤ 0.01 compared to control (non-FhTeg) group. ‡‡, p ≤ 0.01 compared to 
control LPS or BP treated group. 
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5.3.4 Blocking of MGL suppresses FhTeg induced SOCS3 expression in 
dendritic cells, although it does not reverse FhTeg’s inhibition of LPS activated 
dendritic cells. 
In the previous chapter we showed that FhTeg induce SOCS3 transcription in 
dendritic cells and mast cells. We wished to see if the blocking of CLRs, possible 
receptors of FhTeg, could inhibit FhTeg induced SOCS3 up-regulation. We tested if 
the blocking of MR and MGL inhibits the up-regulation of SOCS3 by FhTeg. In this 
experiment dendritic cells were used as they are more reactive and showed higher 
SOCS3 transcription levels than mast cells in previous experiments. SOCS3 
transcription level was up-regulated by FhTeg in control (3.7 ± 0.9, p £ 0.05) and 
anti-MR treated (4.6 ± 0.8, p £ 0.05) cells. Neutralisation of MGL but not MR 
inhibited FhTeg induced SOCS3 (Figure 5.7) suggesting the involvement of other 
inhibitory molecules in the immunostimulatory effect of FhTeg on immune cells. 
 
Figure 5.7. Blocking of MGL but not MR inhibit FhTeg induced SOCS3 transcription. BMDCs 
were stimulated with PBS (control), anti-MR and anti-MGL blocking antibody (1 mg/ml) 30 min 
before treated with FhTeg (10 mg/ml) for 2.5 hours.  Total RNA was extracted and after reverse 
transcription cDNA was analysed with qPCR for SOCS3. RNA expression was normalized to 
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GAPDH, b-actin and Gusb control gene expression and showed relative to PBS control using Pfaffl’s 
method; Figure is representative of two independent experiments with 3 control genes (n=3) *, p ≤ 
0.05; compared to control (PBS) group. 
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5.4 Discussion 
Fasciola hepatica expresses a wide range of glycans and glycan conjugated 
molecules on their surface tegumental coat (Wilson et al., 2011; Wuhrer and Geyer, 
2006), such as galactosylceramide or globotriasylceramide with a terminal GalNAc 
motif, a ligand of MGL (Kuijk and van Die, 2010; Wuhrer and Geyer, 2006). This 
study demonstrates that during Fasciola hepatica infection and after FhTeg 
treatment the expression of MR and MGL increased in vivo on mast cells. The cell 
surface levels of these CLRs are also modulated by FhTeg in mast cells and dendritic 
cells in vitro. MGL is involved in the up-regulation of SOCS3 transcription level in 
dendritic cells by FhTeg, although blocking of MGL or MR did not reverse the 
inhibitory effect of FhTeg inflammatory responses from bacterial ligand activated 
immune cells. 
 
Immature dendritic cells express a large variety of CLRs, and these CLRs are often 
down-regulated upon maturation (van Vliet et al., 2008) and different subsets of 
dendritic cells express different CLRs (van Kooyk, 2008). Dendritic cell specific 
DC-SIGN (SignR1), Dectin1, MR and MGL can be found on the surface of 
tolerogenic and monocyte-derived dendritic cells. They were shown to be important 
in the internalization of glycosylated antigens and in the activation of dendritic cells 
during bacterial, viral, fungal and parasitic infections (van Vliet et al., 2008; 
Geijtenbeek and Gringhuis, 2009).  
 
FhTeg induces down-regulation of MGL in dendritic cells in vitro and we 
demonstrated that MGL plays role in FhTeg induced SOCS3 up-regulation, although 
blocking of MGL did not reverse the inhibitory effect of FhTeg. CLRs activation can 
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inhibit TLR signalling (van Vliet et al., 2008; Geijtenbeek and Gringhuis, 2009), and 
up-regulation of negative regulatory molecules might play role in this process. 
Activation of CLRs was shown to induce SOCS expression in dendritic cells; 
however studies predominantly investigate SOCS1. SOCS1 is up-regulated in 
plasmocyloid dendritic cells after binding of hepatitis B antigen to a CLR, BDCA2 
(Xu et al., 2009). Dendritic cells specific DC-SIGN mediated SOCS1 expression can 
suppress IL-12 secretion in mice with Mycobacterium tuberculosis infection 
(Srivastava et al., 2009). Dectin1 was shown to be important in SOCS1 up-regulation 
in zymosan treated BMDCs. Upon CLR-stimulation, IL-12 and IL-10 production 
and NF-κB activation is suppressed in TLR stimulated dendritic cells and these cells 
failed to prime T-cells (Eberle and Dalphe, 2012). Reg2 is a murine C-type lectin 
(HIP/PAP in humans) and was shown to be responsible for STAT3 activation and 
SOCS3 up-regulation (Lieu et al., 2006; Closa et al., 2007).  
 
Our results suggest that FhTeg induces the expression of inhibitory molecules of the 
TLR signalling pathway, such as SOCS3, through MGL. CLR and TLR signalling 
crosstalk is very complicated and not fully understood (Geijtenbeek and Gringhuis, 
2009). Probably the effect of FhTeg on immune cells is complex and it is not limited 
to the up-regulation of SOCS3. FhTeg contains lot of different glycoproteins so it is 
likely that these proteins activate more than one receptor and the activation of these 
receptors together may be responsible for the immunomodulatory effect of FhTeg. 
Further investigation would be to isolate the immunologically active component(s) 
of FhTeg and study its binding properties. 
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There are only few studies investigating CLR expression on mast cells. Mast cells 
were shown to express a specific CLR, mast cells function associated antigen 
(MAFA) (Guthmann et al., 1995a), involved in the inhibition of FceRI-induced 
activation of mast cells (Abramson et al., 2001). Mincle (macrophage-inducible C-
type lectin) and Dectin1 were also shown to be expressed by mast cells, although the 
expression level is very low (Ribbing et al., 2010; Yang and Marshall, 2008). These 
two CLRs are present on both macrophages and dendritic cells and play important 
role in antifungal immunity (Wells et al., 2008). Here we showed that MR, MGL and 
SignR1 can be found on the cell surface of BMMCs and PCMCs. The expression of 
these CLRs were higher on PCMCs which correlates with a study where other 
receptors such as TLR2 and TLR4 was highly expressed on PCMCs as they are more 
mature than BMMCs (Mrabet-Dahbi et al., 2009).  
 
Helminth’s glycans have the potential to interact with CLRs on immune cells and to 
interfere with their functions. SignR1, MR, MGL and Dectin1 have been shown to 
interact with helminths glycans (van Die et al., 2009) and it is likely that they play 
role in immunomodulation. Our results suggest that MR and MGL but not Dectin1 
or SignR1 may be involved in the immunomodulation of immune cells (Table 7.1). 
MGL and MR are markers for M2 macrophages and were shown to be up-regulated 
in mice with Taenia crassiceps infection (Raes et al., 2005). MGL but not DC-SIGN 
was positively regulated in dendritic cells stimulated with the cestode antigens of T. 
crassiceps (Terrazas et al., 2011). MGL and MR induce internalisation of 
Schistosoma mansoni egg antigens, suppress TLR induced dendritic cell maturation 
and induce the development of Th2 phenotype (van Liemt et al., 2006). MGL was 
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also shown to be involved in the suppression of LPS induced cytokine secretion by 
the antigens of T. crassiceps (Terrazas et al 2011). 
 
Our in vivo results correlate with a previous study where murine peritoneal 
macrophages exhibited increased expression levels of MGL and MR, but not Dectin1 
or SignR1 during F. hepatica infection or FhTeg treatment (Adams et al., 
unpublished data), while FhES failed to up-regulate these CLRs. FhES mainly 
contains proteins and enzymes, while FhTeg derived from the glycocalix and its 
main components of FhTeg are carbohydrates and glyco-proteins, which can explain 
the differences between the two antigen preparations. It was shown previously that 
blocking MR with antibody or mannan partially inhibits the modulatory effect of the 
excretory-secretory product of F. hepatica in macrophages (Guasconi et al., 2011).  
 
CLRs have multiple functions in pathogen recognition, although their function is not 
as well studied as TLR receptors. They can induce or inhibit cytokine secretion and 
modulate TLR4 signalling. Here we showed that MR and MGL play role in F. 
hepatica immune cells interaction, although we did not manage to reverse the 
inhibitory effect of FhTeg by blocking these two CLRs. Our results also suggest that 
beside TLR4 MR and MGL may be involved in the activation of mast cells by 
bacterial antigens. Further investigation of immune cell’s CLR – pathogen 
interaction will help us to learn more about mast cell and dendritic cells function in 
innate immunity. 
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6 Chapter 6 - Mannose receptor and macrophage galactose lectin are 
involved in Bordetella pertussis mast cells interaction 
 
6.1 Introduction 
Although blocking of MR or MGL did not interfere with the immunomodulatory 
effect of FhTeg on mast cells, we found significant suppression of BP induced 
cytokine secretion in BMMCs. In this chapter we investigate the involvement of MR 
and MGL in B. pertussis mast cell interaction. 
 
CLRs play a key role in immunity against bacterial infections due to their calcium-
dependent interaction with pathogen-associated glycan epitopes (Lloyd et al., 2007). 
Upon carbohydrate binding, CLRs have the ability to trigger the immune machinery 
by antigen internalization and presentation onto major histocompatibility complex 
(MHC) molecule or by modulation of TLR-mediated signalling pathway (Weis et al., 
1998). Differences in sugar-binding ability and ligand-specificity of the various 
CLRs are conferred by highly conserved carbohydrate-recognition domains (CRD). 
The ubiquitous expression of CLRs by most cell types, including macrophages and 
dendritic cells (Geijtenbeek and Grinhuis, 2009), together with organism-specific 
differences in glycosylation among pathogens make the CLRs a central defence 
system in the innate immunity. 
 
Most bacteria exhibit a thick coat of glyco-conjugate structures in the form of 
polysaccharidic capsule, peptidoglycans, or lipopolysaccharides and other 
glycolipidic moieties (Kusumoto et al., 2010). This coat is usually composed of a 
number of PAMPs, which can activate multiple PRRs (Kawai and Akira, 2011). 
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Mannose receptor (MR) binds to carbohydrates such as mannose, N-
acetylglucosamine and fucose. These saccharides can be found on the surfaces of 
microorganism, including Escheria coli, Pseudomonas aeruginosa or 
Mycobacterium tuberculosis (Weis et al., 1998). Another important CLR, 
macrophage galactose-like lectin (MGL) has been reported to bind to galactose and 
terminal N-acetylgalactosamine (GalNAc)-motifs on filoviruses and Campylobacter 
jejuni (Geijtenbeek and Gringhuis, 2009; van Sorge et al., 2009). Some bacteria can 
interact with more than one CLR, and the restricted expression of CLRs on immune 
cell subsets can contribute to the different immune responses (van Vliet et al., 2007). 
 
To date, the study of CLRs expressed on mast cells is in its infancy. Mast cells 
express a specific CLR, mast cell function associated antigen (MAFA) (Guthmann et 
al., 1995b), later found also in natural killer cells and human basophils (Katz, 2002). 
Stimulation of MAFA leads to the inhibition of FceRI-induced activation of mast 
cells (Abramson et al., 2002). Other CLRs such as macrophage-inducible C-type 
lectin (Mincle) and Dectin1 were also shown to be expressed by mast cells, although 
expression levels are very low (Ribbing et al., 2011; Yang and Marshall, 2009). 
These two CLRs, also present on macrophages and dendritic cells, play important 
roles in antifungal immunity (Wells et al., 2008). Upon CLR-ligand binding ITAM 
and ITAM-like signalling pathways can be activated, promoting the recruitment of 
spleen tyrosine kinase (Syk), which results in the activation of cellular proliferation, 
differentiation and migration (Kerrigan et al., 2010). 
 
Bordetella pertussis is a Gram-negative coccobacillus that causes the respiratory 
infection, whooping cough (Gregory, 2006). Despite being preventable by 
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vaccination, pertussis causes nearly 300,000 deaths in children every year mainly in 
developing countries (Growcroft and Pebody, 2006), although the incidence of 
whooping cough in Europe has increased due to the change in national immunization 
schedules from the whole-cell vaccine to acellular vaccine (Growcroft and Pebody, 
2006). Vaccination can induce protection against infection by inducing strong 
Th1/Th2 immune response; however, the acellular vaccine induces a polarised Th2 
immune response (Growcroft and Pebody, 2006, von Konig et al., 2002) and confers 
protection for a limited time only (von Konig et al., 2002). Better understanding of 
the interaction of the bacteria with immune cells may lead to development of a more 
effective vaccine that induces lifelong immunity. Bordetella was shown to be a 
ligand for TLR4 (Mann et al., 2005), but the immunopathogenesis of B. pertussis is 
not fully understood. The key initiator of inflammatory and immune responses is the 
strain-specific endotoxin component of the bacteria outer membrane; the 
lipooligosaccharides (LOS) (Schaeffer et al., 2004; Marr et al., 2010), while actively 
released protein toxins, such as pertussis toxin, dermonecrotic toxin or adenylate 
cyclase (Locht, 1999; Locht et al., 2001), or other cell wall components, like 
adhesins might contribute to the development of disease (Le Blay et al., 1994). 
 
Despite the crucial role of mast cells in the clearance of bacterial infection from the 
lung and in mediating immune responses (Abraham et al., 1997; Moiseeva and 
Bradding, 2011), only few studies have examined the interaction of mast cells with 
B. pertussis (Mielcarek et al., 2001). In the previous chapters we showed that mast 
cells stimulated with the heat-inactivated B. pertussis antigen (BP) secrete pro-
inflammatory cytokines, such as TNF-a and IL-6 and display enhanced expression 
of ICAM1. BP-stimulated mast cells promote cytokine secretion in T-cells. BP 
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induces the activation of two members of the TLR4 signalling pathway, ERK and 
NF-kB. In this study we investigated the interaction between mast cells and B. 
pertussis with an emphasis on the role of CLRs. 
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6.2 Experimental design 
Since blocking MR and MGL suppresses BP-induced cytokine secretion in BMMCs, 
in this chapter Bordetella pertussis – mast cell interaction was investigated further to 
determine a role of C-type lectin receptors (CLRs). Firstly, it was confirmed that MR 
and MGL are expressed by BMMCs and PCMCs and it was tested if BP-stimulation 
can up-regulate this CLR expression (2.2.12, 2.2.18). PCMCs are more mature than 
BMMCs and they secrete more cytokines (IFN-γ and IL-10) after BP stimulation, so 
effect of anti-MR and anti-MGL blocking antibodies on BP-induced activation of 
mast cells were examined in PCMCs. To confirm that the effect of the blocking 
antibodies is specific for the binding sites of MR and MGL the results were 
confirmed with the specific carbohydrate ligand of these CLRs (mannan and 
GalNAc). EGTA (block all CLRs) and laminarin (ligand for Dectn1) were used as 
controls in these experiments (2.2.18). 
 
BP-stimulated PCMCs were co-cultured with naïve T-cells (2.2.19) to test if 
blocking of MR and MGL on mast cells suppresses mast cell induced cytokine 
secretion in T-cells. Since ICAM1 has been shown to be important in mast cell – T-
cell communication involvement of CLRs in BP-induced ICAM1 up-regulation was 
also tested (2.2.18). BP has been shown to activate NF-κB and ERK in mast cells 
and we tested the involvement of MR and MGL in BP-induced transcription factor 
activation using blocking antibodies (2.2.20-22). Involvement of Syk kinase 
(member of CLR signalling cascade) in cytokine secretion was also tested (2.2.12). 
 
Since LOS is crucial to activate the immune system during Bordetella infection and 
the most probable ligand of CLRs, the role of B. pertussis LOS in CLR-mediated 
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mast cell activation was investigated. LOS from BP heat-inactivated cells was 
isolated by digestion of cell lysate with proteinase K followed by high-speed 
centrifugation (2.2.25). First we confirmed that LOS can mimic BP and promote 
cytokine secretion in mast cells than the effect of blocking anti-MR and anti-MGL 
antibodies on LOS-induced cytokine secretion in BMMCs was examined (2.2.25). 
Due to the presence of traces of proteinase K in LOS preparation, the effect of 
proteinase K on mast cell was also tested. 
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6.3 Results 
6.3.1 MR and MGL are expressed by PCMCs and BP stimulation has no 
effect on this expression. 
Previous studies have reported the expression of mast cell function associated 
antigen (MAFA) (Guthmann et al., 1995a), Dectin1 and Mincle (Yang and Marshall, 
2009) on mast cells. Here the expression of MGL and MR on BMMCs and PCMCs 
was examined by flow cytometry revealing that these CLRs are highly expressed by 
mast cells (Figure 6.1). 
 
 
Figure 6.1. MR and MGL are expressed by mast cells. Cell surface expression of MR (B) and 
MGL (C) were measured by three colour (FcεRI, c-kit and CLR) flow cytometry on PCMCs. On 
histogram (A) isotype control is indicated with grey, MR and MGL are indicated with normal and 
dashed lines, respectively. Data were normalized to isotype controls and are presented as the mean ± 
SD of three independent experiments (n=3). *, p ≤ 0.05; **, p ≤ 0.01 compared to isotype control 
group. 
 
Since neutralization of MR and MGL impairs TNF-α secretion in BP activated 
BMMCs (Figure 5.5) we tested if BP stimulation changes the expression levels of 
MR and MGL. BMMCs and PCMCs were stimulated with PBS or heat inactivated 
BP for 24 hours and expression levels of MR and MGL were measured by flow 
cytometry. There was no significant difference between the stimulated and control 
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groups in the expression of the investigated CLRs (MR: p = 0.12; MGL: p = 0.91) 
(Figure 6.2). 
 
 
Figure 6.2. BP stimulation has no effect on MR and MGL expression. PCMCs were stimulated 
with BP (100 bacteria /cell) or PBS for 24 h. MR (A) and MGL (B) expression level was measured 
with flow cytometry. Data were normalised to isotype controls and are presented as the mean ± SD of 
three independent experiments (n=3). **, p ≤ 0.01 compared to isotype control group. 
 
6.3.2 Anti-MR and anti-MGL blocking antibodies suppress BP-induced TNF-
α, IL-6 and IFN-γ secretion in mast cells. 
As PCMCs are more mature compared to BMMCs and beside TNF-a and IL-6 
secrete also IL-10 and IFN-g after BP stimulation, consequently we repeated the 
CLR neutralization experiment with these cells. Stimulation of PCMCs with BP for 
24 hours induced secretion of cytokines (TNF-a, IL-6, IFN-g (p £ 0.01), IL-10 (p £ 
0.05)) when measured by commercial ELISA (Figure 6.3). TNF-a, IL-6 and IFN-g 
secretion levels were significantly suppressed when PCMCs were treated with anti-
MR (TNF-a, IL-6: p £ 0.05; IFN-g: p £ 0.01) or anti-MGL (TNF-α, IL-6, IFN-γ: p ≤ 
0.01) blocking antibody for 30 minutes prior to BP stimulation (Figure 6.3A-C). IL-
10 secretion by PCMCs was not impaired by either of the antibodies (anti-MR: p = 
0.18, anti-MGL: p = 0.80) (Figure 6.3D). 
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Figure 6.3. Blocking of MR and MGL suppressed BP induced cytokine secretion in mast cells. 
PCMCs were treated with anti-MR or anti-MGL blocking antibody (1 mg/ml) 30 min before 
stimulated with BP (100 bacteria/cell) for 24 hours. TNF-a (A), IL-6 (B), IFN-γ (C) and IL-10 (D) 
secretion was measured with commercial ELISA. Figures are representatives of three independent 
experiments (n=3) and presented as the mean ± SD of three replicate samples from the same 
experiment. *, p ≤ 0.05; **, p ≤ 0.01 compared to control group; and +, p ≤ 0.05; ++, p ≤ 0.01 
compared to control BP stimulated group. 
 
6.3.3 Anti-MR and anti-MGL blocking antibodies reverse T-cell activation by 
BP-primed mast cells. 
PCMCs were stimulated with BP in the presence or absence of anti-MR or anti-MGL 
blocking antibodies for 24 hours to determine if mast cell ability to promote cytokine 
production from naïve CD4+ T-cells can be inhibited. BP-activated PCMCs were co-
cultured with naïve CD4
+ T-cells and cytokine secretion was assessed. Since co-
culture of mast cells with naïve CD4
+ cells in the presence of anti-CD3 is reported to 
promote cytokine secretion per se (Huels et al., 1995; Nakae et al., 2005; Nakae et 
al., 2006), PBS-primed PCMCs were also used in the co-culture experiments as 
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controls. CD4
+
 T-cells co-cultured with BP-stimulated PCMCs secreted higher levels 
of IFN-γ (p £ 0.05), IL-10 (, p £ 0.05) and IL-5 (p £ 0.05) than the control group 
(Figure 6.4A-C), while IL-4 levels remained unchanged (p = 0.55) (Figure 6.4D). 
When PCMCs were pre-treated with anti-MR or anti-MGL prior to BP-stimulation, 
mast cell no longer secreted significant levels of IFN-γ (anti-MR: p = 0.41, anti-
MGL: p = 0.12) and IL-5 (anti-MR: p = 0.13, anti-MGL: p = 0.12) in co-culture 
compared to controls (Figure 6.4A, C). However only PCMCs treated with anti-
MGLdid not secrete IL-10 compared to controls (Figure 6.4B). 
 
 
Figure 6.4. Anti-MR and anti-MGL blocking antibodies interfere with BP-induced T-cell 
activation by PCMCs. PCMCs were treated with anti-MR and anti-MGL blocking antibody (1 
mg/ml) 30 min before stimulated with BP (100 bacteria/cell) for 24 hours. Cells were washed and co-
cultured with naïve CD4
+ T-cells (1:1) for 72 h. IFN-γ (A), IL-10 (B), IL-5 (C)  and IL-4 (D) 
secretion was measured with commercial ELISA. Figures are representatives of three independent 
experiments (n=3) and presented as the mean ± SD of three replicate samples from the same 
experiment; *, p ≤ 0.05 compared to control group. 
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6.3.4 Anti-MR and anti-MGL blocking antibodies do not suppress BP induced 
up-regulation of ICAM1. 
Since ICAM1 is important in T-cell – mast cell communication and was previously 
shown to be up-regulated on mast cells after BP stimulation (Figure 6.5), the 
involvement of CLRs in ICAM1 expression was investigated. PCMCs were treated 
with anti-MR or anti-MGL blocking antibodies prior to stimulation with BP for 24 h 
and ICAM1 expression was measured by flow cytometry. BP induced up-regulation 
of ICAM1 expression in all groups, with no significant effect due to blocking of MR 
or MGL (one-way ANOVA was used to asses if data belong to the same group; p = 
0.97) (Figure 6.5). 
 
 
 
Figure 6.5. Anti-MR and anti-MGL blocking antibodies did not suppress BP induced up-
regulation of ICAM1. PCMCs were treated with anti-MR or anti-MGL blocking antibody (1 mg/ml) 
30 min before stimulated with BP (100 bacteria/cell) for 24 hours. Cell surface marker expression of 
ICAM1 was measured by Flow cytometry. Data are normalized to isotype control and presented as 
the mean ± SD of three independent experiments (n=3); *, p ≤ 0.05; **, p ≤ 0.01 compared to control 
group. 
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6.3.5 Glycans (mannan, GalNac and laminarin) and EGTA suppress BP 
induced TNF-α and IL-6 secretion. 
In order to fully validate that the observed suppression of cytokine secretion is due to 
effective blocking of Ca2+-dependent CRDs on CLRs, BMMCs were treated with 
mannan (50 µg/ml, blocking SignR1 and MR), GalNAc (50 mM, blocking MGL), 
laminarin (100 µg/ml, blocking Dectin1) or EGTA (10 mM, Ca2+-ligand) for 30 min 
before stimulated with BP for 24 h. All the glycans and EGTA suppressed BP 
induced TNF-α and IL-6 secretion significantly (p £ 0.01 to p £ 0.05) (Figure 6.6.).  
Notably, EGTA treatment reduced the cytokines secretion ability not only in BP-
stimulated but also in PBS-primed (control) mast cells (p £ 0.01) (Figure 6.6). 
 
 
Figure 6.6. Carbohydrate treatment impaired BP induced cytokine secretion in mast cells. 
BMMCs were treated with EGTA (10 mM), laminarin (100 µg/ml), mannan (50 µg/ml), GalNAc 
(50mM) 30 min before stimulated with BP (100 bacteria/cell) for 24 hours. TNF-a (A) and IL-6 (B) 
secretion was measured with commercial ELISA. Figures are representatives of three independent 
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experiments (n=3) and presented as the mean ± SD of three replicate samples from the same 
experiment. *, p ≤ 0.05; **, p ≤ 0.01 compared to PBS groups; and +, p ≤ 0.05; ++, p ≤ 0.01 compared 
to control BP stimulated group. 
 
6.3.6 Syk inhibition supresses TNF-α and enhances IL-6 secretion by BP-
stimulated mast cells. 
Spleen tyrosine kinase is involved in CLR signalling; it binds to the phosphorylated 
intracellular domain of the CLR and mediates signalling resulting in transcription 
factor activation and cytokine secretion in dendritic cells (Lang et al., 2011). 
Downstream CLR signalling was investigated by assessing the involvement of Syk 
kinase (Kerrigan and Brown, 2010) in cytokine secretion by BP-stimulated mast 
cells. BMMCs were treated with Syk inhibitor (piceatannol) prior to stimulation with 
BP for 24 h. TNF-α secretion was reverted to basal level by Syk inhibition (Figure 
6A), while IL-6 secretion levels appeared dramatically enhanced in both BP-
stimulated and control groups (Figure 6B). 
 
 
Figure 6.7. Inhibition of Syk suppressed BP-induced TNF-a secretion and enhances IL-6 
secretion in mast cells. BMMCs were treated with PBS (control) or Syk inhibitor (10 µM) 30 min 
before stimulated with BP (100 bacteria/cell) for 24 hours. TNF-a (A) and IL-6 (B) secretion was 
measured with commercial ELISA. Figures are representatives of three independent experiments 
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(n=3) and presented as the mean ± SD of three replicate samples from the same 
experiment; *, p ≤ 0.05; **, p ≤ 0.01 compared to control (PBS) group. 
 
6.3.7 Blocking of MR and MGL has no effect on BP induced ERK 
phosphorylation. 
To further understand the signalling pathways involved in CLR-mediated BP-
stimulation of mast cells, the effect of CLRs blocking on NF-kB p65 and ERK 
phosphorylation was investigated. We previously reported that BP-stimulation of 
mast cells enhances ERK and NF-kB p65 activation. The latter effect could be 
reversed by blocking either MR or MGL (p £ 0.01) (Figure 6.8A, B), whereas CLR-
blocking had no statistical effect on ERK phosphorylation (Figure 6.8A, C). 
 
 
Figure 6.8. Neutralisation of MR and MGL did not interfere with BP induced ERK 
phosphorylation. BMMCs were treated with anti-MR and anti-MGL blocking antibodies prior to 
stimulation with BP for 15 min. Protein samples were analysed by western blot for phosphorylated-
ERK (p-ERK), total-ERK (t-ERK), phosphorylated-NF-kB p65 and b-actin expression (A). Values of 
p-ERK (B), and NF-kB p65 (C) were normalised to t-ERK and b-actin and are expressed in arbitrary 
units as % fold increases over PBS control. Densitometry data are presented as the mean ± SD of 
three independent experiments (n=3); *, p ≤ 0.05; **, p ≤ 0.01 compared to control (PBS) group. 
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6.3.8 Neutralisation of MR and MGL suppresses LOS induced cytokine secretion in 
mast cells 
Whole cell vaccine studies suggest that BP derived lipooligosaccharide (LOS) is 
crucial to activate innate immune cells to generate pro-inflammatory cytokines in 
Bordetella infections (Higgins et al., 2006). The role of B. pertussis LOS in CLR-
mediated mast cell activation was investigated. LOS from BP heat-inactivated cells 
was isolated by digestion of cell lysate with proteinase K followed by high-speed 
centrifugation (Figure 2.5). BMMCs were stimulated with blocking anti-MR and 
anti-MGL antibodies 30 min prior to stimulation with this LOS preparation for 24 h. 
Due to the presence of traces of proteinase K in LOS preparation, the effect of 
proteinase K on mast cell was also tested, resulting in negligible cytokine secretion. 
The neutralisation of MR and MGL on LOS-stimulated mast cells inhibited cytokine 
secretion (Figure 6.9) as previously observed in the case of BP-stimulated cells 
(Figure 6.3A, B). 
 
 
Figure 6.9. Neutralisation of MR and MGL suppressed LOS induced cytokine secretion in mast 
cells. LOS was isolated from BP antigen and BMMCs were stimulated with 2 u/ml (equivalent to 100 
bacteria/cell) for 24 h in the presence and absence of anti-MR or anti-MGL neutralisation antibodies. 
TNF-a (A) and IL-6 (B) secretion was measured by commercial ELISAs. LOS isolation was done by 
Dr Alessandra Ravidà (Dublin City University, Ireland). Data are presented as the mean ± SD of three 
independent experiments; *, p ≤ 0.05; **, p ≤ 0.01 compared to control-LOS group.  
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6.4 Discussion 
Mast cells are a major component of protective immunity against microbial 
infection. These cells are a potent source of pro-inflammatory mediators, such as 
TNF-α and IFN-g that can promote Th1 driven host defence against bacteria and 
protozoa (Abraham and John, 2010; Dawicki and Marshall, 2007; Galli and Tsai, 
2010; Metcalfe et al., 1997; Weller et al, 2011). They have been shown to play a 
crucial role in the clearance of bacterial infection such as Bordetella pertussis or 
Escherichia coli (Mielcarek et al, 2001, Wierzbicki and Brzezinska-Blaszcyk, 2009). 
We showed for the first time that mannose receptor (MR) and macrophage galactose 
lectin (MGL) are also expressed by BMMCs and PCMCs. Furthermore, in B. 
pertussis challenged mast cells, MR and MGL were proven to be functionally 
involved in the induction of cytokine secretion with the use of blocking antibodies 
and CLR specific carbohydrate ligands. In this study, blocking of MR and MGL 
reversed the ability of mast cells to prime naïve CD4+ T-cells and to induce cytokine 
secretion. Both MR and MGL have been reported to play a role in T-cell activation 
by antigen presenting cells as dendritic cells and macrophages (van Vliet at al., 
2008). Activation of MGL leads to maturation of dendritic cells and IFN-g secretion 
in CD8+ T-cells co-cultures (Napoletano et al, 2012). CpG were shown to activate 
dendritic cells to induce IL-17 and IFN-g production from CD4+ T-cells and MGL is 
involved in this process (Denda-Nagai et al, 2010). 
 
Similar to dendritic cells and macrophages, mast cells express pathogen recognition 
receptors such as toll like receptors ((TLR)-2, TLR3, TLR4, TLR6, TLR7 and 
TLR9) that recognise invading pathogens (Marshall et al., 2003; Galli et al., 2008). 
The function of TLRs in B. pertussis – immune cell interaction has been extensively 
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investigated (Mann et al., 2005), whereas less is known about C-type lectin’s (CLR) 
involvement in this process, especially there is no study about the role of mast cell’s 
CLRs in bacteria-mast cell interaction. On mast cells only few types of CLRs have 
been reported to date. Mast cell function associated antigen (MAFA) is specific for 
mast cells and has homology with several CLRs (Guthmann et al., 1995a; Guthmann 
et al., 1995b). Dectin1 and Mincle have been detected on mast cells, although they 
are expressed in very low levels (Yang and Marshall, 2009). 
 
In the case of MR, our findings correlate with studies in other immune cells. MR was 
shown to be involved in the activation of macrophages by Mycobacterium 
tuberculosis in vitro (Rajaram et al., 2010). In macrophage-like placental trochoblast 
giant cells MR also proved to play a role in the uptake of various bacteria like 
Listeria monocytogenes, Bacillus subtilis and Echerichia coli (Hashino et al., 2012). 
On the contrary, in most literature MGL has been associated with the suppression 
rather than induction of cytokine secretion by bacteria-stimulated immune cells. In 
dendritic cells, a Campylobacter jejunum mutant lacking of functional MGL ligand 
induced increased IL-6 production compared to wild type (van Sorge et al., 2009). 
Similarly, modulation of MGL on dendritic cells by cestode antigens leads to 
inhibition of LPS induced pro-inflammatory cytokine secretion (Terrazas et al., 
2011). Our results reveal a new stimulatory function of MGL in pathogen-immune 
cell interaction. 
 
BP stimulation has been reported to cause ERK phosphorylation on mast cells via 
activation of TLR4 signalling pathway (Desai and Thurmond, 2011; Li et al., 2009) 
and activation of MAPK and NF-kB pathways inducing cytokine secretion and cell 
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surface marker up-regulation in immune cells (Tsang et al., 2005). Blocking of MR 
and MGL on mast cells suppressed NF-kB p65 but not ERK phosphorylation. A 
similar trend has been also observed in LPS-stimulated macrophages where blocking 
the CLR signalling pathway resulted in the suppression of the phosphorylation of 
JNK but not p38 or ERK (Lin et al., 2010). Furthermore, the recently observed link 
between ERK phosphorylation and ICAM1 up-regulation (Tsang et al., 2005) can be 
used to better understand the absence of any effect of CLR neutralization on the 
expression level of ICAM1. Notably, CLRs modulation has been associated with 
impairment of NF-kB activation in LPS-stimulated dendritic cells, suggesting the 
involvement of alternative signalling pathways to TLR4 in LPS challenge (Eberle 
and Dalpke, 2012). 
 
Spleen tyrosine kinase (Syk) is a ubiquitous non-receptor tyrosine kinase with 
diverse biological activity (Miller et al., 2012). It is involved in the signalling from 
B- and T-cell receptors, Fc receptors and CLRs, including Dectin1 (Kerrigan and 
Brown, 2010; Olynych et al., 2006). In macrophages blocking of Syk suppressed 
LPS induced activation of the MAPK pathway (Lin et al., 2010). Interestingly in our 
experiments blocking of Syk had conflicting effects on TNF-α and IL-6 secretion by 
BP-stimulated mast cells. These results could be explained with the diverse function 
of Syk in immune cells. Recently it was reported that Syk binds to TLR4 and plays a 
role in the response to bacterial pathogens or LPS in dendritic cells and macrophages 
(Miller et al., 2012; Chaudhary et al., 2007; Ulanova et al., 2007), leading to pro-
inflammatory cytokine secretion. On the other side, Syk is also activated at different 
stages of the CLRs signalling pathway, resulting in activation or inhibition of TLR 
signalling pathway and effects cellular responses like migration, adhesion, 
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differentiation or inflammatory and regulatory mediator release. The interaction of 
Syk with different receptors has yet to be identified (Kerrigan and Brown, 2010). 
 
It has also to be highlighted that the heat-inactivated BP preparation used in this 
study is a source of heterogeneous antigens, like adhesins and toxins, high levels of 
LOS as well as residual active pertussis toxins (Mahon et al., 1996), interacting with 
many different receptors. In order to simplify our system focussing on the most 
probable ligands of CLRs and TLRs (Locht, 1999), LOS was isolated from heat-
inactivated BP and used in mast cell stimulation assays. LOS is usually a potent 
inducer of TLR4-mediated signalling resulting in the release of pro-inflammatory 
cytokines (Marr et al., 2010; Higgins et al., 2006). In our study, the LOS-induced 
cytokine secretion by mast cells was suppressed by blocking of MR and MGL, thus 
supporting the hypothesis of CLRs involvement in LOS immune cell stimulation. 
Notably, LOS stimulation of mast cells resulted in lower cytokine levels compared to 
the levels obtained with heat-inactivated whole cell BP. This is in agreement with 
previously reported in vitro stimulation of macrophages with BP LOS, resulting in 
reduced levels of TNF-a and IL-6 secretion (Marr et al., 2010). All these data 
suggest the synergistic action of B. pertussis LOS on TLRs and CLRs together with 
other toxins during infection (Locht, 1999). 
 
BP LOS characterisation has been pursued over the years (Chaby et al., 1977; 
Moreau et al., 1984; Martin et al, 1992) and recent analyses revealed strain-
variability in both structure and endotoxicity of BP LOS (Marr et al., 2010; Caroff et 
al., 2001). The LOS of B. pertussis Tohama I has been recently investigated by 
Kubler-Kielb et al in an attempt to develop OS-conjugates with bactericidal 
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properties against Bordetella species (Kubler-Kielb et al., 2011). Human MGL has 
been reported to exhibit a narrow binding specificity towards terminal N-acetyl 
galactosamine (GalNAc) moieties (van Vliet et al., 2005). Notably the LOS structure 
of BP does not feature any Gal or GalNAc residues, but the presence of one terminal 
residue of 2-amino-2-deoxygalacturonic acid (GalNA) has to be noted on this 
complex oligosaccharide. Furthermore, several glucosamine (GlcN) residues are also 
present on the glycan backbone and branches of the LOS with one N-acetylated 
(GlcNAc) monosaccharide terminally located. To date, there are no reports of MGL 
affinity towards neither GalNA nor GlcNAc. It has to be speculated that either mast 
cell derived MGL exhibits alternative binding specificities or the LOS used in this 
study contains additional saccharidic epitopes not previously characterised. 
 
The identification of the potential binding epitopes on BP-derived LOS for the MR is 
somewhat less challenging due to the broad range of ligands reported for this CLR. It 
can be hypothesized that MR recognises the terminal GlcNAc on BP LOS through 
its eight tandemly arranged C-type lectin-like domain (CTLDs) with reported affinity 
for mannose, fucose and GlcNAc (Gazi and Martinez-Pomares, 2009). 
 
Whole cell vaccine studies suggest that BP-derived LOS plays a crucial role in the 
development of polarized Th1 immune responses; and signal trough TLR4 is critical 
in innate immune cells in the generation of inflammatory cytokines in Bordetella 
pertussis infection (Higgins et al., 2009; de Gouw et al., 2011). Our study suggests 
that beside TLR4, CLRs are also involved in BP activation mainly via the LOS 
antigen and in the development of new vaccines carbohydrate moieties could prove 
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to be useful in the activation of CTRs and the promotion of these inflammatory 
immune responses. In summary we showed that MR and MGL are involved in the 
interaction of B. pertussis antigen with mast cells, and the lipooligosaccharides in the 
cell wall are responsible for this activation. This sheds further light on mast cells 
biology and the role of mast cells in the defence system against bacterial infections. 
Bacterial-induced TLR signalling is well studied, although less is known about 
CLRs and their crosstalk with other signalling pathways. Further studies are required 
to examine CLRs involvement in bacteria recognition and their 
stimulatory/inhibitory effect on TLR signalling. 
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7 Chapter 7 - Final discussion 
This study sheds new light on the role of mast cells during helminth infection as for 
the first time the anti-inflammatory properties of Fasciola hepatica antigens on mast 
cell pro-inflammatory immune responses was investigated. In particular, a 
mechanism was described, how Fasciola hepatica antigen suppressed TLR4 
activated mast cells through the induction of negative regulators of the TLR 
pathway. This study also highlights the important role of C-type lectin receptors on 
mast cells during Fasciola and Bordetella pertussis infection. In particular, this study 
was the first to examine the role of MR and MGL. The following discussion 
highlights the key findings from this study and discusses future studies that are 
required to further advance the field of mast cell biology. 
 
7.1 Mast cells are new players in Fasciola hepatica immune modulation 
Mast cells are usually associated with Th2 immune responses during helminth 
infection (Dawicki and Marshall, 2007) and the important role of mast cells in 
intestinal helminth infection is well studied (Hepworth et al., 2012a; Hepworth et al., 
2012b). Typically mast cells are activated by helminth-specific IgE antibody, which 
is secreted by B-cells (Anthony et al., 2007; Erb, 2007). Mast cells degranulate and 
release inflammatory mediators in an IgE dependent manner, releasing mediators 
such as histamine, serine proteases, chymase, tryptase that contribute to the 
expulsion of gut helminths (Metz and Maurer, 2007) by increasing intestinal 
permeability and inducing the influx of neutrophil granulocytes (McDermott et al., 
2003). IgE secreting B-cells are activated by Th2 associated cytokines (IL-4, IL-5, 
IL-9, IL-13 TSLP and IL-33) that are secreted by innate immune cells and Th2 T-
cells. Studies suggest that mast cells are an early source of these cytokines in 
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particular IL-4, TSLP and IL-33 in the early stages of infection and these cells are 
importance in the development of Th2 adaptive immunity (Anthony et al., 2007).  
 
The role of mast cells during infection with tissue dwelling helminths such as F. 
hepatica is not clearly understood. Here the role of these cells was investigated 
during F. hepatica infection where, at least in vitro, they do not promote a Th2 
immune response despite increase in mast cell number prior to the development of 
Th2 adaptive immunity (Appendix B, preliminary data). This suggests that there may 
be another role for mast cells during infection. Since host immunity to F. hepatica 
infection requires a strong Th1 immune response (Moreau and Chauvin, 2010), and 
in order for Fasciola to survive within the host, it must suppress this Th1 immune 
response. Further studies are required to investigate the role of mast cells during 
infection. Future studies could involve the role of mast cell knockout mice as this 
will confirm if mast cells are important for the development of Th2 immune 
responses, protection against helminth infection, wound healing or reduction in 
helminth burden. 
 
The tegumental coat antigen of F. hepatica (FhTeg) was shown previously to 
suppress TLR ligand and non-TLR ligand stimulated dendritic cells by inhibiting 
their ability to secrete cytokines, express cell surface markers or prime T-cells 
(Hamilton et al., 2009; Vukman et al., 2013 – Appendix E). It was shown previously 
that FhTeg suppresses the phosphorylation of NF-kB in LPS activated dendritic cells 
(Hamilton et al., 2009). Here it was found that the MAPK pathway is also affected 
and a role for the inhibitory molecule SOCS3 in this process was determined. 
Therefore we hypothesize that SOCS3 induction inhibits the TLR signalling pathway 
 163 
 
by suppressing the activation of NF-kB and MAPK transcription factors that lead to 
the inhibition of cytokine secretion, cell surface marker expression and ultimately T-
cell priming (Figure 7.1).  
 
 
Figure 7.1. Possible mechanism how FhTeg suppress LPS/BP induced cytokine secretion in 
mast cells. FhTeg induce SOCS3 transcription. SOCS3 is an inhibitor of TLR4 signalling and 
suppress the activation of both MAPK and NF-kB pathways impairing pro-inflammatory cytokine 
secretion and ICAM1 up-regulation. There might be other mechanisms than SOCS3 how FhTeg 
suppress TLR4 signalling, and it is suggested that the effect of FhTeg is not limited to TLR4. 
 
Here it was shown for the first time that similar to dendritic cells, mast cells 
activated by bacterial ligands in the presence of FhTeg cannot prime Th1 immune 
responses (Figure 7.2). The immunomodulatory effect of FhTeg on dendritic cells 
and mast cells is summarised in Figure 7.1. However, it is possible that FhTeg up-
regulates inhibitory molecules other than SOCS3 and that these molecules act 
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together on the TLR and non-TLR signalling pathway in these cells. For example, 
other inhibitors such as A20 or MyD88s have been shown in knockout cell lines to 
directly target TLR signalling by suppressing TRAF6 activation and IRAK1/2 
phosphorylation, important molecules of the TLR4 signalling pathway (Mogensen, 
2009; Lu et al., 2008). Using specific inhibitors of these regulatory molecules or 
gene silencing techniques (si-RNA, sh-RNA) may help to define a role for these 
molecules in immunomodulation by FhTeg. However, currently the work presented 
in this thesis used primary immune cells. Si-RNA can modify the in vitro 
development of primary cells making them a poor in vitro model to investigate the 
role of SOCS3 .The development of models using cell lines therefore is required 
before further investigations can be performed. Preliminary stuies were performed 
with zoledronic acid, the only known inhibitor of SOCS3, (Scheller et al., 2011) 
following the in vitro method described by Bringmann et al. (2007). Using this drug 
is not possible in primary cells to investigate the role of SOCS3 as zoledronic acid 
impairs the ability of these cells to be stimulated with bacterial ligands (Appendix 
C). 
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Figure 7.1. FhTeg directly modulates dendritic cells and mast cells by inhibiting their ability to 
drive Th1 immune responses. Bacterial ligand (LPS or BP) induced pro-inflammatory cytokine 
secretion, cell surface marker up-regulation, and transcription factor up-regulation is inhibited by 
FhTeg (indicated with green dots) from the tegumental coat of F. hepatica in dendritic cells and mast 
cells. These cells also fail to induce Th1-type immune responses in T-cells. 
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Mast cells play key role in the development of Th1 immune responses (Marshall et 
al., 2003) and mast cell-induced Th1 immune response is crucial in the clearance of 
protozoan and bacterial infection, such as Escherichia coli (Wierzbicki and 
Brzezinska-Blaszczyk, 2009) or Pseudomonas aeruginosa (Siebenhaar et al., 2007) 
infections. The immunomodulatory effect of helminths on macrophages and 
dendritic cells during bystander bacterial infection, such as Mycobacterium 
tuberculosis (Resende Co et al., 2007; Potian et al., 2011), is well studied, but before 
this study, to our best knowledge, nobody investigated the effect of Fasciola 
hepatica infection on pro-inflammatory mast cells. Given the important role of mast 
cells in the clearance of microbial infections future studies examining bystander 
response of helminths should also consider the role of mast cells in this process.   
 
Mast cells are associated with many Th1-mediated inflammatory disorders such as 
autoimmune disease (Weller et al., 2011). Studies with mast cell-deficient mice 
demonstrated that mast cells-derived pro-inflammatory cytokines, such as TNF-a 
contributes to the pathology (Metz and Maurer, 2007; Weller et al., 2011). For 
example, mast cell knockout mice are resistant to rheumatoid arthritis where mast 
cell derived cytokines are involved in the development of inflammation (Metz and 
Maurer, 2007). Similarly, mast cells and mast cell-derived TNF-α is important in the 
development of EAE (the murine model for multiple sclerosis) (Christy et al., 2012; 
Costanza et al., 2012) and mast cells-deficient mice show delayed and decreased 
severity with less blood-brain-barrier damage. 
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Helminth derived antigens were shown to prevent the initiation of inflammatory 
diseases in animal models (Imai et al., 2001; Harnett and Harnett, 2008) and this 
study demonstrated that FhTeg suppresses TNF-a secretion in mast cells. It is 
possible that the bystander effect of helminth infection on autoimmune diseases is 
because they target mast cells and impair their inflammatory responses. Further 
studies required to investigate this using mast cell-knockout and mast cell-
reconstructed mice. Targeting mast cells and identification of mast cell inhibitors 
have therapeutic potential in the treatment of inflammatory disorders such as IBD, 
the inflammatory autoimmune disorder of the gut (He, 2004). Identification and 
characterisation of helminth-derived molecules could lead to new therapeutic 
approaches. 
 
7.2 The role of mast cells in tissue repair during helminth infection 
Fasciola hepatica larvae penetrate through the gut wall into the peritoneum and then 
into the liver, causing extensive tissue damage (Robinson et al., 2010) and since 
mast cells together with macrophages are at the site of infection within days post 
infection it is possible that these cells work together to promote wound healing 
following the tissues destruction by the migrating flukes.  
 
Mast cells are important in tissue remodelling as they induce fibronectin turn-over 
and angiogenesis (Metcalfe et al., 1997). In the acute phase of tissue damage 
endothelial cell-derived IL-3 and SCF induce migration, proliferation and local 
differentiation of mast cells (Noli and Milo, 2001). These activated mast cells secrete 
mediators, such as histamine, serotonin, enzymes and cytokines and induce the 
influx of neutrophil, basophil and eosinophil granulocytes and other leukocytes to 
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the site of the tissue damage (Maltby et al., 2009). These mediators are also 
important in inducing fibroblast proliferation, increased vascular permeability 
(marker for wound healing responses) and angiogenesis (Noli and Miolo, 2001; 
Maurer et al., 2003; Weller et al., 2006). Mast cells are also crucial in scar formation 
(Wilgus, 2008). The use of mast cell-deficient mice will determine whether the F. 
hepatica-infected mutant mice develop more severe disease as a result of the 
improper wound healing and if the activation of other cell types, involved in tissue 
remodelling (e.g. macrophages or granulocytes), is impaired. 
 
7.3  Advances in mast cells’ crosstalk with other immune cells 
The study demonstrates new findings about mast cell - T-cell cross talk, as it was 
shown that ICAM1 is involved in T-cell activation. While studies have highlighted 
the importance of ICAM1 expression on T-cells (Brill et al., 2004), it was shown for 
the first time here that ICAM1 expression on mast cells is crucial in this process. 
Interaction of mast cells with T-cells requires further investigation as mast cells 
express many cell surface markers, adhesion molecules, co-stimulatory and co-
inhibitory molecules on their surface (Kambayashi et al., 2009, Kashiwakura et al., 
2004, Sayed and Brown, 2007) and the effect of FhTeg on the expression of these 
molecules, such as VCAM-1 or LFA-1, and their role in T-cell – mast cells 
communication should be examined. These results may help us to gain better 
understanding of the mechanism how mast cells are involved in the development of 
adaptive immune response and how helminths inhibit these responses. 
 
In addition, mast cells – dendritic cell interaction seems to be critical in the 
development of appropriate adaptive immune response against pathogens (Bryce et 
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al., 2004; Mazzoni et al., 2006) and in this study it was demonstrated that during F. 
hepatica infection dendritic cell-derived chemokines may induce migration of mast 
cells to the site of infection. Mast cells may also modulate dendritic cell function 
during helminth infection as mast cells are known to modify the function of dendritic 
cells during antigen presentation to T-cells and are important in the development of 
adaptive immunity. For example, in vitro antigen stimulated mast cells were shown 
to activate dendritic cells to induce immune responses in CD4+ T-cells (Dudeck et 
al., 2011) where mast cell-derived TNF-a is important in dendritic cell activation 
(Gri et al., 2012). 
 
Pro-inflammatory responses in dendritic cells can be directly suppressed by FhTeg 
and it might be interesting to see whether indirectly, FhTeg stimulated mast cells 
could inhibit dendritic cell function during helminth infection. This can be 
investigated in vitro by co-culturing FhTeg-treated mast cells with dendritic cells to 
see if their pro-inflammatory responses are suppressed or not. In vivo Th2 immune 
responses can be induced by exposing immune cells to helminth products and inject 
them into recipients (Balic et al., 2004). This experiment can be repeated using 
FhTeg-treated mast cells, to decide if FhTeg-activated mast cells injected into wild 
type or mast cell-deficient mice can induce other immune cells types (e.g. dendritic 
cells and macrophages) or inhibit their Th1 immune responses. 
 
7.4 Functional classification of mast cells 
Given the expanding role of mast in the immune system we propose a new functional 
classification for mast cells based upon their ability to promote adaptive immune 
response. To develop this classification the functional characterisation of dendritic 
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cells and macrophages subsets should first be considered. Dendritic cells and 
macrophages are classified into different subsets based upon their different function 
in different environments (MacDonald and Maizels, 2008; Biswas and Mantovani, 
2010). Dendritic cells have at least four subsets: conventionally mature, tolerogenic, 
Th17 and modulated dendritic cells. Conventionally mature dendritic cells are 
activated by bacterial, viral or protozoan antigens and secrete pro-inflammatory 
cytokines such as IL-12 and can induce Th1 immune response. They are important in 
the clearance of intracellular and extracellular pathogen infection and also in 
autoimmune diseases (Perona-Wright et al., 2006). Tolerogenic dendritic cells 
induce regulatory-type (Treg) immune responses through the secretion of IL-10 and 
TGF-b (MacDonald and Maizels, 2008) and are important in maintaining tolerance 
against apoptotic cells and commensal bacteria (Perona-Wright et al., 2006). Th17 
dendritic cells induce CD4+ T-cells to secrete TGF-b, IL-23 and IL-6. They take part 
in the immune defence against fungi and extracellular bacteria and also contribute to 
the pathogenesis of many autoimmune conditions. Modulated dendritic cells are 
orchestrated to Th2 immunity during helminth infections and their pro-inflammatory 
function is down-regulated (MacDonald and Maizels, 2008, Anthony et al., 2007; 
Jackson et al., 2009). 
 
There are two different subsets of macrophages, M1 and M2 (Kreider et al., 2007). 
M1 or classically activated macrophage can stimulate Th1 T-cells and NK cells, 
inducing IFN-g production (Biswas and Mantovani, 2010). Alternatively activated 
(M2) macrophages are characterised by arginase1 activity and IL-10 secretion 
(Biswas and Mantovani, 2010, Anthony et al., 2007; Flynn et al., 2007). During 
helminth infection these macrophages can induce Th2/Treg immune response, 
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suppress Th1 immunity and are important in tissue remodelling, wound healing and 
immunoregulation (Allen and Maizels, 2011). 
 
Conventional classification of mast cells is based on phenotypical differences. 
Historically rodent mast cells were divided into two groups: connective tissue type 
mast cells (CTMC) and mucosal mast cells (MMC). CTMCs are in the skin and 
peritoneal cavity and MMCs can be found in the intestinal propria of mice. These 
subsets differ also in their origin and biochemistry (Metcalfe et al., 1997). For human 
mast cells there is another type of classification based on the different metachromatic 
staining properties of mast cells. These subpopulations differ in protease content of 
their vesicles in the cytoplasm. MCTC mast cells contain trypase, chymase, chatepsin 
G-like protein and carboxypeptidase in their vesicles while MCT-type mast cells 
contain only trypase (Irani et al., 1989). MCT predominate in the lung and in the 
small intestine mucosa while MCTC can be found in the skin and in the small 
intestine submucose. Localisation and staining similarities suggest that MCT could 
be the human homologues of murine MMCs and human MCTC corresponds most 
closely to CTMCs (Metcalfe et al., 1997). Although between these groups there are 
functional differences as well, functional studies of mast cells from different tissues 
suggest further heterogeneity, and a function-based classification, similar to 
macrophages and dendritic cells, may have some advantages. 
 
Given the advances in mast cell biology there could be a new classification of mast 
cell based upon their ability to drive different adaptive immune responses. If we 
follow similar functional characterisation of macrophages and dendritic cells, at least 
two mast cells subsets can be distinguished as illustrated in Figure 7.3. The mast 
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cells subsets can be called as MC1 and MC2 based on their analogy to M1 and M2 
macrophages. MC1 mast cells could be the subset that are important in the clearance 
of bacterial and viral infections (Marshall, 2004) and are able to activate the adaptive 
Th1 immune system by secreted cytokines, chemokines and can also act as antigen 
presenting cells. These mast cells are characterised by the lack of degranulation and 
the production pro-inflammatory mediators, like TNF-α. These cells also contribute 
to pathology in inflammatory disorders, such as autoimmune diseases (Metz and 
Maurer, 2007; Sutherland et al., 2011; Weller et al., 2011).  
 
MC2 mast cells could be mast cells that are activated in the effector phase of the Th2 
immune responses. They express the high affinity FcεRI receptor, which in the 
presence of antigens and the antigen-specific IgE antibody induce cell degranulation 
and the release of inflammatory mediators such as histamine, cytokines or 
chemokines (Melendez et al., 2007; Pearce, 2007). These mast cells have beneficial 
effect during gut helminth infection but also contribute to the pathology of Th2-type 
inflammatory diseases like allergy. 
 
Mast cells can produce IL-33 and when co-cultured with dendritic cells they 
indirectly induce IL-17 secretion in T-cells (Dudeck et al., 2011) suggesting their 
involvement in the development of Th17 immune responses. Mast cells also play 
role in maintaining the homeostasis of the body. For example, these homeostatic 
mast cells are important in wound healing, tissue remodelling and angiogenesis 
(Metcalfe et al., 1997; Maurer et al., 2003; Weller et al., 2011) suggesting other 
possible mast cell subsets. There is no evidence in the literature about mast cells 
involved in the regulation of immune responses. During helminth infection mast 
 173 
 
cells produce TGF-b and IL-10 and it is possible that with dendritic cells and 
macrophages they contribute to the activation of Treg-cells. Further studies with 
mast cells knockout mice could prove the existence of a MCreg subtype of mast 
cells. 
 
Figure 7.3. Suggested functional classification of mast cells. Allergy and helminth infection are 
associated with Th2-type mast cells (MC2)  They express the high affinity FcεRI receptor, which in 
the presence of antigens and B-cell-derived specific IgE antibody induce cell degranulation and the 
release of inflammatory mediators such as histamine, cytokines or chemokines. During viral or 
bacterial infections Th1-type mast cells are able to activate the adaptive Th1 immune system by 
secreted pro-inflammatory cytokines, chemokines and can also act as antigen presenting cells (MC1). 
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Mast cells may also take part in the development of Treg (MCreg) and Th17 (MC17) immune 
responses and was showed to be important in the homeostasis of the body, and contribute to wound 
healing, tissue remodelling and angiogenesis. 
 
7.5 New role of C-type lectin receptors on mast cells in immunity against 
pathogens 
MR and MGL are expressed by subsets of dendritic cells and macrophages on their 
surface (van Vliet et al., 2008; Geijtenbeek and Gringhuis, 2009) and studies have 
shown that they are involved in the recognition of several pathogens such as 
Leishmania donovani, Mycobacterium tuberculosis or Schistosoma mansoni 
(Geijtenbeek and Gringhuis, 2009; Akilow et al., 2007) and play an important role 
during innate immune responses. This study demonstrates for the first time that these 
C-type lectin receptors (CLRs) are also expressed by mast cells and may play an 
important role in helminth and bacterial infection. 
 
7.5.1 CTLs, mast cells and Fasciola hepatica 
CLRs are known to play an important role in helminth infection as helminths release 
and express glycol-conjugates such as glycoproteins and glycolipids. CTLs are 
important in the induction of M2 macrophages and in the maturation and activation 
of dendritic cells during helminth infection (Thomas and Harn, 2004). In table 7.1 in 
vivo and in vitro data of MR, MGL, Dectin 1 and SignR1 expression on mast cells, 
dendritic cells and macrophages is summarised. The results suggest that MR and 
MGL but not Dectin 1 and SignR1 are expressed during F. hepatica infection and 
this can be mimicked in vivo and in vitro by its antigens. These findings are further 
supported as MGL activation is involved in FhTeg induced SOCS3 up-regulation in 
dendritic cells as blocking of MGL inhibited the FhTeg-dependent induction of 
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SOCS3 but supports our hypotheses that more than one inhibitor is important in 
infection as blocking this receptor could not reverse the suppressive effect of FhTeg.  
 
Table 7.1 Effect of F. hepatica infection or FhTeg treatment on CLR expression 
of immune cells in vitro and in vivo 
  Dectin1 MR MGL SignR1 
F. hepatica infection mast cells 
Æ ­ ­ Æ 
 macrophages
1 
Æ ­ ­ Æ 
FhTeg injection mast cells 
­ Æ ­ Æ 
macrophages1 
Æ ­ ­ ­ 
In vitro FhTeg 
treatment 
BMMCs 
Æ ­ Æ Æ 
PCMCs 
­ ­ ­ Æ 
BMDCs 
Æ ­ ¯ Æ 
macrophages1 
Æ ­ ­ Æ 
­, up-regulated; ¯, down-regulated; Æ, no significant change, 1(Adams et al., unpublished data) 
 
FhTeg contains many proteins with different carbohydrate moieties and 
identification of CLRs, that play role in the immunomodulation by FhTeg, may help 
to find the biological active component of this antigen. Bioassays with recombinant 
CHO cell lines, expressing only one CLR on their surfaces, are available to 
investigate CLR binding properties in vitro. When the possible receptors for FhTeg 
are identified, fluorescent labelling of FhTeg or its active component with the help of 
CLR-specific antibody could prove that FhTeg binds to this CLR. There are MGL or 
MR knockout mice commercially available, and these mice could be used in the next 
step of the investigation in vivo, or with primary cells isolated from these cells in 
vitro, to examine the role of these CTRs during Fasciola infections. CLRs are 
possible candidates as therapeutic targets in inflammatory autoimmune disease, 
targeting these receptors and identification and characterisation of the biological 
active component molecules of FhTeg could lead to new therapeutic approaches to 
cure inflammatory disorders. 
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7.5.2 CLRs on mast cells in Bordetella pertussis infection 
Mast cells, together with dendritic cells and macrophages are crucial in the clearance 
of bacterial infection, such as Bordetella pertussis, from the lung (Mielcarek et al., 
2001) and in mediating protective immune responses. TLRs on immune cells were 
shown to play key role in the activation of these cells (Geijtenbeek and Gringhuis, 
2009, Mann et al., 2005). Here it was demonstrated for the first time that beside 
TLR4 (Mann et al., 2005) MR and MGL are also involved in the activation of mast 
cells with B. pertussis antigen by blocking CLRs with neutralising antibodies and 
carbohydrates. This study demonstrates novel results about mast cell-induced Th1 
immune responses during bordetellosis (such as the involvement of ICAM1 in BP 
induced T-cell activation), and these findings may help us to gain better 
understanding of mast cell biology and the role of mast cells in the defence system 
against bacterial infection. 
 
Further studies are required to investigate the role of mast cells during bordetellosis, 
for example, MR and MGL play role in the internalization of Mycobacterium 
tuberculosis (Kang and Schlesinger, 1998; Denda-Nagai et al., 2010) and B. 
pertussis can adhere and be phagocytised by mast cells (Miercarek et al., 2001). By 
blocking CLRs or using labelled BP antigens it could be examined whether MR and 
MGL are involved in the endocytosis of B. pertussis by mast cells and whether this 
endocytosis is crucial in the development of proper immune responses. It would be 
interesting to study if these CLRs are involved in mast cells – T-cell communication 
with the help of CLR-specific antibodies. Both MR and MGL were shown to play 
role in T-cell activation by antigen representing cells as dendritic cells and 
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macrophages (van Vliet et al., 2008; Napoletano et al., 2012), but, to our best 
knowledge, there is no study about mast cells. 
 
In vaccine studies the role of mast cells are usually not considered however their 
importance in protective immunity against anthrax and Heliobacter infections 
following vaccination was demonstrated (McLachan et al., 2008; Velin et al., 2005). 
Successful acellular and cellular vaccines are available against B. pertussis, although 
acellular vaccination do not give life-long immunity and cellular vaccine has serious 
side effects (Crowcroft and Pebody, 2006; von Konig et al., 2002.), therefore, 
identifying novel targets in bordetellosis vaccine development may have some 
advantages. Targeting mast cells and receptors other than TLRs on immune cells 
may lead to development of novel and better vaccine; for example, by using 
adjuvants that activate mast cells or CLRs. 
 
7.6 Summary 
This studies presented in this thesis have shed new light on the role of mast cells 
during pathogen infections and these findings contribute to the better understanding 
of mast cell biology. It is hoped that the publications form this thesis will prompt 
further studies to investigate the expanding role of mast cells particular as 
therapeutic targets to inhibit inflammatory mast cells in autoimmune diseases and 
examine the importance of this cells in the promotion of protective immune 
responses to infectious diseases. 
  
 178 
 
8 Literature 
Abe T, Nawa Y. 1988. Worm expulsion and mucosal mast cell response induced by 
repetitive IL-3 administration in Strongyloides ratti-infected nude mice. Immunology 
63(2):181-185. 
Abraham SN, St John AL. 2010. Mast cell-orchestrated immunity to pathogens. Nat Rev 
Immunol 10(6):440-452. 
Abraham SN, Thankavel K, Malaviya R. 1997. Mast cells as modulators of host defense in 
the lung. Front Biosci 2: d78-87. 
Abramson J, Xu R, Pecht I. 2002. An unusual inhibitory receptor--the mast cell function-
associated antigen (MAFA). Mol Immunol 38(16-18):1307-1313. 
Aitken MM, Hughes DL, Jones PW, Hall GA, Smith GS. 1979. Immunological responses 
of fluke-infected and fluke-free cattle to Salmonella dublin and other antigens. Res 
Vet Sci 27(3):306-312. 
Akilov OE, Kasuboski RE, Carter CR, McDowell MA. 2007. The role of mannose 
receptor during experimental leishmaniasis. J Leukocyte Biol 81:1188-1196. 
Allen JE, Maizels RM. 2011. Diversity and dialogue in immunity to helminths. Nat Rev 
Immunol 11(6):375-388. 
Andrews SJ. 1999. The Life Cycle of Fasciola hepatica. Dalton, JP, Fasciolosis CAB 
International, Wallingford:1-30. 
Anthony RM, Rutitzky LI, Urban JF, Jr., Stadecker MJ, Gause WC. 2007. Protective 
immune mechanisms in helminth infection. Nat Rev Immunol 7(12):975-987. 
 179 
 
Arizono N, Yamada M, Tegoshi T, Okada M, Uchikawa R, Matsuda S. 1994. Mucosal 
mast cell proliferation following normal and heterotopic infections of the nematode 
Nippostrongylus brasiliensis in rats. APMIS 102(8):589-596. 
Balic A, Harcus Y, Holland MJ, Maizels RM. 2004. Selective maturation of dendritic cells 
by Nippostrongylus brasiliensis-secreted proteins drives Th2 immune responses. Eur 
J Immunol 34(11):3047-3059. 
Bamaiyi PH. 2012. Factors Militating against the control of Helminthosis in Liverstock in 
developing countries. Vet World 5(1):42-47. 
Barger IA. 1993. Control of gastrointestinal nematodes in Australia in the 21st century. 
Vet Parasitol 46(1-4):23-32. 
Behm CA, Sangster NC. 1999. Pathology, pathophysiology and clinical aspects. Dalton, 
JP, Fasciolosis CAB International, Wallingford:185-224. 
Bethony J, Brooker S, Albonico M, Geiger SM, Loukas A, Diemert D, Hotez PJ. 2006. 
Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet 
367(9521):1521-1532. 
Betts CJ, Else KJ. 1999. Mast cells, eosinophils and antibody-mediated cellular 
cytotoxicity are not critical in resistance to Trichuris muris. Parasite Immunol 
21(1):45-52. 
Bian K, Zhong M, Harari Y, Lai M, Weisbrodt N, Murad F. 2005. Helminth regulation of 
host IL-4Ralpha/Stat6 signaling: mechanism underlying NOS-2 inhibition by 
Trichinella spiralis. Proc Natl Acad Sci U S A 102(11):3936-3941. 
Biswas SK, Mantovani A. 2010. Macrophage plasticity and interaction with lymphocyte 
subsets: cancer as a paradigm. Nat Immunol 11(10):889-896. 
 180 
 
Bossaert K, Jacquinet E, Saunders J, Farnir F, Losson B. 2000. Cell-mediated immune 
response in calves to single-dose, trickle, and challenge infections with Fasciola 
hepatica. Vet Parasitol 88(1-2):17-34. 
Braschi S, Curwen RS, Ashton PD, Verjovski-Almeida S, Wilson A. 2006. The tegument 
surface membranes of the human blood parasite Schistosoma mansoni: a proteomic 
analysis after differential extraction. Proteomics 6(5):1471-1482. 
Brady MT, O'Neill SM, Dalton JP, Mills KH. 1999. Fasciola hepatica suppresses a 
protective Th1 response against Bordetella pertussis. Infect Immun 67(10):5372-
5378. 
Braschi S, Wilson RA. 2006. Proteins exposed at the adult schistosome surface revealed 
by biotinylation. Mol Cell Proteomics 5(2):347-356. 
Briand V, Watier L, JY LEH, Garcia A, Cot M. 2005. Coinfection with Plasmodium 
falciparum and schistosoma haematobium: protective effect of schistosomiasis on 
malaria in senegalese children? Am J Trop Med Hyg 72(6):702-707. 
Brill A, Baram D, Sela U, Salamon P, Mekori YA, Hershkoviz R. 2004. Induction of mast 
cell interactions with blood vessel wall components by direct contact with intact T 
cells or T cell membranes in vitro. Clin Exp Allergy 34(11):1725-1731. 
Bringmann A, Schmidt SM, Weck MM, Brauer KM, von Schwarzenberg K, Werth D, 
Grunebach F, Brossart P. 2007. Zoledronic acid inhibits the function of Toll-like 
receptor 4 ligand activated monocyte-derived dendritic cells. Leukemia 21(4):732-
738. 
 181 
 
Brint EK, Xu D, Liu H, Dunne A, McKenzie AN, O'Neill LA, Liew FY. 2004. ST2 is an 
inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains 
endotoxin tolerance. Nat Immunol 5(4):373-379. 
Brown MA, Sayed BA, Christy A. 2008. Mast cells and the adaptive immune response. J 
Clin Immunol 28(6):671-676. 
Bryce PJ, Miller ML, Miyajima I, Tsai M, Galli SJ, Oettgen HC. 2004. Immune 
sensitization in the skin is enhanced by antigen-independent effects of IgE. Immunity 
20(4):381-392. 
Caffrey CR. 2012. Parasitic Helminths: Targets, Screens, Drugs and Vaccines. Willey-
VHC Verlag GmbH and Co KGaA. 
Caldas IR, Correa-Oliveira R, Colosimo E, Carvalho OS, Massara CL, Colley DG, 
Gazzinelli G. 2000. Susceptibility and resistance to Schistosoma mansoni 
reinfection: parallel cellular and isotypic immunologic assessment. Am J Trop Med 
Hyg 62(1):57-64. 
Carod-Artal FJ. 2008. Neurological complications of Schistosoma infection. Trans R Soc 
Trop Med Hyg 102(2):107-116. 
Caroff M, Aussel L, Zarrouk H, Martin A, Richards JC, Therisod H, Perry MB,, Karibian 
D. 2001. Structural variability and originality of the Bordetella endotoxins. J 
Endotoxin Res 7: 63-68. 
Carranza F, Falcon CR, Nunez N, Knubel C, Correa SG, Bianco I, Maccioni M, Fretes R, 
Triquell MF, Motran CC, Cervi L. 2012. Helminth antigens enable CpG-activated 
dendritic cells to inhibit the symptoms of collagen-induced arthritis through Foxp3+ 
regulatory T cells. PLoS One 7(7):e40356. 
 182 
 
Carvalho EM, Bastos LS, Araujo MI. 2006. Worms and allergy. Parasite Immunol 
28(10):525-534. 
Carvalho L, Sun J, Kane C, Marshall F, Krawczyk C, Pearce EJ. 2009. Review series on 
helminths, immune modulation and the hygiene hypothesis: mechanisms underlying 
helminth modulation of dendritic cell function. Immunology 126(1):28-34. 
Cervi L, Borgonovo J, Egea M, Chiapello L, Masih D. 2004. Immunization of rats against 
Fasciola hepatica using crude antigens conjugated with Freund's adjuvant or 
oligodeoxynucleotides. Vet Immunol Immunopathol 97(1-2):97-104. 
Chaby R, Moreau M, Szabo L. 1977. 2-O-(beta-D-glucuronyl)-7-O-(2-amino-2-deoxy-
alpha-D-glucopyranosyl)-L-glycero-D- manno-heptose: a constituent of the 
Bordetella pertussis endotoxin. Eur J Biochem 76: 453-460. 
Charbon JL, Spahni M, Wicki P, Pfister K. 1991. Cellular reactions in the small intestine 
of rats after infection with Fasciola hepatica. Parasitol Res 77(5):425-429. 
Chaudhary A, Fresquez TM, Naranjo MJ. 2007. Tyrosine kinase Syk associates with toll-
like receptor 4 and regulates signaling in human monocytic cells. Immunol Cell Biol 
85: 249-256. 
Christy AL, Walker ME, Hessner MJ, Brown MA. 2012. Mast cell activation and 
neutrophil recruitment promotes early and robust inflammation in the meninges in 
EAE. J Autoimmun. 
Chuang TH, Ulevitch RJ. 2004. Triad3A, an E3 ubiquitin-protein ligase regulating Toll-
like receptors. Nat Immunol 5(5):495-502. 
 183 
 
Claridge J, Diggle P, McCann CM, Mulcahy G, Flynn R, McNair J, Strain S, Welsh M, 
Baylis M, Williams DJ. 2012. Fasciola hepatica is associated with the failure to 
detect bovine tuberculosis in dairy cattle. Nat Commun 3:853. 
Clery D, Torgerson P, Mulcahy G. 1996. Immune responses of chronically infected adult 
cattle to Fasciola hepatica. Vet Parasitol 62(1-2):71-82. 
Closa D, Motoo Y, Iovanna JL. 2007. Pancreatitis-associated protein: from a lectin to an 
anti-inflammatory cytokine. World J Gastroenterol 13(2):170-174. 
Collins PR, Stack CM, O'Neill SM, Doyle S, Ryan T, Brennan GP, Mousley A, Stewart 
M, Maule AG, Dalton JP, Donnelly S. 2004. Cathepsin L1, the major protease 
involved in liver fluke (Fasciola hepatica) virulence: propetide cleavage sites and 
autoactivation of the zymogen secreted from gastrodermal cells. J Biol Chem 
279(17):17038-17046. 
Costanza M, Colombo MP, Pedotti R. 2012. Mast cells in the pathogenesis of multiple 
sclerosis and experimental autoimmune encephalomyelitis. Int J Mol Sci 
13(11):15107-15125. 
Crowcroft NS, Pebody RG. 2006. Recent developments in pertussis. Lancet 367: 1926-
1936. 
Dalpke AH, Opper S, Zimmermann S, Heeg K. 2001. Suppressors of cytokine signaling 
(SOCS)-1 and SOCS-3 are induced by CpG-DNA and modulate cytokine responses 
in APCs. J Immunol 166(12):7082-7089. 
Dalton JP. 1999. Fascioosis. CABI Publishing. 
Dawicki W, Marshall JS. 2007. New and emerging roles for mast cells in host defence. 
Curr Opin Immunol 19(1):31-38. 
 184 
 
de Gouw D, Diavatopoulos DA, Bootsma HJ, Hermans PW, Mooi FR. 2011. Pertussis: a 
matter of immune modulation. FEMS Microbiol Rev 2011; 35: 441-474. 
De Winter BY, van den Wijngaard RM, de Jonge WJ. 2011. Intestinal mast cells in gut 
inflammation and motility disturbances. Biochim Biophys Acta 1822(1):66-73. 
Denda-Nagai K, Aida S, Saba K, Suzuki K, Moryama S, Oo-Puthinan S, Tsuiji M, 
Morikawa A, Kumamoto Y, Sugiura D, Kudo A, Akimoto Y, Kawakami H, Bovin 
NV, Imura T. 2010. Distribution and function of macrophage galactose-type C-type 
lectin 2 (MGL2/CD301b): efficient uptake and presentation of glycosylated antigens 
by dendritic cells. J Biol Chem 285: 19193-19204. 
Desai P, Thurmond RL. 2011. Histamine H receptor activation enhances LPS-induced IL-
6 production in mast cells via ERK and PI3K activation. Eur J Immunol 41(6):1764-
1773. 
Divanovic S, Trompette A, Petiniot LK, Allen JL, Flick LM, Belkaid Y, Madan R, Haky 
JJ, Karp CL. 2007. Regulation of TLR4 signaling and the host interface with 
pathogens and danger: the role of RP105. J Leukoc Biol 82(2):265-271. 
Donnelly S, O'Neill SM, Sekiya M, Mulcahy G, Dalton JP. 2005. Thioredoxin peroxidase 
secreted by Fasciola hepatica induces the alternative activation of macrophages. 
Infect Immun 73(1):166-173. 
Donnelly S, O'Neill SM, Stack CM, Robinson MW, Turnbull L, Whitchurch C, Dalton JP. 
2009. Helminth cysteine proteases inhibit TRIF-dependent activation of 
macrophages via degradation of TLR3. J Biol Chem 285(5):3383-3392. 
 185 
 
Donnelly S, Stack CM, O'Neill SM, Sayed AA, Williams DL, Dalton JP. 2008. Helminth 
2-Cys peroxiredoxin drives Th2 responses through a mechanism involving 
alternatively activated macrophages. FASEB J 22(11):4022-4032. 
Dowling DJ, Hamilton CM, Donnelly S, La Course J, Brophy PM, Dalton J, O'Neill SM. 
2009. Major secretory antigens of the helminth Fasciola hepatica activate a 
suppressive dendritic cell phenotype that attenuates Th17 cells but fails to activate 
Th2 immune responses. Infect Immun 78(2):793-801. 
Dudeck A, Suender CA, Kostka SL, von Stebut E, Maurer, M. 2011. Mast cells promote 
Th1 and Th17 responses by modulating dendritic cell maturation and function. Eur J 
Immunol 41:1883-1893. 
Duraes FV, Carvalho NB, Melo TT, Oliveira SC, Fonseca CT. 2009. IL-12 and TNF-alpha 
production by dendritic cells stimulated with Schistosoma mansoni schistosomula 
tegument is TLR4- and MyD88-dependent. Immunol Lett 125(1):72-77. 
Eberle ME, Dalpke AH. 2012. Dectin-1 stimulation induces suppressor of cytokine 
signaling 1, thereby modulating TLR signaling and T cell responses. J Immunol 
188(11):5644-5654. 
Echtenacher B, Mannel DN, Hultner L. 1996. Critical protective role of mast cells in a 
model of acute septic peritonitis. Nature 381(6577):75-77. 
Erb KJ. 2007. Helminths, allergic disorders and IgE-mediated immune responses: where 
do we stand? Eur J Immunol 37(5):1170-1173. 
 186 
 
Everts B, Adegnika AA, Kruize YC, Smits HH, Kremsner PG, Yazdanbakhsh M. 2010a. 
Functional impairment of human myeloid dendritic cells during Schistosoma 
haematobium infection. PLoS Negl Trop Dis 4(4):e667. 
Everts B, Smits HH, Hokke CH, Yazdanbakhsh M. 2010b. Helminths and dendritic cells: 
sensing and regulating via pattern recognition receptors, Th2 and Treg responses. 
Eur J Immunol 40(6):1525-1537. 
Fairweather I, Lawrence T, Threadgold T, Hanna REB. 1999. Development of Fasciola 
hepatica in the Mammalian Host. Fasciolosis; Edited by Dalton, JP, Cab 
international, Wallingford, UK ISBN 0851992609:47-63. 
Ferreras MC, Garcia-Iglesias MJ, Manga-Gonzalez MY, Perez-Martinez C, Mizinska Y, 
Ramajo V, Gonzalez-Lanza MC, Escudero A, Garcia-Marin JF. 2000. 
Histopathological and immunohistochemical study of lambs experimentally infected 
with Fasciola hepatica and Schistosoma bovis. J Vet Med B Infect Dis Vet Public 
Health 47(10):763-773. 
Falcon CR, Carranza FA, Aoki P, Motran CC, Cervi L. 2012. Adoptive transfer of 
dendritic cells pulsed with Fasciola hepatica antigens and lipopolysaccharides 
confers protection against fasciolosis in mice. J Infect Dis 205(3):506-514. 
Feary JR, Venn AJ, Mortimer K, Brown AP, Hooi D, Falcone FH, Pritchard DI, Britton 
JR. 2009. Experimental hookworm infection: a randomized placebo-controlled trial 
in asthma. Clin Exp Allergy 40(2):299-306. 
Finkelman FD. 2007. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol 
120(3):506-515; quiz 516-507. 
 187 
 
Finkelman FD, Shea-Donohue T, Morris SC, Gildea L, Strait R, Madden KB, Schopf L, 
Urban JF, Jr. 2004. Interleukin-4- and interleukin-13-mediated host protection 
against intestinal nematode parasites. Immunol Rev 201:139-155. 
Fiore F, Castella B, Nuschak B, Bertieri R, Mariani S, Bruno B, Pantaleoni F, Foglietta M, 
Boccadoro M, Massaia M. 2007. Enhanced ability of dendritic cells to stimulate 
innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 
110(3):921-927. 
Flynn RJ, Irwin JA, Olivier M, Sekiya M, Dalton JP, Mulcahy G. 2007. Alternative 
activation of ruminant macrophages by Fasciola hepatica. Vet Immunol 
Immunopathol 120(1-2):31-40. 
Flynn RJ, Mulcahy G. 2008. The roles of IL-10 and TGF-beta in controlling IL-4 and IFN-
gamma production during experimental Fasciola hepatica infection. Int J Parasitol 
38(14):1673-1680. 
Flynn RJ, Mulcahy G, Elsheikha HM. 2010. Coordinating innate and adaptive immunity in 
Fasciola hepatica infection: implications for control. Vet Parasitol 169(3-4):235-240. 
Flynn RJ, Mulcahy G, Welsh M, Cassidy JP, Corbett D, Milligan C, Andersen P, Strain S, 
McNair J. 2009. Co-Infection of cattle with Fasciola hepatica and Mycobacterium 
bovis- immunological consequences. Transbound Emerg Dis 56(6-7):269-274. 
Galli SJ, Grimbaldeston M, Tsai M. 2008. Immunomodulatory mast cells: negative, as 
well as positive, regulators of immunity. Nat Rev Immunol 8: 478-486. 
Galli SJ, Nakae S, Tsai M. 2005. Mast cells in the development of adaptive immune 
responses. Nat Immunol 6(2):135-142. 
 188 
 
Galli SJ, Tsai M. 2010. Mast cells in allergy and infection: versatile effector and regulatory 
cells in innate and adaptive immunity. Eur J Immunol 40(7):1843-1851. 
Gazi U, Martinez-Pomares L. 2009. Influence of the mannose receptor in host immune 
responses. Immunobiology 214: 554-561. 
Geijtenbeek TB, Gringhuis SI. 2009. Signalling through C-type lectin receptors: shaping 
immune responses. Nat Rev Immunol 9(7):465-479. 
Gerken SE, Mota-Santos TA, Vaz NM. 1990. Evidence for the participation of mast cells 
in the innate resistance of mice to Schistosoma mansoni: effects on in vivo treatment 
with the ionophore 48-80. Braz J Med Biol Res 23(6-7):559-565. 
Gilfillan AM, Austin SJ, Metcalfe DD. 2011. Mast cell biology: introduction and 
overview. Adv Exp Med Biol 716:2-12. 
Gong J, Wei T, Stark RW, Jamitzky F, Heckl WM, Anders HJ, Lech M, Rossle SC. 2010. 
Inhibition of Toll-like receptors TLR4 and 7 signaling pathways by SIGIRR: a 
computational approach. J Struct Biol 169(3):323-330. 
Greenhill CJ, Rose-John S, Lissilaa R, Ferlin W, Ernst M, Hertzog PJ, Mansell A, Jenkins 
BJ. 2011. IL-6 trans-signaling modulates TLR4-dependent inflammatory responses 
via STAT3. J Immunol 186(2):1199-1208. 
Gregory DS. 2006. Pertussis: a disease affecting all ages. Am Fam Physician 74: 420-426. 
Gregory GD, Robbie-Ryan M, Secor VH, Sabatino JJ, Jr., Brown MA. 2005. Mast cells 
are required for optimal autoreactive T cell responses in a murine model of multiple 
sclerosis. Eur J Immunol 35(12):3478-3486. 
 189 
 
Gri G, Frossi B, D'Inca F, Danelli L, Betto E, Mion F, Sibilano R, Pucillo C. 2012. Mast 
cell: an emerging partner in immune interaction. Front Immunol 3:120. 
Grimaud JA. 1987. Cell-matrix interactions in schistosomal portal fibrosis: a dynamic 
event. Mem Inst Oswaldo Cruz 82 Suppl 4:55-65. 
Gruden-Movsesijan A, Milosavljevic Lj S. 2006. The involvement of the macrophage 
mannose receptor in the innate immune response to infection with parasite 
Trichinella spiralis. Vet Immunol Immunopathol 109(1-2):57-67. 
Guasconi L, Serradell MC, Garro AP, Iacobelli L, Masih DT. 2011. C-type lectins on 
macrophages participate in the immunomodulatory response to Fasciola hepatica 
products. Immunology 133(3):386-396. 
Guha M, Mackman N. 2001. LPS induction of gene expression in human monocytes. Cell 
Signal 13(2):85-94. 
Guthmann MD, Tal M, Pecht I. 1995a. A new member of the C-type lectin family is a 
modulator of the mast cell secretory response. Int Arch Allergy Immunol 107(1-
3):82-86. 
Guthmann MD, Tal M, Pecht I. 1995b. A secretion inhibitory signal transduction molecule 
on mast cells is another C-type lectin. Proc Natl Acad Sci U S A 92(20):9397-9401. 
Hacariz O, Sayers G, Mulcahy G. 2010. A preliminary study to understand the effect of 
Fasciola hepatica tegument on naive macrophages and humoral responses in an 
ovine model. Vet Immunol Immunopathol 139(2-4):245-249. 
Hacariz O, Sayers G, Baykal AT. 2012. A proteomic approach to investigate the 
distribution and abundance of surface and internal Fasciola hepatica proteins during 
 190 
 
the chronic stage of natural liver fluke infection in cattle. J Proteome Res 11:3592-
3604. 
Halton DW. 2004. Microscopy and the helminth parasite. Micron 35(5):361-390. 
Hamilton CM, Dowling DJ, Loscher CE, Morphew RM, Brophy PM, O'Neill SM. 2009. 
The Fasciola hepatica tegumental antigen suppresses dendritic cell maturation and 
function. Infect Immun 77(6):2488-2498. 
Harn DA, McDonald J, Atochina O, Da'dara AA. 2009. Modulation of host immune 
responses by helminth glycans. Immunol Rev 230(1):247-257. 
Harnett W, Harnett MM. 2008. Therapeutic immunomodulators from nematode parasites. 
Expert Rev Mol Med 10:e18. 
Hartgers FC, Obeng BB, Kruize YC, Dijkhuis A, McCall M, Sauerwein RW, Luty AJ, 
Boakye DA, Yazdanbakhsh M. 2009. Responses to malarial antigens are altered in 
helminth-infected children. J Infect Dis 199(10):1528-1535. 
Hashimoto K, Uchikawa R, Tegoshi T, Takeda K, Yamada M, Arizono N. 2009. 
Immunity-mediated regulation of fecundity in the nematode Heligmosomoides 
polygyrus--the potential role of mast cells. Parasitology 137(5):881-887. 
Hashino M, Tachibana M, Shimizu T, Watarai M. 2012. Mannose receptor, C type 1 
contributes to bacterial uptake by placental trophoblast giant cells. FEMS Immunol 
Med Microbiol. 
He SH. 2004. Key role of mast cells and their major secretory products in inflammatory 
bowel disease. World J Gastroenterol 10(3):309-318. 
 191 
 
Helmby H, Kullberg M, Troye-Blomberg M. 1998. Altered immune responses in mice 
with concomitant Schistosoma mansoni and Plasmodium chabaudi infections. Infect 
Immun 66(11):5167-5174. 
Henz B, Maurer M, Lippert U, Babina M. 2001. Mast cells as initiators of immunity and 
host defense. Exp Dermatol 10:1-10. 
Hepworth MR, Danilowicz-Luebert E, Rausch S, Metz M, Klotz C, Maurer M, Hartmann 
S, 2012a. Mast cells orchestrate type 2 immunity to helminths through regulation of 
tissue-derived cytokines. Proc Natl Acad Sci U S A 109, 6644-6649. 
Hepworth MR, Maurer M, Hartmann S, 2012b. Regulation of type 2 immunity to 
helminths by mast cells. Gut Microbes 3, 476-481. 
Higgins SC, Jarnicki AG, Lavelle EC, Mills KH. 2006. TLR4 mediates vaccine-induced 
protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. 
J Immunol 177(11):7980-7989. 
Hillyer GV. 1980. Isolation of Fasciola hepatica tegument antigens. J Clin Microbiol 
12(5):695-699. 
Hochdorfer T, Kuhny M, Zorn CN, Hendriks RW, Vanhaesebroeck B, Bohnacker T, 
Krystal G, Huber M. 2011. Activation of the PI3K pathway increases TLR-induced 
TNF-alpha and IL-6 but reduces IL-1beta production in mast cells. Cell Signal 
23(5):866-875. 
Hu X, Chen J, Wang L, Ivashkiv LB. 2007. Crosstalk among Jak-STAT, Toll-like 
receptor, and ITAM-dependent pathways in macrophage activation. J Leukoc Biol 
82(2):237-243. 
 192 
 
Huels C, Germann T, Goedert S, Hoehn P, Koelsch S, Hultner L, Palm N, Rude E, Schmitt 
E. 1995. Co-activation of naive CD4+ T cells and bone marrow-derived mast cells 
results in the development of Th2 cells. Int Immunol 7(4):525-532. 
Imai S, Tezuka H, Fujita K. 2001. A factor of inducing IgE from a filarial parasite prevents 
insulin-dependent diabetes mellitus in nonobese diabetic mice. Biochem Biophys 
Res Commun 286(5):1051-1058. 
Ince MN, Elliott DE, Setiawan T, Blum A, Metwali A, Wang Y, Urban JF, Jr., Weinstock 
JV. 2006. Heligmosomoides polygyrus induces TLR4 on murine mucosal T cells 
that produce TGFbeta after lipopolysaccharide stimulation. J Immunol 176(2):726-
729. 
Into T, Inomata M, Nakashima M, Shibata K, Hacker H, Matsushita K. 2008. Regulation 
of MyD88-dependent signaling events by S nitrosylation retards toll-like receptor 
signal transduction and initiation of acute-phase immune responses. Mol Cell Biol 
28(4):1338-1347. 
Inzana TJ, Glindemann G, Cox AD, Wakarchuk W, Howard MD. 2002. Incorporation of 
N-acetylneuraminic acid into Haemophilus somnus lipooligosaccharide (LOS): 
enhancement of resistance to serum and reduction of LOS antibody binding. Infect 
Immun 70(9):4870-4879. 
Ip WK, Takahashi K, Ezekowitz RA, Stuart LM. 2009. Mannose-binding lectin and innate 
immunity. Immunol Rev 230: 9-21. 
Irani AM, Bradford TR, Kepley CL, Schechter NM, Schwartz LB. 1989. Detection of 
MCT and MCTC types of human mast cells by immunohistochemistry using new 
 193 
 
monoclonal anti-tryptase and anti-chymase antibodies. J Histochem Cytochem 
37(10):1509-1515. 
Jackson JA, Friberg IM, Little S, Bradley JE. 2009. Review series on helminths, immune 
modulation and the hygiene hypothesis: immunity against helminths and 
immunological phenomena in modern human populations: coevolutionary legacies? 
Immunology 126(1):18-27. 
Johnston MJ, MacDonald JA, McKay DM. 2009. Parasitic helminths: a pharmacopeia of 
anti-inflammatory molecules. Parasitology 136(2):125-147. 
Juremalm M, Nilsson G. 2005. Chemokine receptor expression by mast cells. Chem 
Immunol Allergy 87:130-144. 
Kambayashi T, Allenspach EJ, Chang JT, Zou T, Shoag JE, Reiner SL, Caton AJ, 
Koretzky GA. 2009. Inducible MHC class II expression by mast cells supports 
effector and regulatory T cell activation. J Immunol 182(8):4686-4695. 
Kane CM, Cervi L, Sun J, McKee AS, Masek KS, Shapira S, Hunter CA, Pearce EJ. 2004. 
Helminth antigens modulate TLR-initiated dendritic cell activation. J Immunol 
173(12):7454-7461. 
Kane CM, Jung E, Pearce EJ. 2008. Schistosoma mansoni egg antigen-mediated 
modulation of Toll-like receptor (TLR)-induced activation occurs independently of 
TLR2, TLR4, and MyD88. Infect Immun 76(12):5754-5759. 
Kang BK, Schlesinger LS. 1998. Characterization of mannose receptor-dependent 
phagocytosis mediated by Mycobacterium tuberculosis lipoarabinomannan. Infect 
Immun 66(6):2769-2777. 
 194 
 
Kashiwakura J, Yokoi H, Saito H, Okayama Y. 2004. T cell proliferation by direct cross-
talk between OX40 ligand on human mast cells and OX40 on human T cells: 
comparison of gene expression profiles between human tonsillar and lung-cultured 
mast cells. J Immunol 173(8):5247-5257. 
Kasugai T, Tei H, Okada M, Hirota S, Morimoto M, Yamada M, Nakama A, Arizono N, 
Kitamura Y. 1995. Infection with Nippostrongylus brasiliensis induces invasion of 
mast cell precursors from peripheral blood to small intestine. Blood 85(5):1334-
1340. 
Katz HR. 2002. Inhibitory receptors and allergy. Curr Opin Immunol 14(6):698-704. 
Kawai T, Akira S. 2011. Toll-like receptors and their crosstalk with other innate receptors 
in infection and immunity. Immunity 34(5):637-650. 
Keck S, Muller I, Fejer G, Savic I, Tchaptchet S, Nielsen PJ, Galanos C, Huber M, 
Freudenberg MA. 2011. Absence of TRIF signaling in lipopolysaccharide-stimulated 
murine mast cells. J Immunol 186(9):5478-5488. 
Keiser J, Morson G. 2008. Fasciola hepatica: tegumental alterations in adult flukes 
following in vitro and in vivo administration of artesunate and artemether. Exp 
Parasitol 118(2):228-237. 
Kerrigan AM, Brown GD. 2010. Syk-coupled C-type lectin receptors that mediate cellular 
activation via single tyrosine based activation motifs. Immunol Rev 234(1):335-352. 
Kimura I, Moritani Y, Tanizaki Y. 1973. Basophils in bronchial asthma with reference to 
reagin-type allergy. Clin Allergy 3(2):195-202. 
 195 
 
Kittelberger R, Hilbink F. 1993. Sensitive silver-staining detection of bacterial 
lipopolysaccharides in polyacrylamide gels. J Biochem Biophys Methods 26(1):81-
86. 
Klabunde J, Berger J, Jensenius JC, Klinkert MQ, Zelck UE, Kremsner PG, Kun JF. 2000. 
Schistosoma mansoni: adhesion of mannan-binding lectin to surface glycoproteins of 
cercariae and adult worms. Exp Parasitol 95(4):231-239. 
Klementowicz JE, Travis MA, Grencis RK. 2012. Trichuris muris: a model of 
gastrointestinal parasite infection. Semin Immunopathol 34(6):815-828. 
Kreider T, Anthony RM, Urban JF, Jr., Gause WC. 2007. Alternatively activated 
macrophages in helminth infections. Curr Opin Immunol 19(4):448-453. 
Kubler-Kielb J, Vinogradov E, Lagergard T, Ginzberg A, King JD, Preston A, Maskell DJ, 
Pozsgay V, Keith JM, Robbins JB, Schneerson R. 2011. Oligosaccharide conjugates 
of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition 
to pertussis vaccine. Proc Natl Acad Sci U S A 108(10):4087-4092. 
Kuijk LM, Klaver EJ, Kooij G, van der Pol SM, Heijnen P, Bruijns SC, Kringel H, Pinelli 
E, Kraal G, de Vries HE, Dijkstra CD, Bouma G, van Die I. 2012. Soluble helminth 
products suppress clinical signs in murine experimental autoimmune 
encephalomyelitis and differentially modulate human dendritic cell activation. Mol 
Immunol 51(2):210-218. 
Kuijk LM, van Die I. 2010. Worms to the rescue: can worm glycans protect from 
autoimmune diseases? IUBMB Life 62(4):303-312. 
 196 
 
Kunii J, Takahashi K, Kasakura K, Tsuda M, Nakano K, Hosono A, Kaminogawa S. 2011. 
Commensal bacteria promote migration of mast cells into the intestine. 
Immunobiology 216(6):692-697. 
Kusumoto S, Fukase K, Shiba T. 2010. Key structures of bacterial peptidoglycan and 
lipopolysaccharide triggering the innate immune system of higher animals: chemical 
synthesis and functional studies. Proc Jpn Acad Ser B Phys Biol Sci 86: 322-337. 
Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 227(5259):680-685. 
Lang, R., Schoenen, H., Desel, C. 2011. Targeting Syk-Card9-activating C-type lectin 
receptors by vaccine adjuvants: findings, implications and open questions. 
Immunobiology 216, 1184-91. 
Le Blay K, Caroff M, Richards JC, Perry MB, Chaby R. 1994. Specific and cross-reacting 
monoclonal antibodies to Bordetella parapertussis and Bordetella bronchiseptica 
lipopolysaccharides. Microbiology 140 ( Pt 9):2459-2465. 
Lee JJ, Lee NA. 2005. Eosinophil degranulation: an evolutionary vestige or a universally 
destructive effector function? Clin Exp Allergy 35(8):986-994. 
Levinger B. 1992. Nutrition, Health and Learning: Current Issues and Trends. Educational 
Development Center, Incorporated:45. 
Li G, Domenico J, Jia Y, Lucas JJ, Gelfand EW. 2009. NF-kappaB-dependent induction of 
cathelicidin-related antimicrobial peptide in murine mast cells by lipopolysaccharide. 
Int Arch Allergy Immunol 150(2):122-132. 
Lieu HT, Simon MT, Nguyen-Khoa T, Kebede M, Cortes A, Tebar L, Smith AJ, Bayne R, 
Hunt SP, Brechot C, Christa L. 2006. Reg2 inactivation increases sensitivity to Fas 
 197 
 
hepatotoxicity and delays liver regeneration post-hepatectomy in mice. Hepatology 
44(6):1452-1464. 
Lin YC, Huang DY, Chu CL, Lin WW. 2010. Anti-inflammatory actions of Syk inhibitors 
in macrophages involve non-specific inhibition of toll-like receptors-mediated JNK 
signaling pathway. Mol Immunol 47: 1569-1578. 
Liu Z, Liu Q, Bleich D, Salgame P, Gause WC. 2009. Regulation of type 1 diabetes, 
tuberculosis, and asthma by parasites. J Mol Med (Berl) 88(1):27-38. 
Lloyd DH, Viac J, Werling D, Reme CA, Gatto H. 2007. Role of sugars in surface 
microbe-host interactions and immune reaction modulation. Vet Dermatol 
18(4):197-204. 
Locht C. 1999. Molecular aspects of Bordetella pertussis pathogenesis. Int Microbiol 2: 
137-144. 
Locht C, Antoine R, Jacob-Dubuisson F. 2001. Bordetella pertussis, molecular 
pathogenesis under multiple aspects. Curr Opin Microbiol 4: 82-89. 
Lu YC, Yeh WC, Ohashi PS. 2008. LPS/TLR4 signal transduction pathway. Cytokine 
42(2):145-151. 
Ludwig-Portugall I, Layland LE. 2012. TLRs, Treg, and B Cells, an Interplay of 
Regulation during Helminth Infection. Front Immunol 3:8. 
Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G. 1999. An 
advanced culture method for generating large quantities of highly pure dendritic cells 
from mouse bone marrow. J Immunol Methods 223(1):77-92. 
Lyke KE, Dabo A, Sangare L, Arama C, Daou M, Diarra I, Plowe CV, Doumbo OK, 
Sztein MB. 2006. Effects of concomitant Schistosoma haematobium infection on the 
 198 
 
serum cytokine levels elicited by acute Plasmodium falciparum malaria infection in 
Malian children. Infect Immun 74(10):5718-5724. 
Lyke KE, Dicko A, Dabo A, Sangare L, Kone A, Coulibaly D, Guindo A, Traore K, Daou 
M, Diarra I, Sztein MB, Plowe CV, Doumbo OK. 2005. Association of Schistosoma 
haematobium infection with protection against acute Plasmodium falciparum malaria 
in Malian children. Am J Trop Med Hyg 73(6):1124-1130. 
MacDonald AS, Araujo MI, Pearce EJ. 2002. Immunology of parasitic helminth 
infections. Infect Immun 70(2):427-433. 
MacDonald AS, Maizels RM. 2008. Alarming dendritic cells for Th2 induction. J Exp 
Med 205(1):13-17. 
Mahon BP, Ryan MS, Griffin F, Mills KH. 1996. Interleukin-12 is produced by 
macrophages in response to live or killed Bordetella pertussis and enhances the 
efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells. Infect 
Immun 64(12):5295-5301. 
Maizels RM, Balic A, Gomez-Escobar N, Nair M, Taylor MD, Allen JE. 2004. Helminth 
parasites--masters of regulation. Immunol Rev 201:89-116. 
Maizels RM, Yazdanbakhsh M. 2003. Immune regulation by helminth parasites: cellular 
and molecular mechanisms. Nat Rev Immunol 3(9):733-744. 
Maltby S, Khazaie K, McNagny KM. 2009. Mast cells in tumor growth: angiogenesis, 
tissue remodelling and immune-modulation. Biochim Biophys Acta 1796(1):19-26. 
Mann PB, Wolfe D, Latz E, Golenbock D, Preston A, Harvill ET. 2005. Comparative toll-
like receptor 4-mediated innate host defense to Bordetella infection. Infect Immun 
73(12):8144-8152. 
 199 
 
Marr N, Novikov A, Hajjar AM, Caroff M, Fernandez RC. 2010. Variability in the 
lipooligosaccharide structure and endotoxicity among Bordetella pertussis strains. J 
Infect Dis 202(12):1897-1906. 
Marshall JS. 2004. Mast-cell responses to pathogens. Nat Rev Immunol 4(10):787-799. 
Marshall JS, King CA, McCurdy JD. 2003. Mast cell cytokine and chemokine responses to 
bacterial and viral infection. Curr Pharm Des 9(1):11-24. 
Martin D, Peppler MS, Brodeur BR. 1992. Immunological characterization of the 
lipooligosaccharide B band of Bordetella pertussis. Infect Immun 60: 2718-2725. 
Mason NJ, Artis D, Hunter CA. 2004. New lessons from old pathogens: what parasitic 
infections have taught us about the role of nuclear factor-kappaB in the regulation of 
immunity. Immunol Rev 201:48-56. 
Matsushima H, Yamada N, Matsue H, Shimada S. 2004. TLR3-, TLR7-, and TLR9-
mediated production of proinflammatory cytokines and chemokines from murine 
connective tissue type skin-derived mast cells but not from bone marrow-derived 
mast cells. J Immunol 173(1):531-541. 
Maurer M, Lopez Kostka S, Siebenhaar F, Moelle K, Metz M, Knop J, von Stebut E. 2006. 
Skin mast cells control T cell-dependent host defense in Leishmania major 
infections. FASEB J 20(14):2460-2467. 
Maurer M, Theoharides T, Granstein RD, Bischoff SC, Bienenstock J, Henz B, Kovanen 
P, Piliponsky AM, Kambe N, Vliagoftis H, Levi-Schaffer F, Metz M, Miyachi Y, 
Befus D, Forsythe P, Kitamura Y, Galli S. 2003. What is the physiological function 
of mast cells? Exp Dermatol 12(6):886-910. 
 200 
 
Mazzoni A, Siraganian RP, Leifer CA, Segal DM. 2006. Dendritic cell modulation by 
mast cells controls the Th1/Th2 balance in responding T cells. J Immunol 
177(6):3577-3581. 
McCole DF, Doherty ML, Torgerson PR, Baird AW. 1998. Local immune responses in 
colon from cattle infected with Fasciola hepatica. Int J Parasitol 28(11):1733-1737. 
McCole DF, Doherty ML, Baird AW, Davies WC, McGill K, Torgerson PR. 1999. T cell 
subset involvement in immune responses to Fasciola hepatica infection in cattle. 
Parasite Immunol 21(1):1-8. 
McCurdy JD, Lin TJ, Marshall JS. 2001. Toll-like receptor 4-mediated activation of 
murine mast cells. J Leukoc Biol 70(6):977-984. 
McDermott JR, Bartram RE, Knight PA, Miller HR, Garrod DR, Grencis RK. 2003. Mast 
cells disrupt epithelial barrier function during enteric nematode infection. Proc Natl 
Acad Sci U S A 100(13):7761-7766. 
McLachlan JB, Shelburne CP, Hart JP, Pizzo SV, Goyal R, Brooking-Dixon R, Staats HF, 
Abraham SN. 2008. Mast cell activators: a new class of highly effective vaccine 
adjuvants. Nat Med 14(5):536-541. 
McManus DP, Dalton JP. 2006. Vaccines against the zoonotic trematodes Schistosoma 
japonicum, Fasciola hepatica and Fasciola gigantica. Parasitology 133 Suppl:S43-61. 
McSorley HJ, Maizels RM. 2012. Helminth infections and host immune regulation. Clin 
Microbiol Rev 25(4):585-608. 
Melendez AJ, Harnett MM, Pushparaj PN, Wong WS, Tay HK, McSharry CP, Harnett W. 
2007. Inhibition of Fc epsilon RI-mediated mast cell responses by ES-62, a product 
of parasitic filarial nematodes. Nat Med 13(11):1375-1381. 
 201 
 
Metcalfe DD, Baram D, Mekori YA. 1997. Mast cells. Physiol Rev 77(4):1033-1079. 
Metcalfe DD, Peavy RD, Gilfillan AM. 2009. Mechanisms of mast cell signaling in 
anaphylaxis. J Allergy Clin Immunol 124(4):639-646; quiz 647-638. 
Metz M, Maurer M. 2007. Mast cells--key effector cells in immune responses. Trends 
Immunol 28(5):234-241. 
Mielcarek N, Hornquist EH, Johansson BR, Locht C, Abraham SN, Holmgren J. 2001. 
Interaction of Bordetella pertussis with mast cells, modulation of cytokine secretion 
by pertussis toxin. Cell Microbiol 3(3):181-188. 
Mikita J, Dubourdieu-Cassagno N, Deloire MS, Vekris A, Biran M, Raffard G, Brochet B, 
Canron MH, Franconi JM, Boiziau C, Petry KG. 2011. Altered M1/M2 activation 
patterns of monocytes in severe relapsing experimental rat model of multiple 
sclerosis. Amelioration of clinical status by M2 activated monocyte administration. 
Mult Scler 17(1):2-15. 
Miller CM, Smith NC, Ikin RJ, Boulter NR, Dalton JP, Donnelly S. 2009. Immunological 
interactions between 2 common pathogens, Th1-inducing protozoan Toxoplasma 
gondii and the Th2-inducing helminth Fasciola hepatica. PLoS One 4(5):e5692. 
Miller YI, Choi SH, Wiesner P, Bae YS. 2012. The SYK side of TLR4: signalling 
mechanisms in response to LPS and minimally oxidized LDL. Br J Pharmacol 
167(5):990-999. 
Mogensen TH. 2009. Pathogen recognition and inflammatory signaling in innate immune 
defenses. Clin Microbiol Rev 22(2):240-273 
 202 
 
Moiseeva EP, Bradding P. 2011. Mast cells in lung inflammation. Adv Exp Med Biol 716: 
235-269. 
Moreau M, Chaby R, Szabo L. 1984. Structure of the terminal reducing heptasaccharide of 
polysaccharide 1 isolated from the Bordetella pertussis endotoxin. J Bacteriol 159: 
611-617. 
Moreau E, Chauvin A. 2010. Immunity against helminths: interactions with the host and 
the intercurrent infections. J Biomed Biotechnol 2010:428593. 
Moreau E, Chauvin A, Boulard C. 1998. IFN gamma and IL-10 production by hepatic 
lymph node and peripheral blood lymphocytes in Fasciola hepatica infected sheep. 
Parasite 5(4):307-315. 
Morphew RM, Hamilton CM, Wright HA, Dowling DJ, O'Neill SM, and Brophy PM. 
2012. Identification of the major proteins of an immune modulating fraction from 
adult Fasciola hepatica released by Nonidet P40. Vet Parasitol 191(3-4):379-85 
Mrabet-Dahbi S, Metz M, Dudeck A, Zuberbier T, Maurer M. 2009. Murine mast cells 
secrete a unique profile of cytokines and prostaglandins in response to distinct TLR2 
ligands. Exp Dermatol 18(5):437-444. 
Mulcahy G, O'Connor F, Clery D, Hogan SF, Dowd AJ, Andrews SJ, Dalton JP. 1999. 
Immune responses of cattle to experimental anti-Fasciola hepatica vaccines. Res Vet 
Sci 67(1):27-33. 
Mulcahy G, O'Neill S, Donnelly S, Dalton JP. 2004. Helminths at mucosal barriers--
interaction with the immune system. Adv Drug Deliv Rev 56(6):853-868. 
Murphy KM. 2011. Janeway's Immunobiology. Garland Sience, New York, USA. 
 203 
 
Murrell KD. 1991. Economic losses resulting from food-borne parasitic zoonoses. 
Southeast Asian J Trop Med Public Health 22 Suppl:377-381. 
Nacher M. 2011. Interactions between worms and malaria: good worms or bad worms? 
Malar J 10:259. 
Nakae S, Suto H, Iikura M, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. 2006. Mast cells 
enhance T cell activation: importance of mast cell costimulatory molecules and 
secreted TNF. J Immunol 176(4):2238-2248. 
Nakae S, Suto H, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. 2005. Mast cells enhance T 
cell activation: Importance of mast cell-derived TNF. Proc Natl Acad Sci U S A 
102(18):6467-6472. 
Napoletano C, Zizzari IG, Rughetti A, Rahimi H, Irimura T, Clausen H, wandall HH, 
Belleudi F, Bellati F, Pierelli L, Frati L, Nuti M. 2012. Targeting of macrophage 
galactose-type C-type lectin (MGL) induces DC signaling and activation. Eur J 
Immunol 42: 936-945. 
Ndhlovu PD, Mduluza T, Kjetland EF, Midzi N, Nyanga L, Gundersen SG, Friis H, Gomo 
E. 2007. Prevalence of urinary schistosomiasis and HIV in females living in a rural 
community of Zimbabwe: does age matter? Trans R Soc Trop Med Hyg 101(5):433-
438. 
Nie X, Cai G, Zhang W, Wang H, Wu B, Li Q, Shen Q. 2011. Lipopolysaccharide 
mediated mast cells induce IL-10 producing regulatory T cells through the 
ICOSL/ICOS axis. Clin Immunol 142(3):269-279. 
Noli C, Miolo A. 2001. The mast cell in wound healing. Vet Dermatol 12(6):303-313. 
 204 
 
Nookala S, Srinivasan S, Kaliraj P, Narayanan RB, Nutman TB. 2004. Impairment of 
tetanus-specific cellular and humoral responses following tetanus vaccination in 
human lymphatic filariasis. Infect Immun 72(5):2598-2604. 
O'Brien LM, Fitzpatrick E, Baird AW, Campion DP. 2008. Eosinophil-nerve interactions 
and neuronal plasticity in rat gut associated lymphoid tissue (GALT) in response to 
enteric parasitism. J Neuroimmunol 197(1):1-9. 
O'Neill SM, Brady MT, Callanan JJ, Mulcahy G, Joyce P, Mills KH, Dalton JP. 2000. 
Fasciola hepatica infection downregulates Th1 responses in mice. Parasite Immunol 
22(3):147-155. 
O'Neill SM, Mills KH, Dalton JP. 2001. Fasciola hepatica cathepsin L cysteine proteinase 
suppresses Bordetella pertussis-specific interferon-gamma production in vivo. 
Parasite Immunol 23(10):541-547. 
Oberhelman RA, Guerrero ES, Fernandez ML, Silio M, Mercado D, Comiskey N, 
Ihenacho G, Mera R. 1998. Correlations between intestinal parasitosis, physical 
growth, and psychomotor development among infants and children from rural 
Nicaragua. Am J Trop Med Hyg 58(4):470-475. 
Olynych TJ, Jakeman DL, Marshall JS. 2006. Fungal zymosan induces leukotriene 
production by human mast cells through a dectin-1-dependent mechanism. J Allergy 
Clin Immunol 118(4):837-843. 
Otsuka A, Kubo M, Honda T, Egawa G, Nakajima S, Tanizaki H, Kim B, Matsuoka S, 
Watanabe T, Nakae S, Miyachi Y, Kabashima K. 2011. Requirement of interaction 
between mast cells and skin dendritic cells to establish contact hypersensitivity. 
PLoS One 6(9):e25538. 
 205 
 
Padigel UM, Lee JJ, Nolan TJ, Schad GA, Abraham D. 2006. Eosinophils can function as 
antigen-presenting cells to induce primary and secondary immune responses to 
Strongyloides stercoralis. Infect Immun 74(6):3232-3238. 
Paveley RA, Aynsley SA, Turner JD, Bourke CD, Jenkins SJ, Cook PC, Martinez-
Pomares L, Mountford AP. 2011. The Mannose Receptor (CD206) is an important 
pattern recognition receptor (PRR) in the detection of the infective stage of the 
helminth Schistosoma mansoni and modulates IFNgamma production. Int J Parasitol 
41(13-14):1335-1345. 
Pearce EJ. 2007. Worms tame mast cells. Nat Med 13(11):1288-1289. 
Peng J, Yuan Q, Lin B, Panneerselvam P, Wang X, Luan XL, Lim SK, Leung BP, Ho B, 
Ding JL. 2010. SARM inhibits both TRIF- and MyD88-mediated AP-1 activation. 
Eur J Immunol 40(6):1738-1747. 
Pennock JL, Grencis RK. 2006. The mast cell and gut nematodes: damage and defence. 
Chem Immunol Allergy 90:128-140. 
Perona-Wright G, Jenkins SJ, MacDonald AS. 2006. Dendritic cell activation and function 
in response to Schistosoma mansoni. Int J Parasitol 36(6):711-721. 
Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-
PCR. Nucleic Acids Res 29(9):e45. 
Piconese S, Costanza M, Musio S, Tripodo C, Poliani PL, Gri G, Burocchi A, Pittoni P, 
Gorzanelli A, Colombo MP, Pedotti R. 2011. Exacerbated experimental autoimmune 
encephalomyelitis in mast cell-deficient (KitW-sh/W-sh) mice. Lab Invest 91(4):627-
641. 
 206 
 
Posselt G, Schwarz H, Duschl A, Horejs-Hoeck J. 2011. Suppressor of cytokine signaling 
2 is a feedback inhibitor of TLR-induced activation in human monocyte-derived 
dendritic cells. J Immunol 187(6):2875-2884. 
Potian JA, Rafi W, Bhatt K, McBride A, Gause WC, Salgame P. 2011. Preexisting 
helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense 
by engaging the IL-4 receptor pathway. J Exp Med 208(9):1863-1874. 
Raes G, Brys L, Dahal BK, Brandt J, Grooten J, Brombacher F, Vanham G, Noel W, 
Bogaert P, Boonefaes T, Kindt A, Van den Bergh R, Leenen PJ, De Baetselier P, 
Ghassabeh GH. 2005. Macrophage galactose-type C-type lectins as novel markers 
for alternatively activated macrophages elicited by parasitic infections and allergic 
airway inflammation. J Leukoc Biol 77(3):321-327. 
Rahko T. 1969. The pathology of natural Fasciola hepatica infection in cattle. Pathol Vet 
6(3):244-256. 
Rajaram MV, Brooks MN, Morris JD, Torrelles JB, Azad AK, Schlesinger LS. 2010. 
Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-
activated receptor gamma linking mannose receptor recognition to regulation of 
immune responses. J Immunol 185(2):929-942. 
Rawlings JS, Rosler KM, Harrison DA. 2004. The JAK/STAT signaling pathway. J Cell 
Sci 117(Pt 8):1281-1283. 
Reddy A, Fried B. 2009. An update on the use of helminths to treat Crohn's and other 
autoimmunune diseases. Parasitol Res 104(2):217-221. 
 207 
 
Resende Co T, Hirsch C, Toossi Z, Dietze R, Ribeiro-Rodrigues R. 2007. Intestinal 
helminth co-infection has a negative impact on both anti-Mycobacterium 
tuberculosis immunity and clinical response to tuberculosis therapy. Clin Exp 
Immunol 147(1):45-52. 
Ribbing C, Engblom C, Lappalainen J, Lindstedt K, Kovanen PT, Karlsson MA, 
Lundeberg L, Johansson C, Nilsson G, Lunderius-Andersson C, Scheynius A. 2011. 
Mast cells generated from patients with atopic eczema have enhanced levels of 
granule mediators and an impaired Dectin-1 expression. Allergy 66(1):110-119. 
Robinson MW, Dalton J, O'Neill SM, Donnelly SM. 2012a. Mechanism of immune 
modulation by Fasciola hepatica: Importance of vaccine development and novel 
immunotherapeutics. Caffrey, CR: Parasitic helminths: Targets, Screens, Drugs, and 
Vaccines; Wiley-VHC Verlag GmbH and Co KGaA:453-466. 
Robinson MW, Dalton JP, O'Brien BA, Donnelly S. 2012b. Fasciola hepatica: The 
therapeutic potential of a worm secretome. Int J Parasitol 43(3-4):283-291. 
Robinson MW, Donnelly S, Hutchinson AT, To J, Taylor NL, Norton RS, Perugini MA, 
Dalton JP. 2011. A family of helminth molecules that modulate innate cell responses 
via molecular mimicry of host antimicrobial peptides. PLoS Pathog 7(5):e1002042. 
Robinson MW, Hutchinson AT, Donnelly S, Dalton JP. 2010. Worm secretory molecules 
are causing alarm. Trends Parasitol 26(8):371-372. 
Rodriguez-Sosa M, David JR, Bojalil R, Satoskar AR, Terrazas LI. 2002. Cutting edge: 
susceptibility to the larval stage of the helminth parasite Taenia crassiceps is 
mediated by Th2 response induced via STAT6 signaling. J Immunol 168(7):3135-
3139. 
 208 
 
Ruyssers NE, De Winter BY, De Man JG, Loukas A, Herman AG, Pelckmans PA, 
Moreels TG. 2008. Worms and the treatment of inflammatory bowel disease: are 
molecules the answer? Clin Dev Immunol 2008:567314. 
Sakamoto Y, Hiromatsu K, Ishiwata K, Inagaki-Ohara K, Ikeda T, Nakamura-Uchiyama F, 
Nawa Y. 2004. Chronic intestinal nematode infection induces Stat6-independent 
interleukin-5 production and causes eosinophilic inflammatory responses in mice. 
Immunology 112(4):615-623. 
Sandig H, Bulfone-Paus S. 2012. TLR signaling in mast cells: common and unique 
features. Front Immunol 3:185. 
Saunders SP, Barlow JL, Walsh CM, Bellsoi A, Smith P, McKenzie AN, Fallon PG. 2010. 
C-type lectin SIGN-R1 has a role in experimental colitis and responsiveness to 
lipopolysaccharide. J Immunol 184(5):2627-2637. 
Sayed BA, Brown MA. 2007. Mast cells as modulators of T-cell responses. Immunol Rev 
217:53-64. 
Schaeffer LM, McCormack FX, Wu H, Weiss AA. 2004. Bordetella pertussis 
lipopolysaccharide resists the bactericidal effects of pulmonary surfactant protein A. 
J Immunol 173(3):1959-1965. 
Scheller EL, Hankenson KD, Reuben JS, Krebsbach PH. 2011. Zoledronic acid inhibits 
macrophage SOCS3 expression and enhances cytokine production. J Cell Biochem 
112(11):3364-3372. 
 209 
 
Schopf LR, Hoffmann KF, Cheever AW, Urban JF, Jr., Wynn TA. 2002. IL-10 is critical 
for host resistance and survival during gastrointestinal helminth infection. J Immunol 
168(5):2383-2392. 
Seidl A, Panzer M, Voehringer D. 2011. Protective immunity against the gastrointestinal 
nematode Nippostrongylus brasiliensis requires a broad T-cell receptor repertoire. 
Immunology 134(2):214-223. 
Semnani RT, Venugopal PG, Leifer CA, Mostbock S, Sabzevari H, Nutman TB. 2008. 
Inhibition of TLR3 and TLR4 function and expression in human dendritic cells by 
helminth parasites. Blood 112(4):1290-1298. 
Serradell MC, Guasconi L, Cervi L, Chiapello LS, Masih DT. 2007. Excretory-secretory 
products from Fasciola hepatica induce eosinophil apoptosis by a caspase-dependent 
mechanism. Vet Immunol Immunopathol 117(3-4):197-208. 
Shi M, Deng W, Bi E, Mao K, Ji Y, Lin G, Wu X, Tao Z, Li Z, Cai X, Sun S, Xiang C, 
Sun B. 2008. TRIM30 alpha negatively regulates TLR-mediated NF-kappa B 
activation by targeting TAB2 and TAB3 for degradation. Nat Immunol 9(4):369-
377. 
Siebenhaar F, Syska W, Weller K, Magerl M, Zuberbier T, Metz M, Maurer M. 2007. 
Control of Pseudomonas aeruginosa skin infections in mice is mast cell-dependent. 
Am J Pathol 170(6):1910-1916. 
Sobhon P, Dangprasert T, Chauanchaiyakul S, Meepool A, Khawsuk W, C. W, V. V, E.S. 
U. 2000. Fasciola gigantica: Ultrastructure of the Adult Tegumant. ScienceAsia 
26:137-148. 
 210 
 
Song X, Shen J, Wen H, Zhong Z, Luo Q, Chu D, Qi Y, Xu Y, Wei W. 2011. Impact of 
Schistosoma japonicum infection on collagen-induced arthritis in DBA/1 mice: a 
murine model of human rheumatoid arthritis. PLoS One 6(8):e23453. 
Srivastava V, Manchanda M, Gupta S, Singla R, Behera D, Das G, Natarajan K. 2009. 
Toll-like receptor 2 and DC-SIGNR1 differentially regulate suppressors of cytokine 
signaling 1 in dendritic cells during Mycobacterium tuberculosis infection. J Biol 
Chem 284(38):25532-25541. 
Stadecker MJ, Asahi H, Finger E, Hernandez HJ, Rutitzky LI, Sun J. 2004. The 
immunobiology of Th1 polarization in high-pathology schistosomiasis. Immunol 
Rev 201:168-179. 
Su X, Zhang L, Jin L, Ye J, Guan Z, Chen R. 2010. Coculturing dendritic cells with 
zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer 
cells. J Clin Immunol 30(5):766-774. 
Supajatura V, Ushio H, Nakao A, Akira S, Okumura K, Ra C, Ogawa H. 2002. Differential 
responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J 
Clin Invest 109(10):1351-1359. 
Supajatura V, Ushio H, Nakao A, Okumura K, Ra C, Ogawa H. 2001. Protective roles of 
mast cells against enterobacterial infection are mediated by Toll-like receptor 4. J 
Immunol 167(4):2250-2256. 
Sutherland RE, Xu X, Kim SS, Seeley EJ, Caughey GH, Wolters PJ. 2011. Parasitic 
infection improves survival from septic peritonitis by enhancing mast cell responses 
to bacteria in mice. PLoS One 6(11):e27564. 
 211 
 
Svensson M, Bell L, Little MC, DeSchoolmeester M, Locksley RM, Else KJ. 2010. 
Accumulation of eosinophils in intestine-draining mesenteric lymph nodes occurs 
after Trichuris muris infection. Parasite Immunol 33(1):1-11. 
Takahashi Y, Dominici M, Swift J, Nagy C, Ihle JN. 2006. Trophoblast stem cells rescue 
placental defect in SOCS3-deficient mice. J Biol Chem 281(17):11444-11445. 
Takeda K, Akira S. 2004. TLR signaling pathways. Semin Immunol 16(1):3-9. 
Taub D, Dastych J, Inamura N, Upton J, Kelvin D, Metcalfe D, Oppenheim J. 1995. Bone 
marrow-derived murine mast cells migrate, but do not degranulate, in response to 
chemokines. J Immunol 154(5):2393-2402. 
Taylor MA. 2012. Emerging parasitic diseases of sheep. Vet Parasitol 189(1):2-7. 
Tegoshi T, Okada M, Nishida M, Arizono N. 1997. Early increase of gut intraepithelial 
mast cell precursors following Strongyloides venezuelensis infection in mice. 
Parasitology 114 ( Pt 2):181-187. 
Terrazas CA, Sanchez-Munoz F, Mejia-Dominguez AM, Amezcua-Guerra LM, Terrazas 
LI, Bojalil R, Gomez-Garcia L. 2011. Cestode antigens induce a tolerogenic-like 
phenotype and inhibit LPS inflammatory responses in human dendritic cells. Int J 
Biol Sci 7(9):1391-1400. 
Theoharides TC, Kalogeromitros D. 2006. The critical role of mast cells in allergy and 
inflammation. Ann N Y Acad Sci 1088:78-99. 
Thomas PG, Harn DA, Jr. 2004. Immune biasing by helminth glycans. Cell Microbiol 
6(1):13-22. 
 212 
 
Threadgold LT. 1963. The tegumant and associated structures of Fasciola hepatica. Quant 
J micr Sci 104(4):505-512. 
Tisdell CA, Harrison SR, Ramsay GC. 1999. The economic impacts of endemic diseases 
and disease control programmes. Rev Sci Tech 18(2):380-398. 
Toner E, Brennan GP, Hanna RE, Edgar HW, Fairweather I. 2010a. Tegumental surface 
changes in adult Fasciola hepatica in response to treatment in vivo with 
triclabendazole in the sheep host. Vet Parasitol 172(3-4):238-248. 
Toner E, Brennan GP, Hanna RE, Edgar HW, Fairweather I. 2010b. Time-dependent 
changes to the tegumental system and gastrodermis of adult Fasciola hepatica 
following treatment in vivo with triclabendazole in the sheep host. Vet Parasitol 
174(3-4):218-227. 
Toner E, Brennan GP, McConvery F, Meaney M, Fairweather I. 2010c. A transmission 
electron microscope study on the route of entry of triclabendazole into the liver 
fluke, Fasciola hepatica. Parasitology 137(5):855-870. 
Trudgett A, Watt AP, Harriott P, Ennis M. 2003. Liver fluke (Fasciola hepatica)-derived 
peptides activate rat peritoneal mast cells. Int Immunopharmacol 3(5):775-781. 
Tsang CM, Wong CK, Ip WK, Lam CW. 2005. Synergistic effect of SCF and TNF-alpha 
on the up-regulation of cell-surface expression of ICAM-1 on human leukemic mast 
cell line (HMC)-1 cells. J Leukoc Biol 78(1):239-247. 
Ulanova M, Asfaha S, Stenton G, Lint A, Gilbertson D, Schreiber A, Befus D.  2007. 
Involvement of Syk protein tyrosine kinase in LPS-induced responses in 
macrophages. J Endotoxin Res 13: 117-125. 
 213 
 
Uneke CJ. 2010. Soil transmitted helminth infections and schistosomiasis in school age 
children in sub-Saharan Africa: efficacy of chemotherapeutic intervention since 
World Health Assembly Resolution 2001. Tanzan J Health Res 12(1):86-99. 
Urban JF, Jr., Schopf L, Morris SC, Orekhova T, Madden KB, Betts CJ, Gamble HR, Byrd 
C, Donaldson D, Else K, Finkelman FD. 2000. Stat6 signaling promotes protective 
immunity against Trichinella spiralis through a mast cell- and T cell-dependent 
mechanism. J Immunol 164(4):2046-2052. 
van Die I, Cummings RD. 2006. Glycans modulate immune responses in helminth 
infections and allergy. Chem Immunol Allergy 90:91-112. 
van Die I, Cummings RD. 2009. Glycan gimmickry by parasitic helminths: a strategy for 
modulating the host immune response? Glycobiology 20(1):2-12. 
van Die I, Cummings RD. 2010. Glycan gimmickry by parasitic helminths: a strategy for 
modulating the host immune response? Glycobiology 20(1):2-12. 
von Konig CH, Halperin S, Riffelmann M, Guiso N. 2002. Pertussis of adults and infants. 
Lancet Infect Dis 2: 744-750. 
van Kooyk Y. 2008. C-type lectins on dendritic cells: key modulators for the induction of 
immune responses. Biochem Soc Trans 36(Pt 6):1478-1481. 
van Liempt E, Bank CM, Mehta P, Garcia-Vallejo JJ, Kawar ZS, Geyer R, Alvarez RA, 
Cummings RD, Kooyk Y, van Die I. 2006. Specificity of DC-SIGN for mannose- 
and fucose-containing glycans. FEBS Lett 580(26):6123-6131. 
van Liempt E, van Vliet SJ, Engering A, Garcia Vallejo JJ, Bank CM, Sanchez-Hernandez 
M, van Kooyk Y, van Die I. 2007. Schistosoma mansoni soluble egg antigens are 
 214 
 
internalized by human dendritic cells through multiple C-type lectins and suppress 
TLR-induced dendritic cell activation. Mol Immunol 44(10):2605-2615. 
Van Milligen FJ, Cornelissen JB, Hendriks IM, Gaasenbeek CP, Bokhout BA. 1998. 
Protection of Fasciola hepatica in the gut mucosa of immune rats is associated with 
infiltrates of eosinophils, IgG1 and IgG2a antibodies around the parasites. Parasite 
Immunol 20(6):285-292. 
van Riet E, Everts B, Retra K, Phylipsen M, van Hellemond JJ, Tielens AG, van der Kleij 
D, Hartgers FC, Yazdanbakhsh M. 2009. Combined TLR2 and TLR4 ligation in the 
context of bacterial or helminth extracts in human monocyte derived dendritic cells: 
molecular correlates for Th1/Th2 polarization. BMC Immunol 10:9. 
van Sorge NM, Bleumink NM, van Vliet SJ Saeland E, van der Pol WL, van Putten JP. 
2009. N-glycosylated proteins and distinct lipooligosaccharide glycoforms of 
Campylobacter jejuni target the human C-type lectin receptor MGL. Cell Microbiol 
11: 1768-1781. 
van Vliet SJ, den Dunnen J, Gringhuis SI, Geijtenbeek TB, van Kooyk Y. 2007. Innate 
signaling and regulation of Dendritic cell immunity. Curr Opin Immunol 19: 435-
440. 
van Vliet SJ, Garcia-Vallejo JJ, van Kooyk Y. 2008. Dendritic cells and C-type lectin 
receptors: coupling innate to adaptive immune responses. Immunol Cell Biol 86: 
580-587. 
van Vliet SJ, van Liempt E, Saeland E, Aarnoudse CA, Appelmelk B, Irimura T, 
Geijtenbeek TB, Blixt O, Alvarez R, van Die I, van Kooyk Y. 2005. Carbohydrate 
profiling reveals a distinctive role for the C-type lectin MGL in the recognition of 
 215 
 
helminth parasites and tumor antigens by dendritic cells. Int Immunol 17(5):661-
669. 
Velin D, Bachmann D, Bouzourene H, Michetti P. 2005. Mast cells are critical mediators 
of vaccine-induced Helicobacter clearance in the mouse model. Gastroenterology 
129(1):142-155. 
Venugopal PG, Nutman TB, Semnani RT. 2009. Activation and regulation of toll-like 
receptors (TLRs) by helminth parasites. Immunol Res 43(1-3):252-263. 
von Konig CH, Halperin S, Riffelmann M, Guiso N. 2002. Pertussis of adults and infants. 
Lancet Infect Dis 2(12):744-750. 
Walsh KP, Brady MT, Finlay CM, Boon L, Mills KH. 2009. Infection with a helminth 
parasite attenuates autoimmunity through TGF-beta-mediated suppression of Th17 
and Th1 responses. J Immunol 183(3):1577-1586. 
Wang LJ, Cao Y, Shi HN. 2008. Helminth infections and intestinal inflammation. World J 
Gastroenterol 14(33):5125-5132. 
Watson S, Mercier S, Bye C, Wilkinson J, Cunningham AL, Harman AN. 2007. 
Determination of suitable housekeeping genes for normalisation of quantitative real 
time PCR analysis of cells infected with human immunodeficiency virus and herpes 
viruses. Virol J 4:130. 
Weis WI, Taylor ME, Drickamer K. 1998. The C-type lectin superfamily in the immune 
system. Immunol Rev 163:19-34. 
Weller CL, Collington SJ, Williams T, Lamb JR. 2011. Mast cells in health and disease. 
Clin Sci (Lond) 120(11):473-484. 
 216 
 
Weller K, Foitzik K, Paus R, Syska W, Maurer M. 2006. Mast cells are required for 
normal healing of skin wounds in mice. FASEB J 20(13):2366-2368. 
Wells CA, Salvage-Jones JA, Li X, Hitchens K, Butcher S, Murray RZ, Beckhouse AG, 
Lo YL, Manzanero S, Cobbold C, Schroder K, Ma B, Orr S, Stewart L, Lebus D, 
Sobieszczuk P, Hume DA, Stow J, Blanchard H, Ashman RB. 2008. The 
macrophage-inducible C-type lectin, mincle, is an essential component of the innate 
immune response to Candida albicans. J Immunol 180(11):7404-7413. 
Whelan RA, Hartmann S, Rausch S. 2011. Nematode modulation of inflammatory bowel 
disease. Protoplasma 249(4):871-86 
WHO 2012. Research priorities for helminth infections. WHO Technical Report Series 
972:1-196. 
Whyte CS, Bishop ET, Ruckerl D, Gaspar-Pereira S, Barker RN, Allen JE, Rees AJ, 
Wilson HM. 2011. Suppressor of cytokine signaling (SOCS)1 is a key determinant 
of differential macrophage activation and function. J Leukoc Biol 90(5):845-854. 
Wierzbicki M, Brzezinska-Blaszczyk E. 2009. Diverse effects of bacterial cell wall 
components on mast cell degranulation, cysteinyl leukotriene generation and 
migration. Microbiol Immunol 53(12):694-703. 
Wilgus TA. 2008. Immune cells in the healing skin wound: influential players at each 
stage of repair. Pharmacol Res 58(2):112-116. 
Wilson MS, Maizels RM. 2004. Regulation of allergy and autoimmunity in helminth 
infection. Clin Rev Allergy Immunol 26(1):35-50. 
 217 
 
Wilson RA, Wright JM, de Castro-Borges W, Parker-Manuel SJ, Dowle AA, Ashton PD, 
Young ND, Gasser RB, Spithill TW. 2011. Exploring the Fasciola hepatica tegument 
proteome. Int J Parasitol 41(13-14):1347-1359. 
Wolfe DN, Buboltz AM, Harvill ET. 2009. Inefficient Toll-like receptor-4 stimulation 
enables Bordetella parapertussis to avoid host immunity. PLoS One 4(1):e4280. 
Wuhrer M, Geyer R. 2006. Glycoconjugate Structures. Parasitic Flatworms: Molecular 
Biology, Biochemistry, Immunology and Physiology Edited by Maule AG and 
Marks NJ Cab International 21:408-420. 
Wynn TA. 2009. Basophils trump dendritic cells as APCs for T(H)2 responses. Nat 
Immunol 10(7):679-681. 
Wynn TA, Cheever AW, Williams ME, Hieny S, Caspar P, Kuhn R, Muller W, Sher A. 
1998. IL-10 regulates liver pathology in acute murine Schistosomiasis mansoni but 
is not required for immune down-modulation of chronic disease. J Immunol 
160(9):4473-4480. 
Xu Y, Hu Y, Shi B, Zhang X, Wang J, Zhang Z, Shen F, Zhang Q, Sun S, Yuan Z. 2009. 
HBsAg inhibits TLR9-mediated activation and IFN-alpha production in 
plasmacytoid dendritic cells. Mol Immunol 46(13):2640-2646. 
Yagil Z, Nechushtan H, Kay G, Yang CM, Kemeny DM, Razin E. 2010. The enigma of 
the role of protein inhibitor of activated STAT3 (PIAS3) in the immune response. 
Trends Immunol 31(5):199-204. 
Yang Z, Marshall JS. 2009. Zymosan treatment of mouse mast cells enhances dectin-1 
expression and induces dectin-1-dependent reactive oxygen species (ROS) 
generation. Immunobiology 214(4):321-330. 
 218 
 
Yoshimura A, Suzuki M, Sakaguchi R, Hanada T, Yasukawa H. 2012. SOCS, 
Inflammation, and Autoimmunity. Front Immunol 3:20. 
Zhang M, Gao Y, Du X, Zhang D, Ji M, Wu G. 2011. Toll-like receptor (TLR) 2 and 
TLR4 deficiencies exert differential in vivo effects against Schistosoma japonicum. 
Parasite Immunol 33(4):199-209. 
Zhang WY, Moreau E, Hope JC, Howard CJ, Huang WY, Chauvin A. 2005. Fasciola 
hepatica and Fasciola gigantica: comparison of cellular response to experimental 
infection in sheep. Exp Parasitol 111(3):154-159. 
 
  
 219 
 
9 Appendix  
9.1 Appendix A – Optimization of methods 
9.1.1 TLR ligands 
To find good candidates to activate mast cells and promote Th1 but not Th2 immune 
response we tried a panel of TLR-ligands (Table 8.1). We measured TNF-a and IL-6 
production as indicators of Th1 immune responses and β-hexosaminidase as 
indicator of Th2 immune response (Figure 8.1). 
Table 8.1. List of stimulants, concentration and the type of TLR they bind to 
Antigen Concentration Toll-like receptor 
PGN 5 µg/ml TLR2/1 
Zymosan 10 µg/ml TLR2/6 
Poli(I:C) 10 µg/ml TLR3 
LPS 100 ng/ml TLR4 
BP 100 bacteria/cell TLR4 
Flagellin 25 µg/ml TLR5 
 
 
Figure 9.1. LPS and BP stimulated mast cells produced TNF-a and IL-6 but no β-
hexosaminidase. BMMCs were cultured with LPS (100 ng/ml), BP (100 bacteria/cell), poli(I:C) 
(pIC; 10 µg/ml), zymosan (Zym; 10 µg/ml), flagellin (Fla; 25 µg/ml) and PGN (5 µg/ml) at 37
oC and 
5% CO2 for 24 hours. PBS was used as negative and A23187 was used as positive control. Cells were 
harvested for analysis and supernatants were removed for measurement of TNF-α, IL-6 by 
commercial ELISA (BD Biosciences). Cells were stimulated with the same ligands and degranulation 
was determined by β-hexosaminidase assay. 
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None of the tested antigens caused degranulation. LPS and BP activated mast cells 
produced significant amount of TNF-a and IL-6. We decided to use these two TLR4 
activators. 
 
9.1.2 Validation of LPS and BP administration 
To optimise our in vitro system concentration and time dependence studies were 
done. The concentrations of LPS were 25, 50, 100, 250, 500, 1000 and 1500 ng/ml. 
BP were used at 10, 25, 50, 100, 500 bacteria/cell. Time dependence was examined 
at four time points: 6, 12, 24 and 48 hours. Cells were harvested for analysis and 
supernatants were removed for measurement of TNF-α, IL-6 (Figure 8.2). 
 
Figure 9.2. Concentration and time dependence of LPS and BP treatment. Mast cells were 
stimulated with LPS and BP with different concentration indicated on the graphs (A-D) for 24 hours. 
For time dependence studies 100 ng/ml LPS and 100 bacteria/cell BP was used for 0, 12, 24, 48 hours 
(E-H). 
 
Based on the concentration and time dependence studies we chose 100 ng/ml and 
100 bacteria/cell as a concentration for LPS and BP and 24 hours as incubation time.  
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9.2 Appendix B – Tim edependence of increase in mast cells ratio in the 
peritoneal cavity after FhTeg treatment  
Mast cell ratio in the peritoneal cavity is increased after 2 weeks of Fasciola 
hepatica infection and it can be mimicked with FhTeg treatment. To investigate if 
mast cells are at the site of infection in early stages, before the adaptive Th2 immune 
response is developed, mice were treated with FhTeg and FhES and percentages of 
mast cells in the peritoneal cavity was measured by flow cytometry. Mast cell ratio 
increased in the peritoneal cavity in all tested time points (4 h: 25.8 ± 29.6%, p = 
0.45; 48 h: 28.7 ± 15.2%, p = 0.15), although was only significant after 1 week 
(60.55 ± 11.3, p £ 0.05) of treatment. FhES had no effect mast cell ratio at these time 
points (Figure 9.3). 
 
Figure 9.3. Mast cell ratio increased in the peritoneal cavity of mice after FhTeg but not FhES 
treatment. BALB/C mice were i.p. treated with  10 mg of FhTeg or FhES. Mice were sacrificed after 
4 h, 48 h and 1 week and peritoneal lavage was performed.  Mast cells ratio in the peritoneal cavity 
was measured by two colour flow cytometry (FceRI and c-kit) and Kimura staining.  
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9.3 Appendix C – Experiment to inhibit SOCS3 in BMDCs and BMMCs by 
zoledronic acid 
The best way to prove that SOCS3 is responsible for the inhibition would be to block 
SOCS3 and see if FhTeg still keeps its effect. As SOCS3-deficient mice die during 
embryotic development as a result of placental defect (Takahashi et al., 2006), we 
tried to block it with zoledronic acid (ZA). ZA is an amino-bisphosphonate used in 
the treatment of osteoarthritis and rheumatoid arthritis. It inhibits the SOCS3 
expression in macrophages and one of the main risk factors in patients treated with 
ZA is the development of SOCS3-related inflammatory disorders, such as Chron’s 
disease (Scheller et al., 2011). 
 
We tried to repeat the experiments of Bringmann et al (Bringmann et al., 2007), 
where they treated monocyte derived dendritic cells with ZA for one week and 
showed inhibition of SOCS3. In our experiments BMDCs did not grow properly and 
they produce high background of nitrite but no IL-12, so it was not possible to 
compare FhTeg effect on ZA trated and untreated groups (Figure 4.16). We repeated 
the same experiment in BMMCs. Altough ZA had no effect on mast cells 
development, the cytokine secretion was impaired upon tratment. ZA had no effect 
on the suppression of bacterila ligand activation by FhTeg (Figure 4.16). 
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Figure 9.4. Zoledronic acid (ZA) impaired dendritic cell and mast cell function to secret 
cytokines after bacterial stimulation. BMDCs and BMMCs were treated with ZA (0.5 µg/ml) every 
second day for one week and then stimulated with LPS (100 ng/ml) or BP (100 bacteria/cell). Nitrite 
(A), IL-12 (B) (BMDCs), TNF-α (C) and IL-6 (D) (BMMCs) were measured after 18/24 h. Data are 
presented as the mean ± SD of three independent experiments. *, p ≤ 0.05; **, p ≤ 0.01 compared to 
control group. 
 
Protocols for in vitro use of ZA, advise a longer pre-treatment (one week) to gain 
sufficient inhibition of SOCS3 expression (Bringmann et al., 2007; Fiore et al., 
2007; Su et al., 2010). We did not manage to use ZA in our experiments as primer 
cells were used and ZA impaired their ability to be activated by bacterial ligands. 
Other method to suppress gene expression, using small interfering (si)-RNA has also 
some difficulties in primer cells. Involving cell lines in this study could solve this 
problem, considering the differences between mast cells in their inflammatory 
responses based on their origin (Hochdorfer et al., 2011; Matsushima et al., 2004; 
McCurdy et al., 2001; Supajatura et al., 2002). 
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9.4 Appendix D 
 
Vukman KV, Visnovitz T, Adams PN, Metz M, Maurer M and O’Neill SM 
Mast cells cultured from IL-3-treated mice show impaired responses to bacterial 
antigen stimulation 
 
Inflammation Research 2012, 61:79-85 
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9.5 Appendix E 
 
Vukman KV, Adams PN, Metz M, Maurer M and O’Neill SM 
Fasciola hepatica tegumental coat impairs mast cell ability to drive Th1 immune 
responses 
 
 The Journal of Immunology 2013, 190(6): 2873-2879 
 
 
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
This text redacted due to 3rd party copyright
 240 
 
9.6 Appendix F 
 
Vukman KV, Adams PN, Dowling D, Metz M, Maurer M and O’Neill S 
The effect of Fasciola hepatica tegumental antigens on mast cell function 
 
International Journal for Parasitology 2013, 43(7): 531-539 
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9.7 Appendix G 
 
Vukman KV, Adams PN and O’Neill S 
Fasciola hepatica tegumental coat antigen suppresses MAPK signalling in dendritic 
cells and up-regulates the expression of SOCS3 
 
Accepted for publication (Parasite Immunology) 
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9.8 Appendix H 
 
Vukman KV, Aldridge A, Ravidà A, Adams PN and O’Neill S 
Mannose receptor and macrophage galactose lectin are involved in Bordetella 
pertussis mast cell interaction 
 
Accepted for publication (Journal of Leukocyte Biology) 
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Publications during PhD 
Dowling DJ, Noone CM, Adams PN, Vukman KV, Molloy SF, Forde J, Asaolu S 
and O’Neill SM: Ascaris lubricoides pseudocoelomic body fluid induces a partially 
activated dendritic cell phenotype with Th2 promoting ability in vivo. International 
Journal of Parasitology, 2010, 41(2):255-61 
 
Vukman KV, Adams PN, Metz M, Maurer M and O’Neill SM: Fasciola hepatica 
tegumental antigens suppress mast cell driven Th1 immune responses. Immunology 
2012, 137(s1):133 (Conference paper) 
 
Vukman KV, Visnovitz T, Adams PN, Metz M, Maurer M and O’Neill SM: Mast 
cells cultured from IL-3 treated mice show impaired responses to bacterial antigen 
stimulation. Inflammation research 2012, 61:79-85 
 
Vukman KV, Adams PN, Metz M, Maurer M and O’Neill SM: Fasciola hepatica 
tegumental coat impairs mast cell ability to drive Th1 immune responses. The 
Journal of Immunology 2013, 190(6): 2873-2879 
 
Vukman KV, Adams PN, Dowling D, Metz M, Maurer M and O’Neill S: The effects 
of Fasciola hepatica tegumental antigens on mast cell function. International 
Journal for Parasitology 2013, 43(7): 531-539 
 
Vukman KV, Adams PN and O’Neill S: Fasciola hepatica tegumental coat antigen 
suppresses MAPK signalling in dendritic cells and up-regulates the expression of 
SOCS3. Accepted for publication (Parasite Immunology) 
 
Vukman KV, Aldridge A, Ravidà A, Adams PN and O’Neill S: Mannose receptor 
and macrophage galactose lectin are involved in Bordetella pertussis mast cell 
interaction. Accepted for publication (Journal of Leukocyte Biology) 
 
Adams PN, Aldridge A, Vukman KV, Donnelly S and O’Neill S: Fasciola hepatica 
tegumental antigens indirectly induce STAT6 dependent alternative activation of 
macrophages. Manuscript in preparation  
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Trainings and courses during PhD 
 
2008 - 2009 
– 1st year of T3 training program 
 
Code Title Credits 
BDI501 Introductory Biology, Chemistry and Physics 1-2 7.5 
BDI505 Advances in Diagnostic Technology 1-2 5 
BDI508 Introduction to Biology and Chemistry 1-2 5 
BE518 Cell Recognition and Targeting 1-2 7.5 
BE519 BPS Optional Module 1-2 5 
BE520 Functional Definitions of Drug Targets 1-2 7.5 
BE552 Advanced Technologies in Therapeutics* 1-2 10 
BE598 Literature Review and Presentation 1-2 7.5 
BE599 Lab Rotations** 1-2 30 
CS508 Drug Design 1-2 5 
XXX Neurotherapeutics 1-2 5 
XXX Workshop in Commercialization/IP 2.5 
 
– * Technical training 
· Flow cytometry 
· q-PCR 
– ** Lab rotations (2x2 months) 
· The role of SNARE s in dendritic cells following activation by Toll like receptor 
ligands (supervisor: Dr Christine Loscher) 
· To develop an in vitro model system to examine differential activation of mast cells 
(supervisor: Dr Sandra O’Neill) 
 
2009 
– Animal Cell Culture Theory and Techniques (October 2009, NICB) 
– MMI: Techniques and Strategies in Molecular Medicine (December 2009, UCD) 
 
2010 
– Health and Safety Module 1-2 (January 2010, DCU) 
– LAST Ireland Animal Handling Course (January 2010, UCC) 
– Out of Hours Access (March 2010, DCU) 
– Genomics and Proteomics Technical road show (March 2010, NICB) 
 
2011 
– Molecular Biology Seminar (May 2011; DCU, Dublin) 
– Experimental Design Workshop (February 2011; DCU, Dublin) 
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Research trips 
 
– Charité Universitätmedizin Berlin, 1 week visit (November, 2009) 
· Mast cell culture techniques 
– University College Dublin, Ireland, 2 days visit (February, 2011) 
· Histology 
· Microscopic techniques 
 
Conferences, Meetings and workshops 
 
2010 
– School of Biotechnology Annual Research Day (January 2010, DCU) 
– EMBL: Bring the Excellence of the EMBL to Ireland (February 2010, TCD) 
– Innate Immunity:  Mechanisms Linking with Adaptive Immunity, Keystone 
symposia (June 2010, TCD) 
– Cell Symposia: Inflammation and Diseases (September 2010, Lisbon, Portugal): 
poster “Inflammatory Responses in Mast Cells to Different Th1 Stimuli” 
– 25th Anniversary Symposium Annual Meeting “Autoimmunity” (Irish Society for 
Immunology) (October 2010; TCD, Dublin) 
– VI. Meeting of the Irish Cytometry Society (November 2010; Dublin) 
 
2011 
– BPS Research Day (January 2011; DCU, Dublin): poster “SNARE Profiles in 
Proinflammatory Mast Cells”  
– Biotechnology Research Day (January 2011; DCU, Dublin): poster “Inflammatory 
Responses in Mast Cells to Different Th1 Stimuli” 
– BRS Postgraduate talks (March 2011; DCU, Dublin): talk “Strategies to inhibit 
inflammatory responses in mast cells” 
– UK & Ireland NF-κB Workshop (June 2011; NUIM, Maynooth)  
– International Mast Cell and basophil Meeting (November 2011, Southampton, 
United Kingdom): poster “Tegumental antigen of Fasciola hepatica (FhTeg) 
suppresses inflammatory immune responses in mast cells” 
 
2012 
– Irish Society for Parasitology 2012 Meeting (January 2012, TCD): talk “Fasciola 
hepatica tegumental antigens impair mast cell ability to drive Th1 immune 
responses” 
– School of Biotechnology Annual Research Day (January 2012, DCU): talk Fasciola 
hepatica tegumental antigens impair Mast Cells ability to drive Th1 immune 
responses by blocking TLR-driven pro-inflammatory responses 
- 75th Anniversary of Albert Szent-Györgyi’s Nobel Prize Award (March 2012, 
Szeged, Hungary): talk “Fasciola hepatica tegumental antigens suppress Th1 
promoting mast cells” 
- Institute of Animal Technology Ireland Branch Symposium (May 2012, TCD, 
Dublin) 
- Special Symposium of Immunology (July 2012, TCD, Dublin) 
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- European Congress of Immunology (September 2012, Glasgow, United Kingdom): 
talk “Fasciola hepatica tegumental antigens suppress mast cell driven Th1 immune 
responses” 
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Curriculum vitae   
 
Personal information: 
 
Name:  Krisztina V. Vukman 
 
Address:  Jókai Mór utca 22. Dunaharaszti, H-2330 
Mobil:  +36-20-437-1474 
E-mail:  sztitussz@gmail.com 
 
Marital status:  married 
Nationality:  Hungarian 
Date of birth:  21st October 1982 
 
Education and Qualification: 
 
2008 – Targeted Therapeutics and Theranostics 
 School of Nursing and Human Science, Dublin City University 
 Dublin, Ireland 
 4th year PhD student 
2011 Last Ireland animal handling course 
 Licence to perform procedures on animals 
2001 – 2006 Faculty of Science, Eötvös Loránd University 
 Budapest, Hungary 
 MSc Biologist 
2001 – 2002  Course of Mycology 
 Certificated Inspector of Mushrooms 
1992 – 2001 Nagy László Secondary School 
 Final examination at secondary school 
 
Work experience: 
 
2006 – 2008 SOLVO Biotechnology 
 Budaörs, Hungary 
 Scientist: Member of Toxicology Group 
2006 Durham University 
 Durham, United Kingdom 
 2 mounts internship 
 
Topics of researches: 
 
2009 –  To investigate Toll-like receptor activated mast cells (DCU, 
Ireland) 
2008 – 2009 Training program in Immunology, Neurobiology and Chemistry (DCU, Ireland) 
2006 – 2008 ABC transporters and toxicology (SOLVO, Hungary) 
2006 Bacterial co-expression systems (Durham University, UK) 
2003 – 2006 Chemotaxonomy of Ganoderma species (ELTE, Hungary) 
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Used methods: 
 
Animal work (mouse): 
Intraperitoneal injection   
Cervical dislocation 
Peritoneal and lung lavage 
Bone marrow isolation 
Blood and plasma collection 
Cell culture techniques: 
Cell line culture (WEHI-3, MC/9, raw MQ, Caco, MDCK, CHO etc.) 
Primary cell culture (peritoneal and bone marrow derived mast cells and 
macrophages, bone marrow derived dendritic cells, and T-cells and B-cell isolation 
from spleen) 
Co-culture 
Cell culturing (animal, fungal and bacterial) 
Cytotoxicity and sensitization tests 
Monolayer techniques (Caco, MDCK) 
Techniques of microscopy: 
Conventional-, inverse-, polarization-, fluorescent-, DIC- microscopy 
Methods of molecular biology: 
PCR and qPCR techniques 
Cloning 
Agarose gel electrophoresis and DNA extraction from the gel 
PAGE (native, SDS, gradient etc.) 
Western blot 
Biochemical methods: 
ATPase activity measurements 
Vesicular transport assays 
Uptake assays 
Cell based biochemical assays 
ELISA/EIA 
Other methods: 
Flow cytometry (BD Facs Aria and Calibur) 
Mating type identification by fungi 
HPLC, TLC 
 
Organisation memberships: 
 
2011 –  Irish Society for Parasitology (ISP; Ireland) 
2011 –  Federation of the Societies of Biochemistry (FEBS; Europe) 
2011 –  Hungarian Societies of Biochemistry (Hungary) 
2010 –  Irish Society of Immunology (Ireland) 
2008 –  Biological Research Society (Ireland) 
2006 –  Hungarian Biological Association (Hungary) 
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Congresses and Symposia: 
 
2013: 
ISP Scientific meeting, Dublin, Ireland (talk) 
 
2012: 
European Congress of Immunology, Glasgow, United Kingdom (talk) 
Special Symposium on Immunology, Dublin, Ireland 
Institute of Animal Technology Ireland Branch Symposium, Dublin, Ireland 
75th Anniversary of Albert Szent-Györgyi’s Nobel Prize Award, Szeged, Hungary 
(talk) 
ISP Scientific Meeting, Dublin, Ireland (talk) 
School of Biotechnology Annual Research Day, Dublin, Ireland (talk) 
 
2011: 
 International Mast Cell and basophil Meeting, Southampton, United Kingdom 
(poster) 
 Biological Research Society Postgraduate Talks, Dublin, Ireland (talk) 
 UK & Ireland NF-kB Workshop, Maynooth, Ireland 
 Molecular Biology Seminar, Dublin, Ireland 
 Experimental Design Workshop Dublin, Ireland 
 Biotechnology Research Day, Dublin, Ireland (poster) 
 BPS Research Day, Dublin, Ireland (poster) 
 
2010: 
 VI. Meeting of the Irish Cytometry Society, Dublin, Ireland 
 Cell Symposia: Inflammation and Diseases, Lisbon, Portugal (poster) 
 25
th
 Anniversary Symposium Annual Meeting “Autoimmunity”, Dublin, Ireland 
 Innate Immunity: Mechanisms Linking with Adaptive Immunity, Keystone 
symposia, Dublin, Ireland 
 Genomics and Proteomics Technical road show, Dublin, Ireland 
 EMBL: Bring the Excellence of the EMBL to Ireland, Dublin, Ireland 
 School of Biotechnology Annual Research Day, Dublin, Ireland 
 
2009: 
 MMI: Techniques and Strategies in Molecular Medicine, Dublin, Ireland 
 Animal Cell Culture Theory and Techniques, Dublin, Ireland 
 
2008: 
 2nd FEBS Special Meeting co-sponsored by FEMS on ATP binding cassette (ABC) 
transport proteins: From multidrug resistance to genetic diseases, Insbruck, Austria 
 SOLVO Transporter Symposium and Training, Budaörs, Hungary (demonstration of 
assays) 
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2005: 
 Congress of Scientific Students’ Association of Eötvös University (TDK), Budapest, 
Hungary (poster) 
 
Publications: 
 
Vukman KV, Adams PN and O’Neill S: Fasciola hepatica tegumental coat antigen 
suppresses MAPK signalling in dendritic cells and up-regulates the expression of 
SOCS3. Accepted for publication (Parasite Immunology) 
 
Vukman KV, Aldridge A, Ravidà A, Adams PN and O’Neill S: Mannose receptor 
and macrophage galactose lectin are involved in Bordetella pertussis mast cell 
interaction. Submitted for publication (Journal of Leukocyte Biology) 
 
Vukman KV, Adams PN, Dowling D, Metz M, Maurer M and O’Neill S: The effects 
of Fasciola hepatica tegumental antigens on mast cell function.. International 
journal for Parasitology 2013, 43(7): 531-539 
 
Vukman KV, Adams PN, Metz M, Maurer M and O’Neill S: Fasciola hepatica 
tegumental coat impairs mast cell ability to drive Th1 immune responses. The 
Journal of Immunology 2013, 190(6): 2873-2879 
 
Vukman KV, Visnovitz T, Adams PN, Metz M, Maurer M and O’Neill SM: Mast 
cells cultured from IL-3 treated mice show impaired responses to bacterial antigen 
stimulation. Inflammation Research 2012, 61:79-85 
 
Dowling DJ, Noone CM, Adams PN, Vukman KV, Molloy SF, Forde J, Asaolu S 
and O’Neill SM: Ascaris lubricoides pseudocoelomic body fluid induces a partially 
activated dendritic cell phenotype with Th2 promoting ability in vivo. International 
Journal of Parasitology, 2010, 41(2):255-61 
 
Dreiseitel A, Oosterhuis B, Vukman KV, Schreier P, Oehme A, Locher S, Hajak G 
and Sand PG: Berry anthocyanins and anthocyanidins exhibit distinct affinities for 
the efflux transporters BCRP and MDR1. British Journal of Pharmacology 2009: 
158(8): 1942-50 
 
Oosterhuis B, Vukman K, Vagi E, Glavinas H, Jablonkai I and Krajcsi P: Specific 
interactions of chloroacetanilide herbicides with human ABC transporter proteins. 
Toxicology 2008, 248(1): 41-51 
 
Conference papers: 
 
Vukman KV, Adams PN, Metz M, Maurer M and O’Neill SM: Fasciola hepatica 
tegumental antigens suppress mast cell driven Th1 immune responses. Immunology 
2012, 137(s1):133 (Conference paper) 
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Oosterhuis B, Vukman K, Vagi E, Glavinas H, Jablonkai I and Krajcsi P: Interaction 
of ABC transporters with environmental toxicants. Toxicology Letters 2009, 189: 
S114-5 (Conference paper) 
 
Oosterhuis B, Vukman K, Vagi E, Glavinas H, Jablonkai I and Krajcsi P: 
Chloroacetanilide herbicides interact with human efflux transporters and modulate in 
vitro drug absorption. Toxicology Letters 2009, 189: S109 (Conference paper) 
 
Oosterhuis B, Vukman K, Vagi E, Glavinas H, Krajcsi P and Jablonkai I: Pesticides 
and their metabolites interact with human efflux transporters. Drug Metabolism 
Reviews 2007, 39(1): 294 (Conference paper) 
 
Personal Skills: 
 
Good team player and can work independently as well, experience in writing 
scientific reports, solving scientific problems, etc. 
 
 
Languages: 
 
Mother language: Hungarian 
Other languages:  English (C1; Hungarian State Language Certification, 
intermediate level - C) 
 German (B1; Hungarian State Language Certification, 
intermediate level - A) 
 
Computer skills: 
 
Microsoft Office (Word, Excel, Power-point), Photoshop, Origin, Flow Jo, Origin, 
ImageJ etc. software at user level and basic knowledge of Pascal/Delphi 
programming language 
 
Driving Licence: 
 
Driving Licence Category “B” 
 
 
